{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "99867169",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.support import expected_conditions as EC\n",
    "from selenium.webdriver import ActionChains\n",
    "import selenium\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.common.keys import Keys\n",
    "import time\n",
    "from webdriver_manager.chrome import ChromeDriverManager"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "e755b096",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver=webdriver.Chrome()\n",
    "driver.get(\"https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal/session/calendar\")\n",
    "driver.maximize_window()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "faff8f1d",
   "metadata": {},
   "outputs": [],
   "source": [
    "days=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "b561ea4a",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# for i in range():\n",
    "ll=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[7]/div/div/div/div[2]/div[2]')\n",
    "lin=ll.find_elements(By.TAG_NAME,'a')\n",
    "k=[]\n",
    "for l in range(len(lin)):\n",
    "    k.append(lin[l].get_attribute('href'))\n",
    "for l in range(len(k)):\n",
    "    if('esmo.org' not in k[l]):\n",
    "        days.append(k[l])\n",
    "#     driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/ul/li['+str(i)+']/a').click()\n",
    "#     driver.implicitly_wait(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "d64da71c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "201"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(days)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "70f0c8e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "dayss=[]\n",
    "for i in range(len(days)):\n",
    "    if('vimeo.com' in days[i]):\n",
    "        continue\n",
    "    else:\n",
    "        dayss.append(days[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "c7623fb9",
   "metadata": {},
   "outputs": [],
   "source": [
    "len(dayss)\n",
    "days=dayss"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "f71b2c5e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(days)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "694cd5b8",
   "metadata": {},
   "outputs": [],
   "source": [
    "items = days\n",
    "file = open('ESMO2022LINKS.txt','w')\n",
    "for item in items:\n",
    "    file.write(item+\"\\n\")\n",
    "file.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "306ebed7",
   "metadata": {},
   "outputs": [],
   "source": [
    "SESSION=[]\n",
    "SUB_SESSION=[]\n",
    "TIME=[]\n",
    "PERSONS=[]\n",
    "DATE=[]\n",
    "ROLE=[]\n",
    "COUNTRY=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "2e65fca9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 1\n",
      "0 2\n",
      "p:  0\n",
      "1 1\n",
      "1 2\n",
      "1 3\n",
      "1 4\n",
      "1 5\n",
      "1 6\n",
      "1 7\n",
      "1 8\n",
      "p:  1\n",
      "2 1\n",
      "2 2\n",
      "2 3\n",
      "2 4\n",
      "2 5\n",
      "2 6\n",
      "2 7\n",
      "p:  2\n",
      "3 1\n",
      "3 2\n",
      "3 3\n",
      "3 4\n",
      "p:  3\n",
      "4 1\n",
      "4 2\n",
      "4 3\n",
      "4 4\n",
      "4 5\n",
      "4 6\n",
      "4 7\n",
      "4 8\n",
      "4 9\n",
      "p:  4\n",
      "5 1\n",
      "5 2\n",
      "5 3\n",
      "5 4\n",
      "p:  5\n",
      "6 1\n",
      "6 2\n",
      "6 3\n",
      "6 4\n",
      "p:  6\n",
      "7 1\n",
      "7 2\n",
      "7 3\n",
      "7 4\n",
      "p:  7\n",
      "8 1\n",
      "8 2\n",
      "8 3\n",
      "8 4\n",
      "8 5\n",
      "8 6\n",
      "8 7\n",
      "8 8\n",
      "8 9\n",
      "p:  8\n",
      "9 1\n",
      "9 2\n",
      "9 3\n",
      "9 4\n",
      "9 5\n",
      "9 6\n",
      "9 7\n",
      "p:  9\n",
      "10 1\n",
      "10 2\n",
      "10 3\n",
      "10 4\n",
      "10 5\n",
      "10 6\n",
      "10 7\n",
      "p:  10\n",
      "11 1\n",
      "11 2\n",
      "11 3\n",
      "11 4\n",
      "p:  11\n",
      "12 1\n",
      "12 2\n",
      "12 3\n",
      "12 4\n",
      "p:  12\n",
      "13 1\n",
      "13 2\n",
      "13 3\n",
      "13 4\n",
      "p:  13\n",
      "14 1\n",
      "14 2\n",
      "14 3\n",
      "14 4\n",
      "14 5\n",
      "14 6\n",
      "p:  14\n",
      "15 1\n",
      "15 2\n",
      "15 3\n",
      "15 4\n",
      "15 5\n",
      "p:  15\n",
      "16 1\n",
      "16 2\n",
      "16 3\n",
      "16 4\n",
      "p:  16\n",
      "17 1\n",
      "17 2\n",
      "17 3\n",
      "17 4\n",
      "17 5\n",
      "17 6\n",
      "17 7\n",
      "p:  17\n",
      "18 1\n",
      "18 2\n",
      "18 3\n",
      "18 4\n",
      "18 5\n",
      "18 6\n",
      "18 7\n",
      "18 8\n",
      "p:  18\n",
      "19 1\n",
      "19 2\n",
      "19 3\n",
      "19 4\n",
      "19 5\n",
      "19 6\n",
      "p:  19\n",
      "20 1\n",
      "20 2\n",
      "20 3\n",
      "20 4\n",
      "20 5\n",
      "20 6\n",
      "p:  20\n",
      "21 1\n",
      "21 2\n",
      "21 3\n",
      "21 4\n",
      "21 5\n",
      "21 6\n",
      "21 7\n",
      "p:  21\n",
      "22 1\n",
      "22 2\n",
      "22 3\n",
      "22 4\n",
      "22 5\n",
      "22 6\n",
      "22 7\n",
      "p:  22\n",
      "23 1\n",
      "23 2\n",
      "23 3\n",
      "23 4\n",
      "23 5\n",
      "23 6\n",
      "p:  23\n",
      "24 1\n",
      "24 2\n",
      "24 3\n",
      "24 4\n",
      "24 5\n",
      "p:  24\n",
      "25 1\n",
      "25 2\n",
      "25 3\n",
      "25 4\n",
      "25 5\n",
      "25 6\n",
      "25 7\n",
      "p:  25\n",
      "26 1\n",
      "26 2\n",
      "26 3\n",
      "26 4\n",
      "26 5\n",
      "26 6\n",
      "26 7\n",
      "26 8\n",
      "p:  26\n",
      "27 1\n",
      "p:  27\n",
      "28 1\n",
      "28 2\n",
      "28 3\n",
      "28 4\n",
      "28 5\n",
      "28 6\n",
      "28 7\n",
      "p:  28\n",
      "29 1\n",
      "29 2\n",
      "29 3\n",
      "29 4\n",
      "29 5\n",
      "29 6\n",
      "29 7\n",
      "p:  29\n",
      "30 1\n",
      "30 2\n",
      "30 3\n",
      "30 4\n",
      "30 5\n",
      "30 6\n",
      "30 7\n",
      "p:  30\n",
      "31 1\n",
      "31 2\n",
      "31 3\n",
      "31 4\n",
      "p:  31\n",
      "32 1\n",
      "32 2\n",
      "32 3\n",
      "32 4\n",
      "32 5\n",
      "32 6\n",
      "32 7\n",
      "p:  32\n",
      "33 1\n",
      "33 2\n",
      "33 3\n",
      "33 4\n",
      "33 5\n",
      "33 6\n",
      "33 7\n",
      "33 8\n",
      "p:  33\n",
      "34 1\n",
      "34 2\n",
      "p:  34\n",
      "35 1\n",
      "35 2\n",
      "35 3\n",
      "35 4\n",
      "35 5\n",
      "35 6\n",
      "35 7\n",
      "p:  35\n",
      "36 1\n",
      "36 2\n",
      "36 3\n",
      "36 4\n",
      "36 5\n",
      "36 6\n",
      "36 7\n",
      "p:  36\n",
      "37 1\n",
      "37 2\n",
      "37 3\n",
      "37 4\n",
      "37 5\n",
      "37 6\n",
      "p:  37\n",
      "38 1\n",
      "38 2\n",
      "38 3\n",
      "38 4\n",
      "p:  38\n",
      "39 1\n",
      "39 2\n",
      "39 3\n",
      "39 4\n",
      "39 5\n",
      "39 6\n",
      "39 7\n",
      "39 8\n",
      "39 9\n",
      "39 10\n",
      "p:  39\n",
      "40 1\n",
      "40 2\n",
      "40 3\n",
      "40 4\n",
      "40 5\n",
      "40 6\n",
      "40 7\n",
      "40 8\n",
      "p:  40\n",
      "41 1\n",
      "41 2\n",
      "41 3\n",
      "41 4\n",
      "41 5\n",
      "41 6\n",
      "41 7\n",
      "41 8\n",
      "41 9\n",
      "41 10\n",
      "41 11\n",
      "41 12\n",
      "p:  41\n",
      "42 1\n",
      "42 2\n",
      "42 3\n",
      "42 4\n",
      "42 5\n",
      "42 6\n",
      "p:  42\n",
      "43 1\n",
      "43 2\n",
      "43 3\n",
      "43 4\n",
      "43 5\n",
      "43 6\n",
      "43 7\n",
      "p:  43\n",
      "44 1\n",
      "44 2\n",
      "44 3\n",
      "44 4\n",
      "44 5\n",
      "44 6\n",
      "44 7\n",
      "44 8\n",
      "p:  44\n",
      "45 1\n",
      "45 2\n",
      "45 3\n",
      "45 4\n",
      "45 5\n",
      "p:  45\n",
      "46 1\n",
      "46 2\n",
      "46 3\n",
      "46 4\n",
      "46 5\n",
      "46 6\n",
      "46 7\n",
      "46 8\n",
      "46 9\n",
      "46 10\n",
      "46 11\n",
      "46 12\n",
      "p:  46\n",
      "47 1\n",
      "47 2\n",
      "p:  47\n",
      "48 1\n",
      "48 2\n",
      "48 3\n",
      "48 4\n",
      "48 5\n",
      "48 6\n",
      "48 7\n",
      "p:  48\n",
      "49 1\n",
      "49 2\n",
      "p:  49\n",
      "50 1\n",
      "50 2\n",
      "50 3\n",
      "50 4\n",
      "p:  50\n",
      "51 1\n",
      "51 2\n",
      "51 3\n",
      "51 4\n",
      "p:  51\n",
      "52 1\n",
      "52 2\n",
      "52 3\n",
      "52 4\n",
      "52 5\n",
      "52 6\n",
      "52 7\n",
      "52 8\n",
      "52 9\n",
      "52 10\n",
      "52 11\n",
      "52 12\n",
      "p:  52\n",
      "53 1\n",
      "53 2\n",
      "p:  53\n",
      "54 1\n",
      "54 2\n",
      "54 3\n",
      "54 4\n",
      "54 5\n",
      "p:  54\n",
      "55 1\n",
      "55 2\n",
      "55 3\n",
      "55 4\n",
      "55 5\n",
      "55 6\n",
      "55 7\n",
      "p:  55\n",
      "56 1\n",
      "56 2\n",
      "56 3\n",
      "56 4\n",
      "56 5\n",
      "p:  56\n",
      "57 1\n",
      "57 2\n",
      "57 3\n",
      "57 4\n",
      "57 5\n",
      "p:  57\n",
      "58 1\n",
      "58 2\n",
      "p:  58\n",
      "59 1\n",
      "59 2\n",
      "59 3\n",
      "59 4\n",
      "59 5\n",
      "59 6\n",
      "59 7\n",
      "59 8\n",
      "59 9\n",
      "p:  59\n",
      "60 1\n",
      "60 2\n",
      "60 3\n",
      "60 4\n",
      "60 5\n",
      "60 6\n",
      "60 7\n",
      "60 8\n",
      "60 9\n",
      "60 10\n",
      "60 11\n",
      "60 12\n",
      "p:  60\n",
      "61 1\n",
      "61 2\n",
      "p:  61\n",
      "62 1\n",
      "62 2\n",
      "62 3\n",
      "62 4\n",
      "62 5\n",
      "62 6\n",
      "62 7\n",
      "62 8\n",
      "p:  62\n",
      "63 1\n",
      "63 2\n",
      "p:  63\n",
      "64 1\n",
      "64 2\n",
      "64 3\n",
      "64 4\n",
      "64 5\n",
      "64 6\n",
      "64 7\n",
      "64 8\n",
      "p:  64\n",
      "65 1\n",
      "65 2\n",
      "65 3\n",
      "65 4\n",
      "65 5\n",
      "65 6\n",
      "65 7\n",
      "65 8\n",
      "65 9\n",
      "65 10\n",
      "p:  65\n",
      "66 1\n",
      "66 2\n",
      "66 3\n",
      "66 4\n",
      "66 5\n",
      "66 6\n",
      "66 7\n",
      "p:  66\n",
      "67 1\n",
      "67 2\n",
      "67 3\n",
      "67 4\n",
      "67 5\n",
      "67 6\n",
      "p:  67\n",
      "68 1\n",
      "68 2\n",
      "68 3\n",
      "68 4\n",
      "68 5\n",
      "68 6\n",
      "68 7\n",
      "p:  68\n",
      "69 1\n",
      "69 2\n",
      "69 3\n",
      "69 4\n",
      "69 5\n",
      "69 6\n",
      "69 7\n",
      "69 8\n",
      "69 9\n",
      "p:  69\n",
      "70 1\n",
      "70 2\n",
      "70 3\n",
      "70 4\n",
      "70 5\n",
      "70 6\n",
      "70 7\n",
      "p:  70\n",
      "71 1\n",
      "71 2\n",
      "71 3\n",
      "71 4\n",
      "71 5\n",
      "71 6\n",
      "71 7\n",
      "p:  71\n",
      "72 1\n",
      "72 2\n",
      "72 3\n",
      "72 4\n",
      "72 5\n",
      "72 6\n",
      "72 7\n",
      "p:  72\n",
      "73 1\n",
      "73 2\n",
      "73 3\n",
      "73 4\n",
      "73 5\n",
      "73 6\n",
      "p:  73\n",
      "74 1\n",
      "74 2\n",
      "74 3\n",
      "74 4\n",
      "74 5\n",
      "74 6\n",
      "74 7\n",
      "74 8\n",
      "74 9\n",
      "74 10\n",
      "74 11\n",
      "74 12\n",
      "p:  74\n",
      "75 1\n",
      "75 2\n",
      "75 3\n",
      "75 4\n",
      "75 5\n",
      "75 6\n",
      "p:  75\n",
      "76 1\n",
      "76 2\n",
      "p:  76\n",
      "77 1\n",
      "77 2\n",
      "77 3\n",
      "77 4\n",
      "77 5\n",
      "77 6\n",
      "77 7\n",
      "p:  77\n",
      "78 1\n",
      "78 2\n",
      "78 3\n",
      "78 4\n",
      "78 5\n",
      "78 6\n",
      "78 7\n",
      "78 8\n",
      "p:  78\n",
      "79 1\n",
      "79 2\n",
      "79 3\n",
      "79 4\n",
      "79 5\n",
      "79 6\n",
      "79 7\n",
      "p:  79\n",
      "80 1\n",
      "80 2\n",
      "80 3\n",
      "80 4\n",
      "80 5\n",
      "p:  80\n",
      "81 1\n",
      "81 2\n",
      "81 3\n",
      "81 4\n",
      "81 5\n",
      "p:  81\n",
      "82 1\n",
      "82 2\n",
      "82 3\n",
      "82 4\n",
      "82 5\n",
      "p:  82\n",
      "83 1\n",
      "83 2\n",
      "p:  83\n",
      "84 1\n",
      "84 2\n",
      "84 3\n",
      "84 4\n",
      "84 5\n",
      "84 6\n",
      "84 7\n",
      "p:  84\n",
      "85 1\n",
      "85 2\n",
      "85 3\n",
      "85 4\n",
      "85 5\n",
      "85 6\n",
      "85 7\n",
      "85 8\n",
      "p:  85\n",
      "86 1\n",
      "86 2\n",
      "86 3\n",
      "86 4\n",
      "86 5\n",
      "86 6\n",
      "86 7\n",
      "86 8\n",
      "p:  86\n",
      "87 1\n",
      "87 2\n",
      "87 3\n",
      "87 4\n",
      "87 5\n",
      "87 6\n",
      "87 7\n",
      "87 8\n",
      "87 9\n",
      "p:  87\n",
      "88 1\n",
      "88 2\n",
      "88 3\n",
      "88 4\n",
      "88 5\n",
      "88 6\n",
      "88 7\n",
      "88 8\n",
      "p:  88\n",
      "89 1\n",
      "89 2\n",
      "89 3\n",
      "89 4\n",
      "p:  89\n",
      "90 1\n",
      "90 2\n",
      "p:  90\n",
      "91 1\n",
      "91 2\n",
      "91 3\n",
      "91 4\n",
      "91 5\n",
      "91 6\n",
      "91 7\n",
      "91 8\n",
      "91 9\n",
      "p:  91\n",
      "92 1\n",
      "92 2\n",
      "92 3\n",
      "92 4\n",
      "92 5\n",
      "p:  92\n",
      "93 1\n",
      "93 2\n",
      "93 3\n",
      "93 4\n",
      "93 5\n",
      "93 6\n",
      "93 7\n",
      "93 8\n",
      "93 9\n",
      "p:  93\n",
      "94 1\n",
      "94 2\n",
      "94 3\n",
      "94 4\n",
      "94 5\n",
      "94 6\n",
      "94 7\n",
      "94 8\n",
      "94 9\n",
      "p:  94\n",
      "95 1\n",
      "95 2\n",
      "95 3\n",
      "95 4\n",
      "95 5\n",
      "95 6\n",
      "95 7\n",
      "p:  95\n",
      "96 1\n",
      "96 2\n",
      "96 3\n",
      "96 4\n",
      "96 5\n",
      "96 6\n",
      "96 7\n",
      "p:  96\n",
      "97 1\n",
      "97 2\n",
      "97 3\n",
      "97 4\n",
      "97 5\n",
      "97 6\n",
      "97 7\n",
      "p:  97\n",
      "98 1\n",
      "98 2\n",
      "p:  98\n",
      "99 1\n",
      "99 2\n",
      "99 3\n",
      "99 4\n",
      "99 5\n",
      "99 6\n",
      "99 7\n",
      "99 8\n",
      "99 9\n",
      "99 10\n",
      "p:  99\n",
      "100 1\n",
      "100 2\n",
      "100 3\n",
      "100 4\n",
      "p:  100\n",
      "101 1\n",
      "101 2\n",
      "101 3\n",
      "101 4\n",
      "101 5\n",
      "101 6\n",
      "p:  101\n",
      "102 1\n",
      "102 2\n",
      "102 3\n",
      "102 4\n",
      "102 5\n",
      "102 6\n",
      "p:  102\n",
      "103 1\n",
      "103 2\n",
      "103 3\n",
      "103 4\n",
      "103 5\n",
      "103 6\n",
      "103 7\n",
      "p:  103\n",
      "104 1\n",
      "104 2\n",
      "104 3\n",
      "104 4\n",
      "104 5\n",
      "104 6\n",
      "104 7\n",
      "104 8\n",
      "104 9\n",
      "104 10\n",
      "104 11\n",
      "104 12\n",
      "p:  104\n",
      "105 1\n",
      "105 2\n",
      "105 3\n",
      "105 4\n",
      "p:  105\n",
      "106 1\n",
      "106 2\n",
      "p:  106\n",
      "107 1\n",
      "107 2\n",
      "107 3\n",
      "107 4\n",
      "107 5\n",
      "107 6\n",
      "p:  107\n",
      "108 1\n",
      "108 2\n",
      "108 3\n",
      "108 4\n",
      "108 5\n",
      "108 6\n",
      "108 7\n",
      "108 8\n",
      "108 9\n",
      "108 10\n",
      "108 11\n",
      "p:  108\n",
      "109 1\n",
      "109 2\n",
      "109 3\n",
      "109 4\n",
      "109 5\n",
      "109 6\n",
      "109 7\n",
      "p:  109\n",
      "110 1\n",
      "110 2\n",
      "p:  110\n",
      "111 1\n",
      "111 2\n",
      "111 3\n",
      "111 4\n",
      "111 5\n",
      "111 6\n",
      "111 7\n",
      "p:  111\n",
      "112 1\n",
      "112 2\n",
      "112 3\n",
      "112 4\n",
      "112 5\n",
      "112 6\n",
      "p:  112\n",
      "113 1\n",
      "113 2\n",
      "p:  113\n",
      "114 1\n",
      "114 2\n",
      "114 3\n",
      "114 4\n",
      "114 5\n",
      "114 6\n",
      "114 7\n",
      "p:  114\n",
      "115 1\n",
      "115 2\n",
      "115 3\n",
      "115 4\n",
      "115 5\n",
      "115 6\n",
      "115 7\n",
      "p:  115\n",
      "116 1\n",
      "116 2\n",
      "116 3\n",
      "116 4\n",
      "p:  116\n",
      "117 1\n",
      "117 2\n",
      "117 3\n",
      "117 4\n",
      "117 5\n",
      "117 6\n",
      "117 7\n",
      "117 8\n",
      "117 9\n",
      "p:  117\n",
      "118 1\n",
      "118 2\n",
      "p:  118\n",
      "119 1\n",
      "119 2\n",
      "119 3\n",
      "119 4\n",
      "119 5\n",
      "119 6\n",
      "119 7\n",
      "119 8\n",
      "119 9\n",
      "119 10\n",
      "119 11\n",
      "p:  119\n",
      "120 1\n",
      "120 2\n",
      "p:  120\n",
      "121 1\n",
      "121 2\n",
      "121 3\n",
      "121 4\n",
      "p:  121\n",
      "122 1\n",
      "122 2\n",
      "122 3\n",
      "122 4\n",
      "122 5\n",
      "122 6\n",
      "122 7\n",
      "p:  122\n",
      "123 1\n",
      "123 2\n",
      "123 3\n",
      "123 4\n",
      "123 5\n",
      "p:  123\n",
      "124 1\n",
      "124 2\n",
      "p:  124\n",
      "125 1\n",
      "125 2\n",
      "125 3\n",
      "125 4\n",
      "125 5\n",
      "125 6\n",
      "p:  125\n",
      "126 1\n",
      "126 2\n",
      "126 3\n",
      "126 4\n",
      "126 5\n",
      "p:  126\n",
      "127 1\n",
      "127 2\n",
      "127 3\n",
      "127 4\n",
      "127 5\n",
      "127 6\n",
      "127 7\n",
      "p:  127\n",
      "128 1\n",
      "128 2\n",
      "128 3\n",
      "128 4\n",
      "128 5\n",
      "128 6\n",
      "128 7\n",
      "p:  128\n",
      "129 1\n",
      "129 2\n",
      "129 3\n",
      "129 4\n",
      "129 5\n",
      "129 6\n",
      "129 7\n",
      "p:  129\n",
      "130 1\n",
      "130 2\n",
      "130 3\n",
      "130 4\n",
      "130 5\n",
      "130 6\n",
      "130 7\n",
      "p:  130\n",
      "131 1\n",
      "131 2\n",
      "131 3\n",
      "131 4\n",
      "131 5\n",
      "131 6\n",
      "131 7\n",
      "131 8\n",
      "131 9\n",
      "p:  131\n",
      "132 1\n",
      "132 2\n",
      "132 3\n",
      "132 4\n",
      "p:  132\n",
      "133 1\n",
      "133 2\n",
      "133 3\n",
      "133 4\n",
      "p:  133\n",
      "134 1\n",
      "134 2\n",
      "134 3\n",
      "134 4\n",
      "134 5\n",
      "134 6\n",
      "p:  134\n",
      "135 1\n",
      "135 2\n",
      "p:  135\n",
      "136 1\n",
      "136 2\n",
      "136 3\n",
      "136 4\n",
      "136 5\n",
      "136 6\n",
      "136 7\n",
      "136 8\n",
      "136 9\n",
      "p:  136\n",
      "137 1\n",
      "137 2\n",
      "137 3\n",
      "137 4\n",
      "137 5\n",
      "137 6\n",
      "137 7\n",
      "137 8\n",
      "p:  137\n",
      "138 1\n",
      "138 2\n",
      "138 3\n",
      "138 4\n",
      "138 5\n",
      "138 6\n",
      "138 7\n",
      "138 8\n",
      "p:  138\n",
      "139 1\n",
      "139 2\n",
      "139 3\n",
      "139 4\n",
      "139 5\n",
      "p:  139\n",
      "140 1\n",
      "140 2\n",
      "140 3\n",
      "p:  140\n",
      "141 1\n",
      "141 2\n",
      "141 3\n",
      "141 4\n",
      "141 5\n",
      "141 6\n",
      "p:  141\n",
      "142 1\n",
      "142 2\n",
      "142 3\n",
      "142 4\n",
      "142 5\n",
      "142 6\n",
      "142 7\n",
      "142 8\n",
      "p:  142\n",
      "143 1\n",
      "143 2\n",
      "143 3\n",
      "143 4\n",
      "143 5\n",
      "143 6\n",
      "143 7\n",
      "143 8\n",
      "p:  143\n",
      "144 1\n",
      "144 2\n",
      "144 3\n",
      "144 4\n",
      "144 5\n",
      "144 6\n",
      "144 7\n",
      "p:  144\n",
      "145 1\n",
      "145 2\n",
      "145 3\n",
      "145 4\n",
      "p:  145\n",
      "146 1\n",
      "146 2\n",
      "146 3\n",
      "146 4\n",
      "146 5\n",
      "146 6\n",
      "p:  146\n",
      "147 1\n",
      "147 2\n",
      "147 3\n",
      "147 4\n",
      "p:  147\n",
      "148 1\n",
      "148 2\n",
      "148 3\n",
      "148 4\n",
      "148 5\n",
      "148 6\n",
      "148 7\n",
      "p:  148\n",
      "149 1\n",
      "149 2\n",
      "p:  149\n",
      "150 1\n",
      "150 2\n",
      "150 3\n",
      "150 4\n",
      "p:  150\n",
      "151 1\n",
      "151 2\n",
      "151 3\n",
      "151 4\n",
      "151 5\n",
      "151 6\n",
      "p:  151\n",
      "152 1\n",
      "152 2\n",
      "152 3\n",
      "152 4\n",
      "152 5\n",
      "152 6\n",
      "152 7\n",
      "152 8\n",
      "152 9\n",
      "152 10\n",
      "p:  152\n",
      "153 1\n",
      "153 2\n",
      "153 3\n",
      "153 4\n",
      "153 5\n",
      "153 6\n",
      "153 7\n",
      "153 8\n",
      "p:  153\n",
      "154 1\n",
      "154 2\n",
      "154 3\n",
      "154 4\n",
      "154 5\n",
      "154 6\n",
      "154 7\n",
      "154 8\n",
      "p:  154\n",
      "155 1\n",
      "155 2\n",
      "155 3\n",
      "155 4\n",
      "155 5\n",
      "155 6\n",
      "155 7\n",
      "p:  155\n",
      "156 1\n",
      "156 2\n",
      "156 3\n",
      "156 4\n",
      "156 5\n",
      "p:  156\n",
      "157 1\n",
      "157 2\n",
      "157 3\n",
      "157 4\n",
      "157 5\n",
      "157 6\n",
      "157 7\n",
      "157 8\n",
      "p:  157\n",
      "158 1\n",
      "158 2\n",
      "158 3\n",
      "158 4\n",
      "158 5\n",
      "158 6\n",
      "158 7\n",
      "158 8\n",
      "158 9\n",
      "p:  158\n",
      "159 1\n",
      "159 2\n",
      "159 3\n",
      "159 4\n",
      "159 5\n",
      "159 6\n",
      "159 7\n",
      "159 8\n",
      "p:  159\n",
      "160 1\n",
      "160 2\n",
      "160 3\n",
      "160 4\n",
      "160 5\n",
      "160 6\n",
      "p:  160\n",
      "161 1\n",
      "161 2\n",
      "p:  161\n",
      "162 1\n",
      "162 2\n",
      "162 3\n",
      "162 4\n",
      "162 5\n",
      "162 6\n",
      "162 7\n",
      "p:  162\n",
      "163 1\n",
      "163 2\n",
      "163 3\n",
      "163 4\n",
      "163 5\n",
      "p:  163\n",
      "164 1\n",
      "164 2\n",
      "164 3\n",
      "164 4\n",
      "164 5\n",
      "164 6\n",
      "164 7\n",
      "p:  164\n",
      "165 1\n",
      "165 2\n",
      "165 3\n",
      "165 4\n",
      "165 5\n",
      "165 6\n",
      "p:  165\n",
      "166 1\n",
      "166 2\n",
      "166 3\n",
      "166 4\n",
      "166 5\n",
      "166 6\n",
      "166 7\n",
      "166 8\n",
      "166 9\n",
      "166 10\n",
      "p:  166\n",
      "167 1\n",
      "167 2\n",
      "p:  167\n",
      "168 1\n",
      "168 2\n",
      "168 3\n",
      "168 4\n",
      "168 5\n",
      "168 6\n",
      "168 7\n",
      "p:  168\n",
      "169 1\n",
      "169 2\n",
      "169 3\n",
      "169 4\n",
      "169 5\n",
      "p:  169\n",
      "170 1\n",
      "170 2\n",
      "170 3\n",
      "170 4\n",
      "p:  170\n",
      "171 1\n",
      "171 2\n",
      "171 3\n",
      "171 4\n",
      "171 5\n",
      "171 6\n",
      "171 7\n",
      "p:  171\n",
      "172 1\n",
      "172 2\n",
      "172 3\n",
      "172 4\n",
      "172 5\n",
      "172 6\n",
      "p:  172\n",
      "173 1\n",
      "173 2\n",
      "173 3\n",
      "173 4\n",
      "173 5\n",
      "173 6\n",
      "173 7\n",
      "173 8\n",
      "173 9\n",
      "173 10\n",
      "173 11\n",
      "p:  173\n",
      "174 1\n",
      "174 2\n",
      "174 3\n",
      "174 4\n",
      "174 5\n",
      "174 6\n",
      "174 7\n",
      "174 8\n",
      "p:  174\n",
      "175 1\n",
      "175 2\n",
      "175 3\n",
      "175 4\n",
      "175 5\n",
      "175 6\n",
      "175 7\n",
      "175 8\n",
      "175 9\n",
      "175 10\n",
      "175 11\n",
      "175 12\n",
      "p:  175\n",
      "176 1\n",
      "176 2\n",
      "176 3\n",
      "176 4\n",
      "176 5\n",
      "p:  176\n",
      "177 1\n",
      "177 2\n",
      "177 3\n",
      "177 4\n",
      "177 5\n",
      "p:  177\n",
      "178 1\n",
      "178 2\n",
      "p:  178\n",
      "179 1\n",
      "179 2\n",
      "179 3\n",
      "179 4\n",
      "179 5\n",
      "179 6\n",
      "179 7\n",
      "p:  179\n",
      "180 1\n",
      "180 2\n",
      "180 3\n",
      "180 4\n",
      "180 5\n",
      "180 6\n",
      "180 7\n",
      "180 8\n",
      "180 9\n",
      "180 10\n",
      "p:  180\n",
      "181 1\n",
      "181 2\n",
      "181 3\n",
      "181 4\n",
      "181 5\n",
      "181 6\n",
      "181 7\n",
      "181 8\n",
      "181 9\n",
      "p:  181\n",
      "182 1\n",
      "182 2\n",
      "182 3\n",
      "182 4\n",
      "182 5\n",
      "182 6\n",
      "182 7\n",
      "p:  182\n",
      "183 1\n",
      "183 2\n",
      "183 3\n",
      "183 4\n",
      "183 5\n",
      "183 6\n",
      "p:  183\n",
      "184 1\n",
      "184 2\n",
      "184 3\n",
      "184 4\n",
      "184 5\n",
      "184 6\n",
      "p:  184\n",
      "185 1\n",
      "185 2\n",
      "p:  185\n",
      "186 1\n",
      "186 2\n",
      "186 3\n",
      "186 4\n",
      "186 5\n",
      "186 6\n",
      "186 7\n",
      "186 8\n",
      "p:  186\n",
      "187 1\n",
      "187 2\n",
      "187 3\n",
      "187 4\n",
      "187 5\n",
      "187 6\n",
      "p:  187\n",
      "188 1\n",
      "188 2\n",
      "188 3\n",
      "188 4\n",
      "188 5\n",
      "p:  188\n",
      "189 1\n",
      "189 2\n",
      "189 3\n",
      "189 4\n",
      "189 5\n",
      "189 6\n",
      "189 7\n",
      "189 8\n",
      "189 9\n",
      "189 10\n",
      "189 11\n",
      "p:  189\n",
      "190 1\n",
      "190 2\n",
      "190 3\n",
      "190 4\n",
      "190 5\n",
      "p:  190\n",
      "191 1\n",
      "191 2\n",
      "p:  191\n",
      "192 1\n",
      "192 2\n",
      "192 3\n",
      "192 4\n",
      "192 5\n",
      "192 6\n",
      "192 7\n",
      "192 8\n",
      "p:  192\n",
      "193 1\n",
      "193 2\n",
      "193 3\n",
      "193 4\n",
      "193 5\n",
      "193 6\n",
      "193 7\n",
      "193 8\n",
      "p:  193\n",
      "194 1\n",
      "194 2\n",
      "194 3\n",
      "194 4\n",
      "194 5\n",
      "194 6\n",
      "194 7\n",
      "194 8\n",
      "p:  194\n",
      "195 1\n",
      "195 2\n",
      "195 3\n",
      "195 4\n",
      "195 5\n",
      "p:  195\n",
      "196 1\n",
      "196 2\n",
      "196 3\n",
      "196 4\n",
      "196 5\n",
      "196 6\n",
      "196 7\n",
      "p:  196\n",
      "197 1\n",
      "197 2\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "197 3\n",
      "197 4\n",
      "p:  197\n",
      "198 1\n",
      "198 2\n",
      "198 3\n",
      "198 4\n",
      "198 5\n",
      "198 6\n",
      "198 7\n",
      "198 8\n",
      "198 9\n",
      "198 10\n",
      "198 11\n",
      "p:  198\n",
      "199 1\n",
      "199 2\n",
      "199 3\n",
      "199 4\n",
      "199 5\n",
      "199 6\n",
      "199 7\n",
      "199 8\n",
      "199 9\n",
      "199 10\n",
      "199 11\n",
      "p:  199\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(days)):\n",
    "    driver.get(days[i])\n",
    "    driver.implicitly_wait(3)\n",
    "    \n",
    "    ch=driver.find_element(By.CLASS_NAME,'internal_moderators')\n",
    "    chai=ch.find_elements(By.TAG_NAME,'li')\n",
    "    cc=[]\n",
    "    for l in range(len(chai)):\n",
    "        cc.append(chai[l].text)\n",
    "    tchairs=[]\n",
    "    country=[]\n",
    "    for n in range(len(cc)):\n",
    "        lc=cc[n].split('(')\n",
    "        tchairs.append(lc[0])\n",
    "        try:\n",
    "            lc[1]=lc[1].replace(')','')\n",
    "            country.append(lc[1])\n",
    "        except:\n",
    "            country.append('')\n",
    "            \n",
    "    for l in range(len(tchairs)):\n",
    "        PERSONS.append(tchairs[l])\n",
    "        COUNTRY.append(country[l])\n",
    "        SESSION.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[1]/h4').text)\n",
    "        SUB_SESSION.append('Introduction')\n",
    "        TIME.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[2]/div[2]').text)\n",
    "        DATE.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[1]/div[2]').text)\n",
    "        ROLE.append('Chair')  \n",
    "        \n",
    "    for j in range(1,20):\n",
    "        try:\n",
    "            driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/h4')\n",
    "            try:\n",
    "                spp=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/div[1]/div[2]/div[2]/ul')\n",
    "                sp=spp.find_elements(By.TAG_NAME,'li')\n",
    "                tsp=[]\n",
    "                for s in range(len(sp)):\n",
    "                    tsp.append(sp[s].text)\n",
    "                speak=[]\n",
    "                place=[]\n",
    "                for m in range(len(tsp)):\n",
    "                    lc=tsp[m].split('(')\n",
    "                    speak.append(lc[0])\n",
    "                    try:\n",
    "                        lc[1]=lc[1].replace(')','')\n",
    "                        place.append(lc[1])\n",
    "                    except:\n",
    "                        place.append('')\n",
    "\n",
    "                for m in range(len(speak)):\n",
    "                    s=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[1]/h4').text\n",
    "                    SESSION.append(s)\n",
    "                    PERSONS.append(speak[m])\n",
    "                    COUNTRY.append(place[m])\n",
    "                    #speakers..............................\n",
    "                    try:\n",
    "                        su=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/h4').text                                        \n",
    "                        SUB_SESSION.append(su)\n",
    "                    except:\n",
    "                        SUB_SESSION.append(None)\n",
    "                    try:\n",
    "                        t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/div[1]/div[3]/div[2]').text\n",
    "                        TIME.append(t)\n",
    "                    except:\n",
    "                        TIME.append(None)\n",
    "                    try:\n",
    "                        d=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[1]/div[2]').text\n",
    "                        DATE.append(d)\n",
    "                    except:\n",
    "                        DATE.append(None)\n",
    "                    ROLE.append('Speaker')\n",
    "                \n",
    "            except:\n",
    "                s=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[1]/h4').text\n",
    "                SESSION.append(s)\n",
    "                PERSONS.append('')\n",
    "                COUNTRY.append('')\n",
    "                ROLE.append('')\n",
    "                #speakers..............................\n",
    "                try:\n",
    "                    su=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/h4').text\n",
    "                    SUB_SESSION.append(su)\n",
    "                except:\n",
    "                    SUB_SESSION.append(None)\n",
    "                try:\n",
    "                    t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/div[1]/div[2]/div[2]').text\n",
    "                    TIME.append(t)\n",
    "                except:\n",
    "                    TIME.append(None)\n",
    "                try:\n",
    "                    d=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[1]/div[2]').text\n",
    "                    DATE.append(d)\n",
    "                except:\n",
    "                    DATE.append(None)\n",
    "            print(i,j)\n",
    "        except:\n",
    "            break\n",
    "    print('p: ',i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "9563380b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Maria Kfoury \n",
      "Teresa M. Amaral \n",
      "Elene Mariamidze \n",
      "\n",
      "Tony S.K. Mok \n",
      "Peter Vuylsteke \n",
      "Marina C. Garassino \n",
      "Alexandra Leary \n",
      "Solange Peters \n",
      "Fabrice André \n",
      "Charles Swanton \n",
      "Amanda Psyrri \n",
      "Karim Fizazi \n",
      "Samra Turajlic \n",
      "Fatima Cardoso \n",
      "Bernard Escudier \n",
      "Solange Peters \n",
      "Clara Montagut Viladot \n",
      "Andrea Sartore Bianchi \n",
      "Clara Montagut Viladot \n",
      "Andrea Sartore Bianchi \n",
      "Rodrigo Dienstmann \n",
      "Guillem Argiles Martinez \n",
      "Myriam Chalabi \n",
      "Andrea Sartore Bianchi \n",
      "\n",
      "Lisa Carey \n",
      "Shaheenah Dawood \n",
      "Stephen Johnston \n",
      "Shanu Modi \n",
      "Lisa Carey \n",
      "All Speakers \n",
      "Peter Schmid \n",
      "Sibylle Loibl \n",
      "Matthew P. Goetz \n",
      "Binghe Xu \n",
      "Hope S. Rugo \n",
      "Meritxell Bellet Ezquerra \n",
      "All Speakers \n",
      "Antonio Marra \n",
      "Laurence Buisseret \n",
      "Peter Schmid \n",
      "All Speakers \n",
      "Elena Castro Marcos \n",
      "Gerhardt Attard \n",
      "Martijn P. Lolkema \n",
      "Himisha Beltran \n",
      "Elena Castro Marcos \n",
      "All Speakers \n",
      "Elizabeth Smyth \n",
      "Lam S. Chan \n",
      "Elizabeth Smyth \n",
      "Jennifer Knox \n",
      "Thierry Conroy \n",
      "All Speakers \n",
      "Elizabeth R. Plimack \n",
      "Enrique Grande \n",
      "Joaquim Bellmunt \n",
      "James Larkin \n",
      "Elizabeth R. Plimack \n",
      "All Speakers \n",
      "Jonathan A. Ledermann \n",
      "Alexandra Leary \n",
      "Isabelle L. Ray-Coquard \n",
      "Paul DiSilvestro \n",
      "Amit M. Oza \n",
      "Jonathan A. Ledermann \n",
      "\n",
      "Jean Emmanuel Kurtz \n",
      "Keiichi Fujiwara \n",
      "Mansoor Raza Mirza \n",
      "All Speakers \n",
      "John B. Haanen \n",
      "Evan J. Lipson \n",
      "Martin H. Schuler \n",
      "Evan J. Lipson \n",
      "All Speakers \n",
      "Andreas Mackensen \n",
      "Omid Hamid \n",
      "David A. Braun \n",
      "All Speakers \n",
      "Timothy A. Yap \n",
      "Violeta Serra \n",
      "Timothy A. Yap \n",
      "Matthew Garnett \n",
      "Violeta Serra \n",
      "Timothy A. Yap \n",
      "Sarah Martin \n",
      "Violeta Serra \n",
      "All Speakers \n",
      "Mariano Provencio Pulla \n",
      "Kersti Oselin \n",
      "Heather Wakelee \n",
      "Mariano Provencio Pulla \n",
      "Sanja Dacic \n",
      "All Speakers \n",
      "Silvia Stacchiotti \n",
      "Herbert Ho Fung Loong \n",
      "Inga-Marie Schaefer \n",
      "Silvia Stacchiotti \n",
      "Hugh Leonard \n",
      "All Speakers \n",
      "Göran Jönsson \n",
      "Sherene Loi \n",
      "Christina Curtis \n",
      "Ruben Casanova \n",
      "Göran Jönsson \n",
      "All Speakers \n",
      "Adil Daud \n",
      "Alessandra Curioni \n",
      "Alessandra Curioni \n",
      "Adil Daud \n",
      "Catherine Sautes-Fridman \n",
      "Kevin R. Litchfield \n",
      "Adil Daud \n",
      "All Speakers \n",
      "Gerard Beets \n",
      "Gunnar Folprecht \n",
      "Gunnar Folprecht \n",
      "Karin M. Haustermans \n",
      "Gerard Beets \n",
      "All Speakers \n",
      "Sapna Patel \n",
      "Teresa Troiani \n",
      "Sapna Patel \n",
      "Jessica C. Hassel \n",
      "Matteo S. Carlino \n",
      "All Speakers \n",
      "Maryam Lustberg \n",
      "Ines Vaz Luis \n",
      "Ines Vaz Luis \n",
      "Maryam Lustberg \n",
      "Olivier Lambotte \n",
      "Ines Vaz Luis \n",
      "Andreas Charalambous \n",
      "All Speakers \n",
      "Maryam Lustberg \n",
      "Giuseppe Minniti \n",
      "Dieta Brandsma \n",
      "Andrew J. Brenner \n",
      "Jian L. Campian \n",
      "Giuseppe Minniti \n",
      "All Speakers \n",
      "Santiago Cabezas-Camarero \n",
      "John F. De Groot \n",
      "Filip Y. De Vos \n",
      "All Speakers \n",
      "Anna Fagotti \n",
      "Jonathan A. Ledermann \n",
      "Maria Kfoury \n",
      "Anna Fagotti \n",
      "All Speakers \n",
      "Maria Kfoury \n",
      "Jonathan A. Ledermann \n",
      "All Speakers \n",
      "Lars Bullinger \n",
      "Lars Bullinger \n",
      "Marius Mayerhoefer \n",
      "Fabrice Jardin \n",
      "Florian Scherer \n",
      "Lars Bullinger \n",
      "\n",
      "Emily Bergsland \n",
      "Halfdan Sorbye \n",
      "Halfdan Sorbye \n",
      "Emily Bergsland \n",
      "Halfdan Sorbye \n",
      "Francesca Demichelis \n",
      "Michael Frumovitz \n",
      "Emily Bergsland \n",
      "All Speakers \n",
      "Christopher A. Curtis \n",
      "Tanja Spanic \n",
      "Mark Lawler \n",
      "Ivica Ratosa \n",
      "Francoise Rimareix \n",
      "Lydia E. Makaroff \n",
      "Christopher A. Curtis \n",
      "All Speakers \n",
      "\n",
      "Natacha Bolanos Fernandez \n",
      "Ananda Plate \n",
      "Bettina Ryll \n",
      "Antonella Cardone \n",
      "Ananda Plate \n",
      "Joanna Fratczak Kazana \n",
      "All Speakers \n",
      "\n",
      "E.G. Elisabeth De Vries \n",
      "Nathan I. Cherny \n",
      "E.G. Elisabeth De Vries \n",
      "Nathan I. Cherny \n",
      "Bishal Gyawali \n",
      "Luís Castelo-Branco \n",
      "E.G. Elisabeth De Vries \n",
      "Stein Kaasa \n",
      "Gudrun M. Kreye \n",
      "Stein Kaasa \n",
      "Gudrun M. Kreye \n",
      "Stein Kaasa \n",
      "Raffaele Giusti \n",
      "All Speakers \n",
      "Stein Kaasa \n",
      "Gudrun M. Kreye \n",
      "Matteo Lambertini \n",
      "Aleix Prat \n",
      "Sofia Braga \n",
      "Elizabeth Connolly \n",
      "Samra Turajlic \n",
      "Alexios Matikas \n",
      "Christoph Benedikt Westphalen \n",
      "Maria Kfoury \n",
      "Natalie Cook \n",
      "Rille Pihlak \n",
      "Maria Elena Elez Fernandez \n",
      "Rodrigo Sanchez Bayona \n",
      "Cesar Serrano \n",
      "Kok Haw Jonathan Lim \n",
      "André Ilbawi \n",
      "Elene Mariamidze \n",
      "Eugenia Trigoso Arjona \n",
      "Nikolina Dodlek \n",
      "Carl Ernst-Guenther \n",
      "André Deschamps \n",
      "Solange Peters \n",
      "Fabrice André \n",
      "Charles Swanton \n",
      "Suzette Delaloge \n",
      "Bernd Kasper \n",
      "Jean-Yves Blay \n",
      "John B. Haanen \n",
      "Ignacio Melero \n",
      "\n",
      "Eva M. Ciruelos \n",
      "Aditya Bardia \n",
      "Eva M. Ciruelos \n",
      "Barbara Pistilli \n",
      "Aditya Bardia \n",
      "Ian Krop \n",
      "Komal Jhaveri \n",
      "Eva M. Ciruelos \n",
      "All Speakers \n",
      "Zofia Piotrowska \n",
      "Jarushka Naidoo \n",
      "Jarushka Naidoo \n",
      "Zofia Piotrowska \n",
      "Antonio Calles Blanco \n",
      "Joop De Langen \n",
      "Rina Hui \n",
      "Zofia Piotrowska \n",
      "All Speakers \n",
      "Ana Oaknin \n",
      "Alexandra Leary \n",
      "Domenica Lorusso \n",
      "Ana Oaknin \n",
      "Eric Pujade-Lauraine \n",
      "All Speakers \n",
      "Sergio Quezada \n",
      "John B. Haanen \n",
      "Sergio Quezada \n",
      "Padmanee Sharma \n",
      "Sebastian Kobold \n",
      "Sergio Quezada \n",
      "Patrick A. Ott \n",
      "Sergio Quezada \n",
      "All Speakers \n",
      "Thomas B. Powles \n",
      "Rana R. McKay \n",
      "Axel Bex \n",
      "Mohamad Allaf \n",
      "Thomas B. Powles \n",
      "All Speakers \n",
      "Enrique Grande Pulido \n",
      "Thomas B. Powles \n",
      "Rana R. McKay \n",
      "\n",
      "Fabrice André \n",
      "Fabrice André \n",
      "Deborah Schrag \n",
      "Angela Lamarca \n",
      "Lam S. Chan \n",
      "Richard S. Finn \n",
      "Shukui Qin \n",
      "Robin Katie Kelley \n",
      "All Speakers \n",
      "Masatoshi Kudo \n",
      "Lam S. Chan \n",
      "All Speakers \n",
      "Angela Lamarca \n",
      "Arndt Vogel \n",
      "Angela Lamarca \n",
      "Francesco Facchinetti \n",
      "Maeve Lowery \n",
      "Arndt Vogel \n",
      "Eileen O'Reilly \n",
      "Arndt Vogel \n",
      "All Speakers \n",
      "Robert A. Huddart \n",
      "Andre P. Fay \n",
      "Robert A. Huddart \n",
      "Bradley McGregor \n",
      "Sylvie Negrier \n",
      "Shankar Siva \n",
      "All Speakers \n",
      "Evandro De Azambuja \n",
      "Nadia Harbeck \n",
      "Aleix Prat \n",
      "Nadia Harbeck \n",
      "Evandro De Azambuja \n",
      "All Speakers \n",
      "Susana Banerjee \n",
      "Iain McNeish \n",
      "Robert L. Coleman \n",
      "Ana Oaknin \n",
      "Sungjong Lee \n",
      "Ana Oaknin \n",
      "Robert L. Coleman \n",
      "Rebecca Kristeleit \n",
      "Qinglei Gao \n",
      "Susana Banerjee \n",
      "David O'Malley \n",
      "Domenica Lorusso \n",
      "Iain McNeish \n",
      "Peter Dubsky \n",
      "Ana Bosch \n",
      "Vivianne C. Tjan-Heijnen \n",
      "Marleen Kok \n",
      "Lucia Del Mastro \n",
      "All Speakers \n",
      "Oleg Gluz \n",
      "Lucia Del Mastro \n",
      "Peter Dubsky \n",
      "All Speakers \n",
      "Shaheenah Dawood \n",
      "Sung-Bae Kim \n",
      "Shom Goel \n",
      "Fabrice André \n",
      "Binghe Xu \n",
      "Sung-Bae Kim \n",
      "Matthew P. Goetz \n",
      "Miguel Martin Jimenez \n",
      "Sara M. Tolaney \n",
      "Shaheenah Dawood \n",
      "Monica Arnedos \n",
      "Frederik Marmé \n",
      "Jon Amund Kyte \n",
      "Elisabetta Munzone \n",
      "Shom Goel \n",
      "Marleen Kok \n",
      "Marleen Kok \n",
      "All Speakers \n",
      "Christian H. Ottensmeier \n",
      "Christophe Le Tourneau \n",
      "\n",
      "\n",
      "Caroline Robert \n",
      "Dirk Schadendorf \n",
      "Caroline Robert \n",
      "Celine Vallot \n",
      "Alpaslan Tasdogan \n",
      "Ben Raphael \n",
      "Caroline Robert \n",
      "Dirk Schadendorf \n",
      "\n",
      "Caroline Robert \n",
      "Ryan J. Sullivan \n",
      "Dirk Schadendorf \n",
      "Reinhard Dummer \n",
      "Caroline Robert \n",
      "\n",
      "Celeste Lebbe \n",
      "Adi Diab \n",
      "Olivier A. Michielin \n",
      "\n",
      "Alfredo Berruti \n",
      "Alfredo Berruti \n",
      "Andrea Frilling \n",
      "Eric Baudin \n",
      "Matthias Kroiss \n",
      "All Speakers \n",
      "Ana Martins Ferreira Varges Gomes \n",
      "Sandra Schmitz \n",
      "Sjoukje Oosting \n",
      "Jolie Ringash \n",
      "Aarti Bhatia \n",
      "Charlotte Lafont \n",
      "Sjoukje Oosting \n",
      "Denis Soulieres \n",
      "Makoto Tahara \n",
      "Jean Bourhis \n",
      "Ana Martins Ferreira Varges Gomes \n",
      "Abirami Sivapiragasam \n",
      "Kenneth J. O'Byrne \n",
      "Panagiota Economopoulou \n",
      "Sandra Schmitz \n",
      "Cornelis J. Punt \n",
      "Diane Goéré \n",
      "Cornelis J. Punt \n",
      "Breelyn A. Wilky \n",
      "Paul Huang \n",
      "Breelyn A. Wilky \n",
      "Paul Huang \n",
      "Fernanda Amary \n",
      "Antoine Italiano \n",
      "Breelyn A. Wilky \n",
      "Paul Huang \n",
      "All Speakers \n",
      "Cora N. Sternberg \n",
      "Ronald De Wit \n",
      "Cora N. Sternberg \n",
      "Pieter Wesseling \n",
      "Enrico Franceschi \n",
      "Pieter Wesseling \n",
      "Carmen Balana \n",
      "Marion Smits \n",
      "All Speakers \n",
      "Eric Deutsch \n",
      "Eric Deutsch \n",
      "Samra Turajlic \n",
      "Emiliano Calvo \n",
      "All Speakers \n",
      "Antonio Di Meglio \n",
      "Gudrun M. Kreye \n",
      "Maryam Lustberg \n",
      "Juhee Cho \n",
      "Maike Sweegers \n",
      "Jana Müller \n",
      "Antonio Di Meglio \n",
      "Gry Assam Taarnhøj \n",
      "Mariane S. Dias \n",
      "Maria Alice Franzoi \n",
      "Maryam Lustberg \n",
      "Emanuela Romano \n",
      "Roman O. Kowalchuk \n",
      "Victoria Depoorter \n",
      "Gudrun M. Kreye \n",
      "Tony S.K. Mok \n",
      "Solange Peters \n",
      "Tony S.K. Mok \n",
      "Matteo Lambertini \n",
      "Matteo Lambertini \n",
      "Matteo Lambertini \n",
      "Sharon Bober \n",
      "Isabelle Demeestere \n",
      "\n",
      "Vivek Subbiah \n",
      "Javier Hernandez-Losa \n",
      "Javier Hernandez-Losa \n",
      "Vivek Subbiah \n",
      "Christoph Benedikt Westphalen \n",
      "Javier Hernandez-Losa \n",
      "Oliver Gautschi \n",
      "\n",
      "Vivek Subbiah \n",
      "Myung-Ju Ahn \n",
      "Myung-Ju Ahn \n",
      "Myung-Ju Ahn \n",
      "Suresh Senan \n",
      "Eric Lim \n",
      "\n",
      "Hanneke W. Van Laarhoven \n",
      "Hanneke W. Van Laarhoven \n",
      "Richard Van Hillegersberg \n",
      "Maria A. Hawkins \n",
      "Sylvie Lorenzen \n",
      "\n",
      "Giovanni Boniolo \n",
      "Nathan I. Cherny \n",
      "Giovanni Boniolo \n",
      "Alexander E. Drilon \n",
      "Shivaani Kummar \n",
      "Aaron Scott \n",
      "Patrick Schoeffski \n",
      "Toshihiko Doi \n",
      "Philippe A. Cassier \n",
      "All Speakers \n",
      "Anthony W. Tolcher \n",
      "Christina Guo \n",
      "Chia-Chi Lin \n",
      "All Speakers \n",
      "Inge-Marie Svane \n",
      "Alessandra Curioni \n",
      "Ignacio Melero \n",
      "Martin Gutierrez \n",
      "Glenn J. Hanna \n",
      "Inge-Marie Svane \n",
      "Stephane Champiat \n",
      "Joris Van De Haar \n",
      "Benjamin P. Fairfax \n",
      "Sebastian Kobold \n",
      "David S Hong \n",
      "Chrisann K. Kyi \n",
      "Weijia Fang \n",
      "Alessandra Curioni \n",
      "Ben J. Solomon \n",
      "Julian Downward \n",
      "Ben J. Solomon \n",
      "Catherine Thieblemont \n",
      "Thomas Cluzeau \n",
      "Chunkang Chang \n",
      "Thomas Cluzeau \n",
      "\n",
      "Yuan-Kai Shi \n",
      "Hong Cen \n",
      "Matthew Frigault \n",
      "Catherine Thieblemont \n",
      "All Speakers \n",
      "Armelle Dufresne \n",
      "Alessandro Gronchi \n",
      "Armelle Dufresne \n",
      "Breelyn A. Wilky \n",
      "Tom Wei-Wu Chen \n",
      "Hiroaki Hiraga \n",
      "Erlinda Gordon \n",
      "Kjetil Boye \n",
      "All Speakers \n",
      "Jeremy SMADJA \n",
      "Raul Perret \n",
      "Jakob N. Kather \n",
      "All Speakers \n",
      "Maeve Lowery \n",
      "Florian Lordick \n",
      "Teresa Macarulla Mercade \n",
      "Liwei Wang \n",
      "Michel P. Ducreux \n",
      "Teresa Macarulla Mercade \n",
      "Arndt Vogel \n",
      "Arndt Vogel \n",
      "Angela Lamarca \n",
      "Maeve Lowery \n",
      "David Tougeron \n",
      "Geoffrey Y. Ku \n",
      "Florian Lordick \n",
      "E.G. Elisabeth De Vries \n",
      "Dario Trapani \n",
      "E.G. Elisabeth De Vries \n",
      "Dario Trapani \n",
      "Panagiotis Kanavos \n",
      "Kiusiang Tay-Teo \n",
      "Bettina Ryll \n",
      "E.G. Elisabeth De Vries \n",
      "\n",
      "Joaquin Mateo \n",
      "Christoph Benedikt Westphalen \n",
      "Christoph Benedikt Westphalen \n",
      "Joaquin Mateo \n",
      "Arnaud Bayle \n",
      "Denis Horgan \n",
      "Joaquin Mateo \n",
      "\n",
      "Gilliosa Spurrier-Bernard \n",
      "Jana Pelouchova \n",
      "Winette T. Van Der Graaf \n",
      "Ellen Verschuur-van der Voort \n",
      "Tom Willgoss \n",
      "Gilliosa Spurrier-Bernard \n",
      "Estelle Lacointe Artzner \n",
      "\n",
      "\n",
      "Ravindran Kanesvaran \n",
      "Christophe Massard \n",
      "Sahar Van Waalwijk van Doorn-Khosrovani \n",
      "Justin T. Moyers \n",
      "Panagiotis Kanavos \n",
      "\n",
      "Anne H. Ree \n",
      "Kjetil Tasken \n",
      "Jean-Yves Blay \n",
      "Christophe Massard \n",
      "\n",
      "Tanja Spanic \n",
      "Vlad V. Voiculescu \n",
      "Andrew Hyde \n",
      "Guendalina Graffigna \n",
      "Alex King \n",
      "Luzia Travado \n",
      "Kathy R. Oliver \n",
      "\n",
      "\n",
      "Fiona Blackhall \n",
      "Lauren Byers \n",
      "Fiona Blackhall \n",
      "Lauren Byers \n",
      "Fiona Blackhall \n",
      "Bjorn Henning Gronberg \n",
      "Taofeek K. Owonikoko \n",
      "Lauren Byers \n",
      "\n",
      "Hendrik K. Van Halteren \n",
      "Michiel H. Strijbos \n",
      "Hendrik K. Van Halteren \n",
      "Dario Trapani \n",
      "Michiel H. Strijbos \n",
      "Albrecht Stenzinger \n",
      "Tanja Spanic \n",
      "Hendrik K. Van Halteren \n",
      "\n",
      "Alice Indini \n",
      "Michiel H. Strijbos \n",
      "Michiel H. Strijbos \n",
      "Giancarlo Pruneri \n",
      "Anna M. Czarnecka \n",
      "Antoine Italiano \n",
      "Alice Indini \n",
      "\n",
      "Enrico Franceschi \n",
      "Patrick Roth \n",
      "Monika E. Hegi \n",
      "Angelika M. Starzer \n",
      "Olav E. Yri \n",
      "Isabella C. Glitza \n",
      "Enrico Franceschi \n",
      "Gaetano Finocchiaro \n",
      "Tobias Weiss \n",
      "Maximilian J. Mair \n",
      "Monika E. Hegi \n",
      "Nader Sanai \n",
      "Ariane Steindl \n",
      "Marta Padovan \n",
      "Patrick Roth \n",
      "Kok Haw Jonathan Lim \n",
      "Pawel Sobczuk \n",
      "Aurélien Marabelle \n",
      "Alfredo Addeo \n",
      "\n",
      "Ahmad H. Awada \n",
      "Jorge Barriuso \n",
      "\n",
      "Claudia Cardone \n",
      "Massimo Di Maio \n",
      "Claudia Cardone \n",
      "Johan De Munter \n",
      "Johan De Munter \n",
      "Pascale Dielenseger \n",
      "Carolina Espina \n",
      "Lesley J. Fallowfield \n",
      "Martin Inderbitzin \n",
      "Johan De Munter \n",
      "\n",
      "Amanda Drury \n",
      "Lena Sharp \n",
      "Marianne Himberg \n",
      "Emily O'Donovan \n",
      "Julie Malo \n",
      "Raquel M. Legido-Diaz \n",
      "Ümran Ege Tanrıkulu \n",
      "Nikolina Dodlek \n",
      "\n",
      "Theresa Wiseman \n",
      "Theresa Wiseman \n",
      "Theresa Wiseman \n",
      "Amanda Shewbridge \n",
      "Theresa Wiseman \n",
      "Merel Van Klinken \n",
      "Elizabeth Wiseman \n",
      "Celia Díez de los Ríos de la Serna \n",
      "Amanda Shewbridge \n",
      "Merel Van Klinken \n",
      "Theresa Wiseman \n",
      "Celia Díez de los Ríos de la Serna \n",
      "Amanda Shewbridge \n",
      "Theresa Wiseman \n",
      "Wendy H. Oldenmenger \n",
      "Andreas Charalambous \n",
      "Catherine Oakley \n",
      "Nicole E. Billingy \n",
      "Leanna Goodwin \n",
      "\n",
      "Johan De Munter \n",
      "Johan De Munter \n",
      "Sylvie Rottey \n",
      "Maaike De Ruijter \n",
      "Matthias B. Hellberg-Nägele \n",
      "Johan De Munter \n",
      "Mary A. Tanay \n",
      "Elaine Tomlins \n",
      "Grigorios Kotronoulas \n",
      "Lucy Matthews \n",
      "Vanessa Boland \n",
      "\n",
      "Andres Cervantes \n",
      "Pawel Sobczuk \n",
      "Kok Haw Jonathan Lim \n",
      "Pawel Sobczuk \n",
      "Rodrigo Sanchez Bayona \n",
      "Elizabeth Connolly \n",
      "Maria Kfoury \n",
      "Karin Jordan \n",
      "Florian Lordick \n",
      "Robert J. Motzer \n",
      "Jean-Pascal Machiels \n",
      "Sapna Patel \n",
      "Myriam Chalabi \n",
      "Sherene Loi \n",
      "James Larkin \n",
      "All Speakers \n",
      "Elena Castro Marcos \n",
      "Karim Fizazi \n",
      "Gerhardt Attard \n",
      "Marina Parry \n",
      "Elena Castro Marcos \n",
      "All Speakers \n",
      "Fred Saad \n",
      "Rahul Aggarwal \n",
      "Johann S. De Bono \n",
      "\n",
      "Andrea Cercek \n",
      "Marco Gerlinger \n",
      "Marinde J. Bond \n",
      "Armando Orlandi \n",
      "Julien Taieb \n",
      "All Speakers \n",
      "Alvaro Arjona-Sanchez \n",
      "Julien Taieb \n",
      "Andrea Cercek \n",
      "All Speakers \n",
      "Helena A. Yu \n",
      "Rina Hui \n",
      "Jordi Remon Masip \n",
      "Julien Mazieres \n",
      "Zofia Piotrowska \n",
      "Helena A. Yu \n",
      "\n",
      "Mustafa Ozguroglu \n",
      "Gerard Zalcman \n",
      "Martin Reck \n",
      "All Speakers \n",
      "Nicolas Girard \n",
      "Noemi Reguart Aransay \n",
      "Masahiro Tsuboi \n",
      "Wenhua Liang \n",
      "Sanjay Popat \n",
      "All Speakers \n",
      "Idris Bahce \n",
      "Edward B. Garon \n",
      "Noemi Reguart Aransay \n",
      "All Speakers \n",
      "Daniel Y. Heng \n",
      "Cristina Suarez Rodriguez \n",
      "Sumanta K. Pal \n",
      "Gabriel Malouf \n",
      "Daniel Y. Heng \n",
      "All Speakers \n",
      "Sherene Loi \n",
      "Sherene Loi \n",
      "John B. Haanen \n",
      "Ton N. Schumacher \n",
      "Ian Chau \n",
      "Hanneke W. Van Laarhoven \n",
      "Sylvie Lorenzen \n",
      "Ian Chau \n",
      "\n",
      "Christelle De la Fouchardiere \n",
      "Hanneke Wilmink \n",
      "\n",
      "Antoine Hollebecque \n",
      "Chiara Braconi \n",
      "\n",
      "Rafal Dziadziuszko \n",
      "Rafal Dziadziuszko \n",
      "Matthias Guckenberger \n",
      "Lizza Hendriks \n",
      "Priscilla Brastianos \n",
      "All Speakers \n",
      "Giuseppe Curigliano \n",
      "Emanuela Romano \n",
      "Carmine Valenza \n",
      "Giuseppe Curigliano \n",
      "All Speakers \n",
      "Rille Pihlak \n",
      "Alwin Krämer \n",
      "All Speakers \n",
      "Elene Mariamidze \n",
      "Arndt Vogel \n",
      "All Speakers \n",
      "Giuseppe Curigliano \n",
      "Emanuela Romano \n",
      "Christoph Oing \n",
      "Thomas B. Powles \n",
      "\n",
      "Daniela Alves \n",
      "Andres J. Ferreri \n",
      "\n",
      "Laura Mezquita \n",
      "Lizza Hendriks \n",
      "All Speakers \n",
      "Ingeborg Tinhofer-Keilholz \n",
      "Lillian L. Siu \n",
      "Lillian L. Siu \n",
      "Ingeborg Tinhofer-Keilholz \n",
      "Rachel Galot \n",
      "Christophe Le Tourneau \n",
      "Ezra E. Cohen \n",
      "Ingeborg Tinhofer-Keilholz \n",
      "All Speakers \n",
      "Carsten Denkert \n",
      "Barbara Pistilli \n",
      "Barbara Pistilli \n",
      "Carsten Denkert \n",
      "Caterina Marchiò \n",
      "Sherene Loi \n",
      "Nick Turner \n",
      "Carsten Denkert \n",
      "All Speakers \n",
      "Stephanie Lheureux \n",
      "Clare L. Scott \n",
      "Clare L. Scott \n",
      "Iain McNeish \n",
      "Stephanie Lheureux \n",
      "Charlie Gourley \n",
      "Isabelle L. Ray-Coquard \n",
      "Stephanie Lheureux \n",
      "All Speakers \n",
      "Robin Katie Kelley \n",
      "Alejandro Forner \n",
      "Robin Katie Kelley \n",
      "Laura Mezquita \n",
      "Tony S.K. Mok \n",
      "Mary E. O'Brien \n",
      "Koichi Goto \n",
      "Myung-Ju Ahn \n",
      "Laura Mezquita \n",
      "Baohui Han \n",
      "Shun Lu \n",
      "Tony S.K. Mok \n",
      "Melissa L. Johnson \n",
      "Marina C. Garassino \n",
      "Silvia Novello \n",
      "Mary E. O'Brien \n",
      "Reinhard Dummer \n",
      "Ulrike Leiter-Stoppke \n",
      "Ulrike Leiter-Stoppke \n",
      "Reinhard Dummer \n",
      "Paolo A. Ascierto \n",
      "All Speakers \n",
      "Masahiro Tsuboi \n",
      "Masahiro Tsuboi \n",
      "All Speakers \n",
      "Jonathan Spicer \n",
      "Suresh Senan \n",
      "All Speakers \n",
      "\n",
      "Sandra Demaria \n",
      "Christian H. Ottensmeier \n",
      "Sandra Demaria \n",
      "Davide Bedognetti \n",
      "John Stagg \n",
      "Sandra Demaria \n",
      "All Speakers \n",
      "All Speakers \n",
      "Susan Chang \n",
      "Anna Sophie S. Berghoff \n",
      "Anna Sophie S. Berghoff \n",
      "Susan Chang \n",
      "Ahmed IdBaih \n",
      "Paul Mischel \n",
      "Anna Sophie S. Berghoff \n",
      "Susan Chang \n",
      "All Speakers \n",
      "Sarah-Jane Dawson \n",
      "Marleen Kok \n",
      "John Stagg \n",
      "Maria Fernanda Mosele \n",
      "Lorena Incorvaia \n",
      "Miriam Hägele \n",
      "François-Xavier DANLOS \n",
      "Marleen Kok \n",
      "Rebecca C. Simpson \n",
      "Meriem Messaoudene \n",
      "John Stagg \n",
      "Wenhua Liang \n",
      "Eric Y. Zhao \n",
      "Felix Feng \n",
      "Sarah-Jane Dawson \n",
      "Karen Steindorf \n",
      "Florian Scotté \n",
      "Karen Steindorf \n",
      "Jann Arends \n",
      "David Hui \n",
      "All Speakers \n",
      "Ines Vaz Luis \n",
      "Ann Partridge \n",
      "Ines Vaz Luis \n",
      "Sandra Schmitz \n",
      "Sandra Schmitz \n",
      "All Speakers \n",
      "Ezra E. Cohen \n",
      "Christian Simon \n",
      "All Speakers \n",
      "\n",
      "Aly-Khan Lalani \n",
      "Kate Young \n",
      "Joaquim Bellmunt \n",
      "Camillo Guglielmo Porta \n",
      "Marc-Oliver Grimm \n",
      "Kate Young \n",
      "Sebastian C. Schmid \n",
      "Nicholas D. James \n",
      "Tim A. Smith \n",
      "Joaquim Bellmunt \n",
      "Jad Chahoud \n",
      "Silke Gillessen \n",
      "Anna K. Jansson \n",
      "Aly-Khan Lalani \n",
      "Philipp Harter \n",
      "Antonio Jose Gonzalez Martin \n",
      "Vicky Makker \n",
      "David Cibula \n",
      "Philipp Harter \n",
      "Rebecca Kristeleit \n",
      "Gauduchon Thibault \n",
      "Susana Banerjee \n",
      "Antonio Jose Gonzalez Martin \n",
      "Carol Moreno \n",
      "Clemens-Martin Wendtner \n",
      "Carol Moreno \n",
      "Rosa Giuliani \n",
      "Lena Sharp \n",
      "Rosa Giuliani \n",
      "Lena Sharp \n",
      "John F. Ryan \n",
      "Rosa Giuliani \n",
      "Lena Sharp \n",
      "Francesco De Lorenzo \n",
      "\n",
      "Rosa Giuliani \n",
      "Lena Sharp \n",
      "Solange Peters \n",
      "Eric Winer \n",
      "Solange Peters \n",
      "Jeremy Warner \n",
      "Francesco Pignatti \n",
      "Judith Bliss \n",
      "Ann Partridge \n",
      "Miriam Koopman \n",
      "Pasi A. Jänne \n",
      "Frederik Marmé \n",
      "David SP Tan \n",
      "Frederik Marmé \n",
      "Shivaani Kummar \n",
      "Chia-Chi Lin \n",
      "Shivaani Kummar \n",
      "Mariano Barbacid \n",
      "Sophie Postel-Vinay \n",
      "Georg Winter \n",
      "Shivaani Kummar \n",
      "Chia-Chi Lin \n",
      "All Speakers \n",
      "Toni K. Choueiri \n",
      "Camillo Guglielmo Porta \n",
      "Toni K. Choueiri \n",
      "Viktor Gruenwald \n",
      "Toni K. Choueiri \n",
      "Camillo Guglielmo Porta \n",
      "Cristina Suarez Rodriguez \n",
      "All Speakers \n",
      "Camillo Guglielmo Porta \n",
      "Keith D. Hunter \n",
      "Lisa F. Licitra \n",
      "Keith D. Hunter \n",
      "Carla Van Herpen \n",
      "Paolo Bossi \n",
      "All Speakers \n",
      "Federica Di Nicolantonio \n",
      "Sandra Demaria \n",
      "Deborah Schrag \n",
      "Haiying Cheng \n",
      "Claire F. Friedman \n",
      "Federica Di Nicolantonio \n",
      "\n",
      "Joleen J. Traets \n",
      "Lilie L. Lin \n",
      "Sandra Demaria \n",
      "All Speakers \n",
      "Anja Lorch \n",
      "Giulia Baciarello \n",
      "Anja Lorch \n",
      "Boris A. Hadaschik \n",
      "Martijn P. Lolkema \n",
      "Nicolas Mottet \n",
      "Karim Fizazi \n",
      "Sarah Burdett \n",
      "Nicolas Mottet \n",
      "Áine M. Haran \n",
      "Gwenaëlle Gravis Mescam \n",
      "Boris A. Hadaschik \n",
      "Christian A. Rothermundt \n",
      "Evan Y. Yu \n",
      "Stephane Oudard \n",
      "Karim Fizazi \n",
      "Martijn P. Lolkema \n",
      "Lakshmi Nayak \n",
      "Martin Van den Bent \n",
      "Lakshmi Nayak \n",
      "Evangelos Terpos \n",
      "Evangelos Terpos \n",
      "Katja Weisel \n",
      "Evangelos Terpos \n",
      "All Speakers \n",
      "George Pentheroudakis \n",
      "Christopher J. Twelves \n",
      "Kamal S. Saini \n",
      "Jordi Remon Masip \n",
      "Christopher J. Twelves \n",
      "Vassilis Golfinopoulos \n",
      "Olli Tenhunen \n",
      "All Speakers \n",
      "All Speakers \n",
      "Sabine Oertelt-Prigione \n",
      "Anna D. Wagner \n",
      "Isabelle Soerjomataram \n",
      "Hermann Brenner \n",
      "Enriqueta Felip \n",
      "Sabine Oertelt-Prigione \n",
      "All Speakers \n",
      "Martine Piccart \n",
      "Priscilla Brastianos \n",
      "Nancy Lin \n",
      "Martine Piccart \n",
      "Rudolf S. Fehrmann \n",
      "Nathalie Lassau \n",
      "Jakob N. Kather \n",
      "Nathalie Lassau \n",
      "Eliahu Golomb \n",
      "Jorge S. Reis-Filho \n",
      "Rudolf S. Fehrmann \n",
      "All Speakers \n",
      "Inga-Marie Schaefer \n",
      "Inga-Marie Schaefer \n",
      "Sylvie Bonvalot \n",
      "Rick L. Haas \n",
      "Dario Callegaro \n",
      "\n",
      "Christopher A. Curtis \n",
      "Natacha Bolanos Fernandez \n",
      "Natacha Bolanos Fernandez \n",
      "Kate Washington \n",
      "Fatima Cardoso \n",
      "Lena Sharp \n",
      "Gabriella Pravettoni \n",
      "\n",
      "All Speakers \n",
      "Ron H. Mathijssen \n",
      "Emiliano Calvo \n",
      "Emiliano Calvo \n",
      "Nielka Van Erp \n",
      "Joseph Ciccolini \n",
      "Caroline Samer \n",
      "Stijn L. Koolen \n",
      "Emiliano Calvo \n",
      "Ron H. Mathijssen \n",
      "Ravindran Kanesvaran \n",
      "Rosa Giuliani \n",
      "Ravindran Kanesvaran \n",
      "Felipe S. Roitberg \n",
      "Paolo G. Casali \n",
      "Marina C. Garassino \n",
      "Ravindran Kanesvaran \n",
      "Rosa Giuliani \n",
      "All Speakers \n",
      "Petra Adamkova \n",
      "Joanna Fratczak Kazana \n",
      "Joanna Fratczak Kazana \n",
      "Petra Adamkova \n",
      "André Deschamps \n",
      "Aleksandra Kuna \n",
      "Joanna Fratczak Kazana \n",
      "Jana Pelouchova \n",
      "\n",
      "Karin Jordan \n",
      "Matteo Lambertini \n",
      "Rayan Kabirian \n",
      "Eric J. Roeland \n",
      "Karin Jordan \n",
      "All Speakers \n",
      "Laura Michel \n",
      "Aditya Bardia \n",
      "Naoto T. Ueno \n",
      "Galina Velikova \n",
      "All Speakers \n",
      "Eva Tiensuu Janson \n",
      "Nicola Fazio \n",
      "Eva Tiensuu Janson \n",
      "Marianne E. Pavel \n",
      "Nicola Fazio \n",
      "All Speakers \n",
      "Cathy Smith \n",
      "Pilar Garrido Lopez \n",
      "Cathy Smith \n",
      "Stella Kyriakides \n",
      "Pilar Garrido Lopez \n",
      "Helena Linardou \n",
      "Pilar Garrido Lopez \n",
      "Andres Cervantes \n",
      "Cathy Smith \n",
      "Elene Mariamidze \n",
      "Teresa M. Amaral \n",
      "Evandro De Azambuja \n",
      "Evandro De Azambuja \n",
      "Angela Lamarca \n",
      "Eleonora Ghisoni \n",
      "Benedetta Pellegrino \n",
      "Teresa M. Amaral \n",
      "Evandro De Azambuja \n",
      "Teresa M. Amaral \n",
      "Matteo Lambertini \n",
      "Pilar Garrido Lopez \n",
      "Matteo Lambertini \n",
      "Teresa M. Amaral \n",
      "Anna Sophie S. Berghoff \n",
      "Nadia Harbeck \n",
      "All Speakers \n",
      "Elena Garralda \n",
      "All Speakers \n",
      "\n",
      "Carlos A. Gomez-Roca \n",
      "All Speakers \n",
      "Francesco Pignatti \n",
      "\n",
      "Gianluca Catania \n",
      "Matthew N. Fowler \n",
      "Mark R. Foulkes \n",
      "Helena Ullgren \n",
      "Fiona E. Barrett \n",
      "Karen Campbell \n",
      "Susanne Wallberg \n",
      "LACE MATARLO SOLVEBRAND \n",
      "\n",
      "Merel Van Klinken \n",
      "Gulcan Bagcivan \n",
      "Wendy H. Oldenmenger \n",
      "Cherith J. Semple \n",
      "Grigorios Kotronoulas \n",
      "Jeffrey R. Hanna \n",
      "STYLIANOS KATSARAGAKIS \n",
      "Andreja Sajnic \n",
      "\n",
      "Nikolina Dodlek \n",
      "Nikolina Dodlek \n",
      "Giannos Toumbis \n",
      "Lavinia Magee \n",
      "Jasminka Miličević \n",
      "Nikolina Dodlek \n",
      "Johan De Munter \n",
      "Wendy McInally \n",
      "Jack Brodie \n",
      "Rejin Kebudi \n",
      "All Speakers \n",
      "Silvija Piskorjanac \n",
      "Silvija Piskorjanac \n",
      "Sandra Karabatic \n",
      "Silvija Piskorjanac \n",
      "Karen J. Clayton \n",
      "Joanna Vick \n",
      "Silvija Piskorjanac \n",
      "Remziye Semerci \n",
      "Lorraine Grover \n",
      "Daren Chircop \n",
      "Celia Díez de los Ríos de la Serna \n",
      "Malin Backman \n",
      "Suriya Kirkpatrick \n",
      "Amanda Drury \n",
      "Eva Pape \n",
      "\n",
      "Andres Cervantes \n",
      "Charles Swanton \n",
      "Toni K. Choueiri \n",
      "Sumanta K. Pal \n",
      "Chris C. Parker \n",
      "Silke Gillessen \n",
      "Melissa L. Johnson \n",
      "Siow Ming Lee \n",
      "Natasha Leighl \n",
      "All Speakers \n",
      "Shahneen K. Sandhu \n",
      "Boris A. Hadaschik \n",
      "Boris A. Hadaschik \n",
      "Neil Bander \n",
      "Daniela Oprea-Lager \n",
      "Shahneen K. Sandhu \n",
      "Karim Fizazi \n",
      "Boris A. Hadaschik \n",
      "All Speakers \n",
      "Natasha Leighl \n",
      "Pasi A. Jänne \n",
      "Luis Paz-Ares \n",
      "Natasha Leighl \n",
      "Martin Reck \n",
      "All Speakers \n",
      "Pasi A. Jänne \n",
      "Pasi A. Jänne \n",
      "Alexander M. Frankell \n",
      "Maximilian Diehn \n",
      "Solange Peters \n",
      "Pasi A. Jänne \n",
      "All Speakers \n",
      "Chiara Cremolini \n",
      "Pieter Tanis \n",
      "Chiara Cremolini \n",
      "Pieter Tanis \n",
      "Timothy J. Price \n",
      "All Speakers \n",
      "Florian Lordick \n",
      "Florian Lordick \n",
      "Nicole Van Grieken \n",
      "Kohei Shitara \n",
      "Valentina Gambardella \n",
      "Florian Lordick \n",
      "All Speakers \n",
      "All Speakers \n",
      "Charles Swanton \n",
      "Charles Swanton \n",
      "Judy Garber \n",
      "Inge-Marie Svane \n",
      "John B. Haanen \n",
      "Inge-Marie Svane \n",
      "Concetta Quintarelli \n",
      "Ulrike Kohl \n",
      "All Speakers \n",
      "Jarushka Naidoo \n",
      "Erica Mayer \n",
      "Erica Mayer \n",
      "Jarushka Naidoo \n",
      "Jean Baptiste Micol \n",
      "Erica Mayer \n",
      "Claire Roddie \n",
      "All Speakers \n",
      "Prudence Francis \n",
      "Luca Malorni \n",
      "Aleix Prat \n",
      "Rebecca A. Dent \n",
      "Andrea Joaquin Garcia \n",
      "Rajendra A. Badwe \n",
      "Prudence Francis \n",
      "Mattia Rediti \n",
      "Valentina Guarneri \n",
      "Luca Malorni \n",
      "John M. Bartlett \n",
      "Isabel Echavarria Diaz-Guardamino \n",
      "Aleix Prat \n",
      "Reinhard Dummer \n",
      "Teresa Petrella \n",
      "Reinhard Dummer \n",
      "Georgina V. Long \n",
      "Sapna Patel \n",
      "All Speakers \n",
      "Jürgen C Becker \n",
      "Neil Gross \n",
      "Christian U. Blank \n",
      "All Speakers \n",
      "Andre P. Fay \n",
      "Laurence Albiges \n",
      "Nizar Tannir \n",
      "Jonathan E. Rosenberg \n",
      "Laurence Albiges \n",
      "All Speakers \n",
      "Jaime Merchan \n",
      "Laurence Albiges \n",
      "Andre P. Fay \n",
      "All Speakers \n",
      "Ines Vaz Luis \n",
      "Justin Jeon \n",
      "Ines Vaz Luis \n",
      "Mariam Jamal-Hanjani \n",
      "Justin Jeon \n",
      "Julienne Bower \n",
      "Etienne Minvielle \n",
      "Justin Jeon \n",
      "All Speakers \n",
      "Matteo Lambertini \n",
      "Matteo Lambertini \n",
      "Kevin Punie \n",
      "Shani Paluch-Shimon \n",
      "Peter Dubsky \n",
      "All Speakers \n",
      "Brigette B. Ma \n",
      "Paolo Bossi \n",
      "Glenn J. Hanna \n",
      "Marcin R. Dzienis \n",
      "Amanda Psyrri \n",
      "All Speakers \n",
      "Han Chong Toh \n",
      "Haitham Mirghani \n",
      "Lisa F. Licitra \n",
      "All Speakers \n",
      "Teresa M. Amaral \n",
      "Omid Hamid \n",
      "Paolo A. Ascierto \n",
      "Sungjune Kim \n",
      "Omid Hamid \n",
      "Teresa M. Amaral \n",
      "Judith M. Versluis \n",
      "Jessica C. Notohardjo \n",
      "Alexander M. Eggermont \n",
      "Michael Lowe \n",
      "Omid Hamid \n",
      "Myriam Chalabi \n",
      "Filippo Pietrantonio \n",
      "Samuel J. Klempner \n",
      "Yasutoshi Kuboki \n",
      "Maria Elena Elez Fernandez \n",
      "All Speakers \n",
      "N. Arvind Dasari \n",
      "Scott Kopetz \n",
      "Filippo Pietrantonio \n",
      "All Speakers \n",
      "Elizabeth Smyth \n",
      "Elizabeth Smyth \n",
      "All Speakers \n",
      "Yelena Y. Janjigian \n",
      "Raghav Sundar \n",
      "All Speakers \n",
      "All Speakers \n",
      "Jennifer A. Wargo \n",
      "Eran Elinav \n",
      "Jennifer A. Wargo \n",
      "Andres Acosta \n",
      "Debbie Robbrecht \n",
      "Debbie Robbrecht \n",
      "Andres Acosta \n",
      "Lars Dyrskjot \n",
      "E.G. Elisabeth De Vries \n",
      "Lisa Derosa \n",
      "Andres Acosta \n",
      "All Speakers \n",
      "Nicholas D. James \n",
      "Nicholas D. James \n",
      "Boris A. Hadaschik \n",
      "Piet Ost \n",
      "Silke Gillessen \n",
      "All Speakers \n",
      "Guillermo Antonio De Velasco Oria \n",
      "Michiel S. Van der Heijden \n",
      "Maxime Meylan \n",
      "Carolina Alves Costa Silva \n",
      "Ramaprasad Srinivasan \n",
      "Guillermo Antonio De Velasco Oria \n",
      "Clarice D. Groeneveld \n",
      "Andrea Necchi \n",
      "Michiel S. Van der Heijden \n",
      "Alexandra Leary \n",
      "Alexandra Leary \n",
      "Christian Marth \n",
      "Jessica McAlpine \n",
      "Stephanie De Boer \n",
      "Alexandra Leary \n",
      "All Speakers \n",
      "Per Pfeiffer \n",
      "Pia J. Osterlund \n",
      "Clara Montagut Viladot \n",
      "Josep Tabernero \n",
      "John H. Strickler \n",
      "Per Pfeiffer \n",
      "Claire Gallois \n",
      "Jeanne Tie \n",
      "Stacey A. Cohen \n",
      "Clara Montagut Viladot \n",
      "Marwan G. Fakih \n",
      "Come Lepage \n",
      "Pia J. Osterlund \n",
      "Anne Tsao \n",
      "Sanjay Popat \n",
      "Anne Tsao \n",
      "Jaume Capdevila Castillon \n",
      "Marianne E. Pavel \n",
      "Marianne E. Pavel \n",
      "Dagmar Führer \n",
      "Jaume Capdevila Castillon \n",
      "Laura D. Locati \n",
      "Maria E. Cabanillas \n",
      "Jaume Capdevila Castillon \n",
      "All Speakers \n",
      "Ryan J. Sullivan \n",
      "Omid Hamid \n",
      "Richard Marais \n",
      "Ryan J. Sullivan \n",
      "Omid Hamid \n",
      "All Speakers \n",
      "Catherine Thieblemont \n",
      "Marco Ladetto \n",
      "Catherine Thieblemont \n",
      "Marco Ladetto \n",
      "Martin Hutchings \n",
      "All Speakers \n",
      "Katerina Politi \n",
      "Sarah-Jane Dawson \n",
      "Sarah-Jane Dawson \n",
      "Katerina Politi \n",
      "Rebecca Lee \n",
      "Nicola Aceto \n",
      "Sarah-Jane Dawson \n",
      "Katerina Politi \n",
      "All Speakers \n",
      "Giuseppe Curigliano \n",
      "Javier Cortés \n",
      "Giuseppe Curigliano \n",
      "Javier Cortés \n",
      "Richard Greil \n",
      "Erika P. Hamilton \n",
      "All Speakers \n",
      "Javier Cortés \n",
      "Luis Paz-Ares \n",
      "Kersti Oselin \n",
      "Mariam Jamal-Hanjani \n",
      "Michael Oh \n",
      "Solange Peters \n",
      "Myung-Ju Ahn \n",
      "Antonio Passaro \n",
      "Gerard Zalcman \n",
      "Kiyotaka Yoh \n",
      "Luis Paz-Ares \n",
      "Jonathan Spicer \n",
      "Enriqueta Felip \n",
      "Janis M. Taube \n",
      "Kersti Oselin \n",
      "Halfdan Sorbye \n",
      "Marcia S. Brose \n",
      "Ramon Salazar \n",
      "Eric Baudin \n",
      "Jonathan Strosberg \n",
      "All Speakers \n",
      "Yansong Lin \n",
      "Jaume Capdevila Castillon \n",
      "Marcia S. Brose \n",
      "All Speakers \n",
      "Mauro Cives \n",
      "Hans Gelderblom \n",
      "Maria E. Cabanillas \n",
      "Christine Dierks \n",
      "Christelle De la Fouchardiere \n",
      "Maria E. Cabanillas \n",
      "Rachel El Ferkh \n",
      "Stephen Liu \n",
      "Halfdan Sorbye \n",
      "Rocio Garcia-Carbonero \n",
      "Thomas A. Walter \n",
      "Mauro Cives \n",
      "Matthew T. Campbell \n",
      "Eric Baudin \n",
      "Hans Gelderblom \n",
      "Giuseppe Minniti \n",
      "Giuseppe Minniti \n",
      "Rupert Bartsch \n",
      "Silvia Formenti \n",
      "Emilie Le Rhun \n",
      "All Speakers \n",
      "Carlos H. Barrios \n",
      "Carlos H. Barrios \n",
      "Javier Cortés \n",
      "Sofia Rivera \n",
      "Elizabeth Mittendorf \n",
      "All Speakers \n",
      "Amanda Psyrri \n",
      "Sjoukje Oosting \n",
      "Amanda Psyrri \n",
      "Brigette B. Ma \n",
      "Pierre Blanchard \n",
      "Brigette B. Ma \n",
      "Wai Kei Jacky Lam \n",
      "Darren Wan-Teck Lim \n",
      "Brigette B. Ma \n",
      "Pierre Blanchard \n",
      "Pierre Blanchard \n",
      "All Speakers \n",
      "Maria Gomes da Silva \n",
      "Irit Avivi \n",
      "Charlotte Syrykh \n",
      "Tao Guan \n",
      "Irit Avivi \n",
      "Yunhong Huang \n",
      "Simon Pahnke \n",
      "Mingyue Wang \n",
      "Maria Gomes da Silva \n",
      "Haiying Wang \n",
      "EUNHEE LEE \n",
      "Irit Avivi \n",
      "Myung-Ju Ahn \n",
      "Ulrik N. Lassen \n",
      "Stefan N. Symeonides \n",
      "Sophie Postel-Vinay \n",
      "Ulrik N. Lassen \n",
      "Timothy A. Yap \n",
      "Joline Lim \n",
      "Irene Brana \n",
      "Manish Patel \n",
      "Komal Jhaveri \n",
      "Myung-Ju Ahn \n",
      "Partha Basu \n",
      "Suzette Delaloge \n",
      "Suzette Delaloge \n",
      "Monserrat Garcia-Closas \n",
      "Samuel Janes \n",
      "Richard Lee \n",
      "Lillian L. Siu \n",
      "Partha Basu \n",
      "All Speakers \n",
      "Rosa Giuliani \n",
      "André Ilbawi \n",
      "Rosa Giuliani \n",
      "Isabelle Soerjomataram \n",
      "Felipe S. Roitberg \n",
      "Rosa Giuliani \n",
      "André Ilbawi \n",
      "All Speakers \n",
      "Kathy R. Oliver \n",
      "Kathy R. Oliver \n",
      "Richard Sullivan \n",
      "Nataliia Hrad \n",
      "Katie Rizvi \n",
      "Wojciech Mlynarski \n",
      "All Speakers \n",
      "David Crosby \n",
      "Nick Turner \n",
      "David Crosby \n",
      "Felipe S. Roitberg \n",
      "Daniel Goldstein \n",
      "Aikaterini Fameli \n",
      "Julie Vancoppenolle \n",
      "Rafael B. Barreto \n",
      "Daniel Goldstein \n",
      "Jeehee Pyo \n",
      "Mario Di Palma \n",
      "Matthew D. Gitlin \n",
      "Felipe S. Roitberg \n",
      "Charles Swanton \n",
      "Fabrice André \n",
      "All Speakers \n",
      "Jean-Philippe Rameau \n",
      "Shiva Malek \n",
      "Eric Vivier \n",
      "Sergio Quezada \n",
      "All Speakers \n",
      "Nicholas McGranahan \n",
      "Fabrice André \n",
      "Nicholas McGranahan \n",
      "Charles M. Rudin \n",
      "Roel G. Verhaak \n",
      "Elena Garralda \n",
      "All Speakers \n",
      "Sebastian Bauer \n",
      "Herbert Ho Fung Loong \n",
      "Javier Martin-Broto \n",
      "Robin L. Jones \n",
      "Cesar Serrano \n",
      "Hans Gelderblom \n",
      "Sebastian Bauer \n",
      "Maria-Veronica Teleanu \n",
      "Georgios Kantidakis \n",
      "Herbert Ho Fung Loong \n",
      "Radwa Sharaf \n",
      "Tom Wei-Wu Chen \n",
      "Elise F. Nassif \n",
      "Javier Martin-Broto \n",
      "Alexios Matikas \n",
      "Kevin Punie \n",
      "Joaquin Mateo \n",
      "Rille Pihlak \n",
      "Anna Sophie S. Berghoff \n",
      "Teresa M. Amaral \n",
      "All Speakers \n",
      "Christoph Oing \n",
      "Philippe G. Aftimos \n",
      "Christoph Oing \n",
      "Grigorios Kotronoulas \n",
      "Anne Marie Rafferty \n",
      "Zeljko Vlaisavljevic \n",
      "Amanda Drury \n",
      "Grazyna Suchodolska \n",
      "Sara Colomer-Lahiguera \n",
      "Mark R. Foulkes \n",
      "Tugba Pehlivan \n",
      "All Speakers \n",
      "Bethany Maynard \n",
      "Nikolina Dodlek \n",
      "Remziye Semerci \n",
      "Bethany Maynard \n",
      "Patricia Hunt \n",
      "Róisín G Lawless \n",
      "Lucia Cadorin \n",
      "Cecilia Olsson \n",
      "All Speakers \n",
      "Virpi Sulosaari \n",
      "Virpi Sulosaari \n",
      "Sara T. Parreira \n",
      "Jann Arends \n",
      "Nicole Erickson \n",
      "Alessandro Laviano \n",
      "Robert S. Greene \n",
      "Virpi Sulosaari \n",
      "Jann Arends \n",
      "Robert S. Greene \n",
      "Sara T. Parreira \n",
      "Alessandro Laviano \n",
      "Nicole Erickson \n",
      "Virpi Sulosaari \n",
      "Mary A. Tanay \n",
      "Mary A. Tanay \n",
      "Christelle Galvez \n",
      "Gemma Jones \n",
      "Allison Sanneh \n",
      "Mary A. Tanay \n",
      "Virpi Sulosaari \n",
      "Virpi Sulosaari \n",
      "Wendy McInally \n",
      "Silvia Ucciero \n",
      "Joao Barros Alfonso \n",
      "All Speakers \n",
      "Virpi Sulosaari \n",
      "Virpi Sulosaari \n",
      "Christoph Oing \n",
      "Kevin Punie \n",
      "Claudia Cardone \n",
      "Alexios Matikas \n",
      "Christoph Oing \n",
      "Teresa M. Amaral \n",
      "Lucia Del Mastro \n",
      "Kevin Punie \n",
      "Gareth Evans \n",
      "Claudia Cardone \n",
      "Mafalda Oliveira \n",
      "Alexios Matikas \n",
      "Giuseppe Curigliano \n",
      "John B. Haanen \n",
      "Ana Bosch \n",
      "Giuseppe Curigliano \n",
      "Clare L. Scott \n",
      "Dieta Brandsma \n",
      "Rosa Giuliani \n",
      "\n",
      "Christian H. Ottensmeier \n",
      "Richard D. Baird \n",
      "Aurelius G. Omlin \n",
      "Maria De Santis \n",
      "Ines Pires da Silva \n",
      "Amanda Psyrri \n",
      "Florian Lordick \n",
      "Teresa Petrella \n",
      "Tom Wei-Wu Chen \n",
      "Jean-Pascal Machiels \n",
      "Christina H. Ruhlmann \n",
      "Ingrid Glimelius \n",
      "\n",
      "Marco Gerlinger \n",
      "Hanneke W. Van Laarhoven \n",
      "Juan W. Valle \n",
      "Masahiro Tsuboi \n",
      "Jessica J. Lin \n"
     ]
    }
   ],
   "source": [
    "#remove 51 page\n",
    "for i in range(len(PERSONS)):\n",
    "    print(PERSONS[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "b6a9536d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction by the Chairs\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Welcome and Presidential address\n",
      "Scientific Co-Chair addresses\n",
      "Scientific Co-Chair addresses\n",
      "Presentation of ESMO awards 2020 and 2021\n",
      "ESMO Award 2022 - Is oncology complex or simple?\n",
      "ESMO Award for Translational Research 2022 - Making sense of cancer evolution for patient benefit\n",
      "ESMO Women for Oncology Award 2022 - Gender gap and women’s rights: One step forward, two steps back?!\n",
      "ESMO Lifetime Achievement Award 2022 - Renal cancer: A model for oncology training\n",
      "Closure of the Opening Ceremony\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Targeting the uncommon molecular alterations\n",
      "Drugging KRAS in CRC: where do we stand?\n",
      "Immunomodulatory strategies for non-MSI-H metastatic colorectal cancer\n",
      "Neoadjuvant immunotherapy in CRC: where do we go from here?\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "ER+ HER2 - advanced breast cancer\n",
      "HER2+ advanced breast cancer\n",
      "Triple negative advanced breast cancer\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)\n",
      "LBA16 - Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial\n",
      "LBA76 - Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)\n",
      "Invited Discussant LBA15, LBA16 and LBA76\n",
      "Q&A\n",
      "210O - Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)\n",
      "LBA17 - Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)\n",
      "Invited Discussant 210O and LBA17\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Matching a molecular readout to a novel therapeutic\n",
      "Neuroendocrine disease: Molecular data and new models\n",
      "Is germline testing needed and does it impact treatment decisions?\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Gastroesophageal cancer\n",
      "Hepatobiliary cancer\n",
      "Pancreatic cancer\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Management of high-risk UC: Latest data\n",
      "Management of high-risk RCC: Latest data\n",
      "Management of oligometastatic renal and urothelial cancers: Incorporating best practices\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA29 - Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)\n",
      "517O - Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial\n",
      "518O - Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation\n",
      "Invited Discussant LBA29, 517O and 518O\n",
      "Q&A\n",
      "LBA30 - Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)\n",
      "LBA31 - Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial\n",
      "Invited Discussant LBA30 and LBA31\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "LBA37 - A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)\n",
      "Invited Discussant LBA37\n",
      "Q&A\n",
      "LBA38 - BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours\n",
      "728O - Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors\n",
      "Invited Discussant LBA38 TBC and 728O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Next generation synthetic lethal target discovery using high-throughput CRISPR technology\n",
      "Modern translational correlatives for synthetic lethality trials\n",
      "Clinical development of next generation DDR agents for molecularly-selected tumours\n",
      "Exploiting synthetic lethality for non-DDR approaches in the clinic\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Perioperative targeted therapy for early-stage NSCLC\n",
      "Perioperative immunotherapy for early-stage NSCLC\n",
      "Pathologic assessment post neo-adjuvant treatment\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "The role of molecular biology in defining new entities\n",
      "New drugs for ultrarare sarcoma\n",
      "Advocating for patients with ultra-rare cancer\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Single cell genomics to understand cancer evolution\n",
      "Single cell pathology using spatial proteomics\n",
      "Spatial gene expression and mapping tumor morphology\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Organ-specific tumour microenvironment\n",
      "The role of B cell/TLS\n",
      "Immune signatures in the tumour microenvironment\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Are we in the era of total neoadjuvant treatment?\n",
      "Role, timing and duration of neo-adjuvant (chemo)radiotherapy\n",
      "The surgeon’s perspective: TME, local excision or watch and wait?\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Uveal melanoma\n",
      "Mucosal melanoma\n",
      "Acral melanoma\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Safety management of Antibody-Drug-Conjugates\n",
      "Immune-check point inhibitors: From acute to long term toxicities\n",
      "New oral targeted therapies: Main toxicities, improve management to increase adherence\n",
      "How to step up systems to better learn and manage new toxicities?\n",
      "Panel discussion on safety management of new anticancer drugs with case discussion and Q&A\n",
      "Conclusions\n",
      "Introduction\n",
      "Introduction\n",
      "277O - The ReSPECT-GBM™ phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial\n",
      "278O - Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295\n",
      "Invited Discussant 277O and 278O\n",
      "Q&A\n",
      "279O - ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma\n",
      "280O - Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results\n",
      "Invited Discussant 279O and 280O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Clinical case 1\n",
      "Case 1 Discussant\n",
      "Case 1 Discussion / Q&A\n",
      "Clinical case 2\n",
      "Case 2 Discussant\n",
      "Case 2 Discussion / Q&A\n",
      "Introduction\n",
      "Acute myeloid leukaemia\n",
      "PET: New applications\n",
      "Molecular classification of aggressive lymphoma\n",
      "Will circulating tumour DNA have a role in treatment decisions?\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Clinical and molecular features distinguish small cell lung carcinoma from extrapulmonary NEC\n",
      "Treatment of gastroenteropancreatic NEC\n",
      "Neuroendocrine prostate cancer (NEPC): A model for phenotypic plasticity\n",
      "Gynaecological NEC\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "The impact of COVID-19 pandemic on cancer patients and early diagnosis - Time to act!\n",
      "The impact of COVID-19 on patient-physician communication and the role of telemedicine\n",
      "The impact of COVID-19 on surgery\n",
      "The impact of COVID-19 on advocacy networks\n",
      "COVID-19 and the pathway for the future to support patients with cancer\n",
      "Discussion\n",
      "Conclusion\n",
      "Introduction\n",
      "Introduction\n",
      "The importance of patients’ involvement in the decision-making process\n",
      "How to interact with policymakers\n",
      "How to grow your network\n",
      "How to get funding\n",
      "Discussion\n",
      "Conclusion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Five years of FDA approvals (2017-2022): A report from the ESMO-MCBS\n",
      "Long term follow-up on single arm registration studies: what have we learned?\n",
      "ICI landscape in solid tumours: what are the scores, are there differences and why?\n",
      "Conclusions and Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Designated Centres Survey: Education, research, programme development – Final results\n",
      "My Path: improving the content, quality and cost-effectiveness of cancer treatment\n",
      "Financial toxicity and out of pocket cost for supportive care medications among cancer patients\n",
      "Panel Discussion\n",
      "Conclusion and next steps\n",
      "Designated Centre and Palliative Care Fellowship Awards\n",
      "Table 1: Clinical oncology\n",
      "Table 1: Clinical oncology\n",
      "Table 2: Clinical oncology\n",
      "Table 2: Clinical oncology\n",
      "Table 3: Translational research\n",
      "Table 3: Translational research\n",
      "Table 4: Translational research\n",
      "Table 4: Translational research\n",
      "Table 5: Becoming an early phase trial oncologist\n",
      "Table 5: Becoming an early phase trial oncologist\n",
      "Table 6: The role of clinician scientist\n",
      "Table 6: The role of clinician scientist\n",
      "Table 7: The role of clinician-scientist\n",
      "Table 7: The role of clinician-scientist\n",
      "Table 8: Policy making and public health\n",
      "Table 8: Policy making and public health\n",
      "Speaker panel\n",
      "Speaker panel\n",
      "Speaker panel\n",
      "Speaker panel\n",
      "Introduction\n",
      "Introduction\n",
      "LBA1 - Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention\n",
      "Invited Discussant LBA1\n",
      "LBA2 - DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)\n",
      "Invited Discussant LBA2\n",
      "LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial\n",
      "Invited Discussant LBA3\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Antibody-drug conjugates: Constructs and targets\n",
      "ADCs for patients with triple negative breast cancer: Moving towards combinations with I-O and agents targeting DDR\n",
      "Which impact of Her2-directed ADCs?\n",
      "Finding the right population and combination to develop ADCs in patients with HR+/Her2- mBC\n",
      "Conclusions and perspectives\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "New therapies and questions for EGFR, Exon 20 and HER2 mutation\n",
      "Targeting KRAS: Current knowledge and future directions\n",
      "How to address resistance\n",
      "Where does IO fit in?\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Endometrial cancer\n",
      "Cervical cancer\n",
      "Ovarian cancer\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Novel immune checkpoints\n",
      "Cytokines\n",
      "Targeting regulatory T cells\n",
      "Vaccines\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection\n",
      "LBA67 - Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial\n",
      "Invited Discussant LBA66 and LBA67\n",
      "Q&A\n",
      "1735O - PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)\n",
      "LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)\n",
      "Invited Discussant 1735O and LBA74\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the Chair\n",
      "What is the future of digital medicine for cancer patients?\n",
      "Introduction\n",
      "Introduction\n",
      "LBA34 - Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)\n",
      "LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial\n",
      "Invited Discussant LBA34 and LBA35\n",
      "Q&A\n",
      "LBA36 - Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma\n",
      "Invited Discussant LBA36\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Approach to inhibition of activating FGFR2 fusions\n",
      "IDH1 and IDH2\n",
      "The role of immunotherapy and other targeted treatments\n",
      "The role of KRAS inhibitor and other new treatment options in pancreatic cancer\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Rare variants of bladder cancer management: The role of radiation therapy\n",
      "Emerging systemic therapies in rare urothelial cancer variants\n",
      "The role of systemic therapy in brain metastases from RCC: Targeted therapy and immunotherapy\n",
      "The emerging role of SBRT in treating the primary and distant metastases from Renal cancer\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Gene expression profiling and chemotherapy: Who to test, which test, and when\n",
      "Neo-adjuvant therapy in luminal breast cancer: Who to treat, which regimen, and what duration?\n",
      "Adjuvant endocrine therapy: Who needs more than 5 years, which regimen, and what duration beyond 5 years?\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "519MO - Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis\n",
      "LBA32 - Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positive and negative\n",
      "520MO - Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358\n",
      "Invited Discussant 519MO, LBA32 and 520MO\n",
      "521MO - Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial\n",
      "522MO - Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial\n",
      "Invited Discussant 521MO and 522MO\n",
      "523MO - Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis\n",
      "524MO - Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel\n",
      "Invited Discussant 523MO and 524MO\n",
      "Introduction\n",
      "Introduction\n",
      "133O - Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial\n",
      "LBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial\n",
      "Invited Discussant 133O and LBA13\n",
      "Q&A\n",
      "LBA14 - Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials\n",
      "134O - Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)\n",
      "Invited Discussant LBA14 and 134O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial\n",
      "LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial\n",
      "Invited Discussant LBA18 and LBA19\n",
      "LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors\n",
      "211MO - Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study\n",
      "212MO - AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)\n",
      "Invited Discussant LBA20, 211MO and 212MO\n",
      "213MO - Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)\n",
      "214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study\n",
      "215MO - ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer\n",
      "216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)\n",
      "Invited Discussant 213MO, 214MO, 215MO and 216MO\n",
      "Introduction\n",
      "Introduction by the Chair\n",
      "Polling 1 (led by chair)\n",
      "Pro: Does hyperprogression exist?\n",
      "Contra: Does hyperprogression exist?\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Plasticity: The door for tumour escape?\n",
      "Discovery of new metabolic pathways and liabilities in cancer cells\n",
      "Single cell dynamics\n",
      "How to target invisible melanoma cells\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "784O - Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial\n",
      "LBA39 - Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)\n",
      "Invited Discussant 784O and LBA39\n",
      "Q&A\n",
      "LBA40 - Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma\n",
      "785O - PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)\n",
      "Invited Discussant LBA40 and 785O\n",
      "Q&A\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "The place of surgery, interventional radiology and radiation\n",
      "Systemic therapy\n",
      "Novel compounds including immunotherapy\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "655MO - Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016\n",
      "656MO - Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma\n",
      "657MO - Effectiveness of geriatric assessment-driven interventions on quality of life for 2 years in older patients with head and neck cancer: Results from the EGeSOR trial\n",
      "Invited Discussant 655MO, 656MO and 657MO\n",
      "658MO - Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040\n",
      "659MO - Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048\n",
      "LBA33 - 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study\n",
      "Invited Discussant 658MO, 659MO and LBA33\n",
      "660MO - Molecular targets in salivary gland cancers: A comprehensive genomic analysis of 1,666 cases\n",
      "654MO - High dimensional immuno-phenotyping of immunotherapy response in head and neck cancer\n",
      "661MO - Evaluation of the DNA damage response (DDR) network as predictor of nivolumab efficacy in head and neck squamous cell carcinoma (HNSCC)\n",
      "Invited Discussant 660MO, 654MO and 661MO\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Targeting the “crack” DNA damage repair deficiency in sarcomas\n",
      "Understanding the sarcoma genome\n",
      "Targeting the epigenetics regulatory machinery in sarcoma\n",
      "Defining molecular targets for immunotherapy\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Update on diagnosis: Novel concepts of WHO\n",
      "Therapeutic implications for gliomas\n",
      "Are molecular subtypes also radiologic subtypes? Radiogenomic mapping of brain tumours\n",
      "Discussion\n",
      "Introduction\n",
      "Can novel radiotherapy techniques pave the way for new combinations?\n",
      "Building infrastructure in academia for truly translational clinical research: going from bedside to the bench (reverse translation)\n",
      "COVID as a catalyst for remodelling approaches to early phase clinical trial development in a resource challenged environment\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "1425MO - Use of psychosocial services and 1-year mortality among newly diagnosed and distressed cancer patients: A real-world study\n",
      "1554MO - Perspectives of patients with metastatic breast cancer on exercise interventions: Results from a survey in five European countries\n",
      "1555MO - Effects of exercise on sleep quality and cancer-related fatigue during neurotoxic chemotherapy\n",
      "Invited Discussant 1425MO, 1554MO and 1555MO\n",
      "1556MO - The iBLAD study: Patient-reported outcomes in bladder cancer during oncological treatment: A multicenter national randomized controlled trial\n",
      "1557MO - Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic shellfish poisoning (PSP) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)\n",
      "1558MO - Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes\n",
      "Invited Discussant 1556MO, 1557MO and 1558MO\n",
      "LBA70 - COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases\n",
      "1264MO - Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy\n",
      "1265MO - Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data\n",
      "Invited Discussant LBA70, 1264MO and 1265MO\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Implementing onco-fertility care to allow patient access to fertility preservation\n",
      "Sexual health: If you don’t address it, patients don’t ask\n",
      "Onco-fertility care is not only fertility preservation: Counseling patients about pregnancy and contraception\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Tumour-agnostic precision therapeutics in molecular oncology: Target versus tissue context: Evidence for benefit and taxonomy considerations\n",
      "NGS tissue testing in the search of actionable biomarkers in solid tumours: When is it indicated?\n",
      "Optimally integrating tumour tissue NGS in the care pathway: Preanalytics, analytics, cost and reimbursement\n",
      "The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems\n",
      "Q&A and discussion\n",
      "Concluding remarks\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Systemic approaches in locally advanced N2/stage III NSCLC: EGFR mutation versus wildtype\n",
      "Radiotherapy approaches in locally advanced N2/stage III NSCLC\n",
      "Considerations for staging and surgical intervention\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "The surgical oncologist perspective\n",
      "The radiation oncologist perspective\n",
      "The medical oncologist perspective\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "451O - Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors\n",
      "452O - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours\n",
      "453O - DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study\n",
      "Invited Discussant 451O, 452O and 453O\n",
      "Q&A\n",
      "450O - Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition\n",
      "454O - A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)\n",
      "Invited Discussant 450O and 454O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "729MO - Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment\n",
      "730MO - First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies\n",
      "731MO - A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors\n",
      "Invited Discussant 729MO, 730MO and 731MO\n",
      "732MO - The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial\n",
      "733MO - γδT cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects\n",
      "734MO - Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy\n",
      "Invited Discussant 732MO, 733MO and 734MO\n",
      "735MO - Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors\n",
      "736MO - Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)\n",
      "737MO - EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers\n",
      "Invited Discussant 735MO, 736MO and 737MO\n",
      "Introduction\n",
      "Treating KRAS mutant tumour\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "617O - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results\n",
      "Invited Discussant 617O\n",
      "Q&A\n",
      "618O - A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma\n",
      "619O - shRNA-mediated PD1 gene knock-down anti-CD19 CAR-T cell therapy for relapsed/refractory b cell malignancies\n",
      "620O - CART-ddBCMA for multiple myeloma: Interim results from phase I study\n",
      "Invited Discussant 618O, 619O and 620O\n",
      "Q&A\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "1482O - A phase III study comparing methotrexate (M), adriamycin (A) and cisplatin (P) with MAP + ifosfamide (MAP + IF) for the treatment of osteosarcoma: JCOG0905\n",
      "1483O - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma\n",
      "Invited Discussant 1482O and 1483O\n",
      "Q&A\n",
      "1485O - Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study\n",
      "1484O - Deep learning predicts patients’ outcome and mutations from H&E slides in gastrointestinal stromal tumor (GIST)\n",
      "Invited Discussant 1485O and 1484O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)\n",
      "1296MO - PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)\n",
      "Invited Discussant LBA61 and 1296MO\n",
      "52MO - A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)\n",
      "53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)\n",
      "54MO - Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial\n",
      "Invited Discussant 52MO, 53MO, 54MO\n",
      "1204MO - PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma\n",
      "1205MO - Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen\n",
      "Invited Discussant 1204MO and 1205MO\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "ESMO ANMS 2.0 survey about access to cancer medicines\n",
      "ESMO’s economic model\n",
      "WHO pricing guidelines to improve access to medicines\n",
      "The patient perspective\n",
      "Conclusions and perspectives\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Applying the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)\n",
      "The ESMO survey on availability and accessibility of biomolecular technologies in oncology\n",
      "Is drug access the bottleneck of precision medicine?\n",
      "Conclusions and perspectives\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "The importance of joining clinical research to improve cancer research outcomes\n",
      "How can patients get involved in clinical trials?\n",
      "How is patient data crucial to advance scientific research?\n",
      "How can patients’ involvement in clinical trial design save lives?\n",
      "Case study: Patients being involved in clinical research\n",
      "Discussion\n",
      "Conclusion\n",
      "Introduction\n",
      "Introduction\n",
      "1312O - From regulating off-label use to creating an environment for drug repurposing in oncology\n",
      "1313O - Assessment of investigational new drugs (INDs) approved in USA and Europe after early phase trials using the ESMO-magnitude of clinical benefit scale (ESMO-MCBS)\n",
      "Invited Discussant 1312O and 1313O\n",
      "Q&A\n",
      "1314O - Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer: The MetAction precision medicine study\n",
      "1315O - Key learnings from building: A precision cancer medicine implementation initiative for Norway\n",
      "1316O - Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network\n",
      "Invited Discussant 1314O, 1315O and 1316O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Caregiver story, the lost voice\n",
      "Patients and caregivers are on the same journey but on different tracks: the importance of family-focused education\n",
      "Psycho-oncology service caregivers in the UK\n",
      "A multidisciplinary approach to support families in managing cancer repercussions\n",
      "Connecting for caregivers’ empowerment\n",
      "Discussion\n",
      "Conclusion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Transcriptomic and immune landscape in SCLC\n",
      "Immunotherapy in the current management of SCLC\n",
      "Controversies in SCLC radiotherapy treatment\n",
      "Future perspectives\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "An ESMO framework for de-escalation of antineoplastic therapies: Principles and considerations\n",
      "Fundamentals of de-escalation\n",
      "The use of biomarkers in de-escalation\n",
      "De-escalation from a patients’ perspective\n",
      "Challenges in de-escalation trials\n",
      "Discussion and Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Defining the role of the pathologist in the era of Next Generation Sequencing\n",
      "Next Generation Sequencing: Power and pitfalls\n",
      "Novel therapeutic targets and tumour agnostic treatment\n",
      "Challenges in the clinical application of Molecular Tumour Boards\n",
      "Discussion and Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "281MO - Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO-1 trial\n",
      "282MO - Brain metastases: Real-life treatment patterns, survival and patient-reported outcomes – Results from a population-based, prospective study in 914 patients\n",
      "283MO - Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort\n",
      "Invited Discussant 281MO, 282MO and 283MO\n",
      "284MO - Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109)\n",
      "285MO - The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma\n",
      "286MO - Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma\n",
      "Invited Discussant 284MO, 285MO and 286MO\n",
      "287MO - A phase 0 ‘trigger’ trial of pamiparib in newly diagnosed and recurrent glioblastoma patients\n",
      "288MO - Brain-only oligometastatic cancer patients present with longer overall survival than patients with extracranial involvement\n",
      "289MO - Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: A large mono institutional experience\n",
      "Invited Discussant 287MO, 288MO and 289MO\n",
      "Introduction\n",
      "Introduction\n",
      "Pro: Tumor mutional burden as a tumor agnostic biomarker?\n",
      "Contra: Tumor mutional burden as a tumor agnostic biomarker?\n",
      "Discussion led by chairs\n",
      "Pro: Medical oncology in 21st century – general or cancer type specialist?\n",
      "Contra: Medical oncology in 21st century: General or cancer type specialist?\n",
      "Discussion led by chairs\n",
      "Introduction\n",
      "Integrating Patient Reported Outcomes in clinical practice\n",
      "Discussion led by Chair\n",
      "Introduction\n",
      "Welcome to EONS15 the conference\n",
      "Welcome from Association Française des Infirmier(e)s de Cancérologie – French Oncology Nurses Society\n",
      "World Code against Cancer Framework: Evidence-based recommendations for cancer prevention\n",
      "Psycho-oncology in cancer care: Current state and future directions\n",
      "My Survival Story: What we can learn from each other to get through cancer\n",
      "EONS Awards: Lifetime Achievement Award and RECaN Award\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "EONS focus on cancer prevention\n",
      "Physical activity and cancer\n",
      "Prevention and early detection for hereditary breast and ovarian cancer syndromes\n",
      "CN12 - Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention\n",
      "CN13 - Nutriscore: Nutritional screening in colorectal cancer patients previous to cancer-specific treatment\n",
      "CN15 - Individual factors leading to delay in diagnosis in patients with colorectal cancer and their illness perceptions\n",
      "CN14 - Cancer prevention awareness among Croatian AYA population\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Welcome\n",
      "FILM (pre-recorded): How people experience of early breast cancer, impact of diagnosis and treatment\n",
      "Evidence re unmet need for people with early breast cancer in Europe\n",
      "FILM (pre-recorded): How people experience of early breast cancer, end of treatment and living well\n",
      "Discussion concerning patient film and evidence\n",
      "Discussion concerning patient film and evidence\n",
      "Discussion concerning patient film and evidence\n",
      "Discussion concerning patient film and evidence\n",
      "Recommendations for future practice\n",
      "Recommendations for future practice\n",
      "Recommendations for future practice\n",
      "Recommendations for future practice\n",
      "Conclusion remarks\n",
      "Introduction\n",
      "Efficiency of eHealth and digital innovations in cancer care\n",
      "Development and implementation of virtual pre-chemotherapy consultations\n",
      "CN1 - Patient-reported symptom monitoring improves health-related quality of life in lung cancer patients: The SYMPRO-Lung trial\n",
      "CN2 - A public involvement process to enhance diversity in technology clinical trials\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Introduction\n",
      "CART, IEC, BITE – what does the new technology mean for patients with solid malignancies\n",
      "Prehab to rehab for patients with CAR T cell therapy – optimising health and wellbeing\n",
      "What supportive care do patients need?\n",
      "Q&A and Conclusion remarks\n",
      "Introduction\n",
      "Supportive care in cancer makes excellent cancer care possible! Recent developments (MASCC)\n",
      "Cognition, sleep and the daily functioning of patients with cancer: A time for multi-modal management interventions\n",
      "CN61 - Patients’ experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): Interview results\n",
      "CN58 - Mapping the measurement of lymphoma survivors’ unmet needs and quality of life outcomes: Evidence for a lymphoma-specific questionnaire\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "How to prepare and present your first poster at a congress\n",
      "Poster walk\n",
      "Poster walk\n",
      "Poster walk\n",
      "Poster walk\n",
      "Poster walk\n",
      "Introduction\n",
      "Introduction\n",
      "LBA4 - Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial\n",
      "LBA5 - Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)\n",
      "LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)\n",
      "LBA7 - Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study\n",
      "Invited Discussant LBA4, LBA5, LBA6, LBA7 - The immunologist point of view\n",
      "Invited Discussant LBA4, LBA5, LBA6, LBA7 - The medical oncologist point of view\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol\n",
      "1358O - Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial\n",
      "Invited Discussant LBA62 and 1358MO\n",
      "Q&A\n",
      "1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)\n",
      "LBA63 - PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)\n",
      "Invited Discussant 1357O and LBA63\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "LBA21 - FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group\n",
      "LBA22 - Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study\n",
      "Invited Discussant LBA21 and LBA22\n",
      "Q&A\n",
      "314O - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study\n",
      "LBA23 - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial\n",
      "Invited Discussant 314O and LBA23\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "LBA51 - Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial\n",
      "LBA52 - Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study\n",
      "LBA53 - ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib\n",
      "Invited Discussant LBA51, LBA52 and LBA53\n",
      "Q&A\n",
      "LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial\n",
      "972O - Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial\n",
      "Invited Discussant LBA54 and 972O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA\n",
      "LBA48 - Community-based mass screening with low-dose CT for lung cancer in Guangzhou\n",
      "Invited Discussant LBA47 and LBA48\n",
      "Q&A\n",
      "950O - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial\n",
      "LBA49 - CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)\n",
      "Invited Discussant 950O and LBA49\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Papillary renal cell carcinoma\n",
      "Translocation renal cell carcinoma\n",
      "Sarcomatoid renal cell carcinoma\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer\n",
      "Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer\n",
      "Introduction\n",
      "Introduction\n",
      "1203O - FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO\n",
      "Invited Discussant 1203O\n",
      "Q&A\n",
      "LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study\n",
      "Invited Discussant LAB60\n",
      "Q&A\n",
      "LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial\n",
      "Invited Discussant LBA12\n",
      "Q&A\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Optimizing local treatment for brain metastasis in lung cancer\n",
      "Role and reliability of systemic treatment for brain metastasis in lung cancer\n",
      "Molecular features of brain metastasis and considerations for precision management\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Early breast cancer: Clinical case\n",
      "Early breast cancer: Discussant\n",
      "Early breast cancer: Discussion / Q&A\n",
      "Cancer of Unknown Primary site (CUP): Clinical case\n",
      "Cancer of Unknown Primary site (CUP): Discussant\n",
      "Cancer of Unknown Primary site (CUP): Discussion / Q&A\n",
      "Biliary tract cancer: Clinical case\n",
      "Biliary tract cancer: Discussant\n",
      "Biliary tract cancer: Discussion / Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Bladder cancer: Clinical case\n",
      "Bladder cancer: Discussant\n",
      "Bladder cancer: Discussion / Q&A\n",
      "Primary CNS lymphoma: Clinical case\n",
      "Primary CNS lymphoma: Discussant\n",
      "Primary CNS lymphoma: Discussion / Q&A\n",
      "Metastatic non-small-cell lung cancer: Clinical case\n",
      "Metastatic non-small-cell lung cancer: Discussant\n",
      "Metastatic non-small-cell lung cancer: Discussion / Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Multi-omic profiling in H&N cancer: Clinical applications\n",
      "Circulating biomarker assays in individualizing targeted therapy and IO for HN cancers: ctDNA\n",
      "New promising targets on the horizon: HRAS, PI3KCA, NTRK, RET, NOTCH1, BRAF...etc\n",
      "Novel platforms to identify neoantigens in personalised immunotherapy\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Rethinking tumor subtype classification: Learning from RNA expression\n",
      "Special subtypes of breast cancer\n",
      "The microenvironment in early breast cancer: TILS and beyond\n",
      "Detecting minimal residual disease for new staging methods\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Can we identify the patients who will most likely benefit through HRD tests?\n",
      "PARPi resistance: What do we know now?\n",
      "DNA damage repair: What targeting strategies show promise over and above PARP inhibition?\n",
      "Other targets beyond DDR in ovarian cancer\n",
      "Conclusions and perspectives\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "LBA55 - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial\n",
      "LBA56 - MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial\n",
      "Invited Discussant LBA55 and LBA56\n",
      "LBA57 - Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study\n",
      "LBA58 - Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study\n",
      "Invited Discussant LBA57 and LBA58\n",
      "LBA59 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)\n",
      "973MO - KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC\n",
      "974MO - 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)\n",
      "Invited Discussant LBA59, 973MO and 974MO\n",
      "Introduction\n",
      "Introduction\n",
      "Merkel cell carcinoma, angiosarcoma & Kaposi\n",
      "Basal cell carcinoma\n",
      "Cutaneous squamous cell carcinoma\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Pro: Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Contra: Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Germline make-up and immune landscape/response to immunotherapy  \n",
      "Targeting the adenosine immune checkpoint to overcome treatment resistance\n",
      "Radiotherapy shapes the tumor antigenic repertoire\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Emerging role of RANO: From idea to practice\n",
      "Novel and less conventional treatment strategies\n",
      "Tailoring treatment according to biology\n",
      "Targeting IDH mutation\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "LBA72 - Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial\n",
      "904MO - Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)\n",
      "68MO - Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies\n",
      "1661MO - Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma\n",
      "Invited Discussant LBA72, 904MO, 68MO and 1661MO\n",
      "1662MO - Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)\n",
      "1663MO - DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice transplanted with human feces\n",
      "Invited Discussant 1662MO and 1663MO\n",
      "905MO - Synergistic combination of clinical, imaging and DNA methylation biomarkers improves the classification of pulmonary nodules\n",
      "1664MO - Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients\n",
      "69MO - 5-Hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions\n",
      "Invited Discussant 905MO, 1664MO and 69MO\n",
      "Introduction\n",
      "Introduction\n",
      "Fatigue, cognitive dysfunction and emotional distress\n",
      "Cachexia\n",
      "Dyspnea and cough\n",
      "Discussion\n",
      "Introduction\n",
      "How to incorporate digital medicine in survivorship care after breast cancer\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Induction and de-escalation\n",
      "TORS and RT\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "1449MO - Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study\n",
      "1450MO - Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC\n",
      "Invited Discussant 1449MO and 1450MO\n",
      "LBA75 - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results\n",
      "1733MO - First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer\n",
      "1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials\n",
      "Invited Discussant LBA75, 1733MO and 1734MO\n",
      "1310MO - Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study\n",
      "512MO - Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database\n",
      "513MO - Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders\n",
      "Invited Discussant 1310MO, 512MO and 513MO\n",
      "Introduction\n",
      "Introduction\n",
      "525MO - Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775\n",
      "526MO - Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)\n",
      "Invited Discussant 525MO and 526MO\n",
      "527MO - Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study\n",
      "528MO - Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?\n",
      "529MO - Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer\n",
      "Invited Discussant 527MO, 528MO and 529MO\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Introduction and scientific background\n",
      "Cancer prevention at the forefront of the political agenda: The European Union vision\n",
      "Why cancer prevention? The medical oncologist’s perspective\n",
      "Implementing cancer prevention: The oncology nurse’s perspective\n",
      "Promoting health for all individuals: The patient’s perspective\n",
      "Discussion and Q&A\n",
      "Conclusion and closing remarks\n",
      "Conclusion and closing remarks\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "How to use real-world data\n",
      "The perspective of the regulator\n",
      "Statistical limitations and the perspective of the statistician\n",
      "Limitations of clinical trials, alternative trial designs and the perspective of the clinician or patient\n",
      "Panel discussion and Q&A\n",
      "Panel discussion and Q&A\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Drugging the undruggable: Next generation KRAS inhibitors\n",
      "Beyond the genome: Novel epigenomic and metabolomic strategies\n",
      "Break it down: New frontiers in protein degradation and refolding\n",
      "From cold to hot: Immunotherapy in the genome-driven arena\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Welcome and introduction\n",
      "Biology and prognostication in advanced clear cell renal cell carcinoma (RCC)\n",
      "State of the art first-line management of patients with advanced RCC\n",
      "The emerging continuum of care in advanced RCC: Second-line and beyond\n",
      "Presentation of two clinical vignettes: Optimising dose-intensity and tolerance\n",
      "Q&A and discussion\n",
      "Concluding remarks\n",
      "Introduction\n",
      "Introduction\n",
      "Pathology of salivary gland cancers and sino-nasal cancers\n",
      "Treatment algorithm for recurrent/metastatic salivary gland cancers\n",
      "Contemporary approach to the multidisciplinary management of sino-nasal cancer\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "903O - A prospective study of a multi-cancer early detection blood test\n",
      "1696O - Genomic profiling and molecular targeting of lung cancer brain metastases\n",
      "66O - MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors\n",
      "Invited Discussant 903O, 1696O and 66O\n",
      "Q&A\n",
      "1660O - Dual immune checkpoint blockade induces analogous alterations in the intratumoral CD8+ T cell and Treg compartments\n",
      "67O - Quantifying poly(ADP-Ribose) polymerase (PARP1) in vivo using a non-invasive PARP1 PET tracer\n",
      "Invited Discussant 1660O and 67O\n",
      "Q&A\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "1360MO - Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study\n",
      "LBA64 - Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data\n",
      "Invited Discussant 1360MO and LBA64\n",
      "1359MO - Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE\n",
      "1361MO - 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial\n",
      "Invited Discussant 1359MO and 1361MO\n",
      "LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial\n",
      "1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study\n",
      "1363MO - Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial\n",
      "1364MO - Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients\n",
      "Invited Discussant LBA65, 1362MO, 1363MO and 1364MO\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Management of renal impairment\n",
      "Management of bone disease\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Line of Therapy: Definitions and guidelines\n",
      "Line of Therapy in the curative setting, challenges and solutions: Clinical vignettes\n",
      "Line of Therapy in the non-curative setting, challenges and solutions: Clinical vignettes\n",
      "Perspectives from the Investigator: Landscape and impact on clinical research\n",
      "Perspectives from the regulator: Landscape and unmet needs\n",
      "Q&A\n",
      "Conclusions\n",
      "Introduction\n",
      "Introduction\n",
      "Gender differences in epidemiology and attributable risk factors of non sex-related cancers\n",
      "Gender differences in colorectal cancer screening\n",
      "Lung cancer biology and outcomes\n",
      "Quality-of-life\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "What is AI?\n",
      "AI applied to radiology\n",
      "AI applied to pathology\n",
      "Key challenges for delivering clinical impact with artificial intelligence\n",
      "Perspectives: Which transformations are expected?\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Isolated limb perfusion\n",
      "RT and radioenhancer: Chemotherapy, TKI and nanoparticles\n",
      "Risk-based criterion to select for neoadjuvant chemotherapy: Dream or reality?\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Patient’s perspective…Am I fine?\n",
      "Caregiver’s perspective... Am I fine?\n",
      "Physician's perspective... Am I fine?\n",
      "Nurse’s perspective... Am I fine?\n",
      "Psycho-oncologist’s perspective\n",
      "Discussion\n",
      "Conclusion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Dosing anti-cancer therapy in patients with moderate and severe kidney and liver dysfunction\n",
      "Dose individualisation of TKIs\n",
      "The relevance of geno- and phenotyping cytochrome P450 prior to anticancer treatment\n",
      "The relevance of endoxifen measurements in the adjuvant tamoxifen treatment of breast cancer\n",
      "The rationale behind selecting recommended dose and schedule in immunotherapy ion\n",
      "Conclusions\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "MCBS: The future of cost-effective care\n",
      "GDPR in oncology: The EU experience\n",
      "ESMO and Covid 19: The trials and tribulations\n",
      "Onco-policy in Asia: ESMO to the fore\n",
      "Conclusions and perspectives\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Setting the scene\n",
      "The Gynecological Oncology Day: The world GO day\n",
      "The impact of prostate cancer treatment on quality of life: EUPROMS study\n",
      "iPoRaku (AfterCancer)\n",
      "Onko Ukraine\n",
      "International Covid Blood Cancer Coalition\n",
      "Conclusion\n",
      "Introduction\n",
      "Introduction\n",
      "1551O - Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study\n",
      "1263O - Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy\n",
      "Invited Discussant 1551O and 1263O\n",
      "Q&A\n",
      "1552O - Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial\n",
      "1553O - Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)\n",
      "217O - Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)\n",
      "Invited Discussant 1552O, 1553O and 217O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "What oncologists need to know about GEP-NET before commencing therapy\n",
      "Treatment of small intestinal NET\n",
      "Treatment of pancreatic NET\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Welcome\n",
      "Video contribution\n",
      "Introduction\n",
      "Live discussion, Q&A, wrap-up\n",
      "Live discussion, Q&A, wrap-up\n",
      "Live discussion, Q&A, wrap-up\n",
      "Live discussion, Q&A, wrap-up\n",
      "Live discussion, Q&A, wrap-up\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "ESMO Research Fellowship Programme: Supporting young oncologists and enhancing careers for more than 30 years\n",
      "Best paper derived from an ESMO Fellowship\n",
      "Best Fellowship project\n",
      "ESMO Fellowship awards ceremony (Research Fellowship, José Baselga, Best Exam)\n",
      "ESMO Fellowship awards ceremony (Research Fellowship, José Baselga, Best Exam)\n",
      "Conclusion\n",
      "Introduction\n",
      "How to write and respond to a critical peer review\n",
      "Discussion led by Chair\n",
      "Introduction\n",
      "Introduction\n",
      "What is a well-designed clinical trial?\n",
      "Discussion\n",
      "Addressing inequality in under-served populations in clinical trials\n",
      "Discussion\n",
      "Coffee break\n",
      "Insfrastructure and policies for global clinical trials: Opportunities and threats\n",
      "Discussion\n",
      "How does the marketing authorization process work?\n",
      "Discussion\n",
      "Introduction\n",
      "Advanced nursing practice in cancer\n",
      "Can we address the problem of the nurses shortage post COVID-19?\n",
      "Cancer nurses and safety around hazardous drugs, outcome of European Oncology Nursing Society advocacy work\n",
      "CN30 - Three stage capacity: Consent process for systemic anti-cancer therapy\n",
      "CN32 - Cancer nurses' experiences and perceptions of potential occupational exposure to cytotoxic drugs: Systematic review utilising framework analysis\n",
      "CN33 - How to work with swiptests in an oncology outpatient ward: An occupational safety project\n",
      "CN31 - Project bedside handover 2022 (a tool for health care professionals to increase patient participation in bedside report)\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Cultural determinants of end of life\n",
      "Gero-oncology integrative view on palliative care\n",
      "Navigating parental cancer when a mum or dad is at end of life\n",
      "CN24 - The perceptions of healthcare professionals on the provision of palliative and end-of-life care in prisons\n",
      "CN25 - Bereaved parents’ experience of adapting to life after the death of a parent with cancer who has dependent children\n",
      "CN27 - Exploring the quality of dying and death of patients with cancer undergoing palliative care (PC)\n",
      "CN23 - The end of life – a topic we avoid: The Croatian National Cancer Patient Experience Survey\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Welcome\n",
      "Nursing roles in cancer pain management\n",
      "Barriers to pain management in cancer\n",
      "Pain management in home settings\n",
      "Conclusion remarks\n",
      "Introduction\n",
      "A life interrupted: Experiences of living with melanoma\n",
      "A life interrupted: Experiences of living with melanoma\n",
      "Approach to febrile neutropenia in children and young adolescents\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Targeted therapies for EGFR NSCLC - what's new?\n",
      "Understanding Targeted Therapy for NSCLC – cancer nurses knowledge, attitude and practice\n",
      "Diagnosing a person with a mutation positive lung cancer\n",
      "What does a diagnosis mean\n",
      "Discussion and Conclusion remarks\n",
      "Introduction\n",
      "Sexual wellbeing in cancer care\n",
      "Malta: How cancer carers live with their own chronic conditions\n",
      "What really matters to you? A Delphi study on priority patient-reported outcomes to evaluate when caring for people with advanced liver or advanced renal cancer\n",
      "CN60 - OptiBra study: An RCT, optimal postoperative bra support after breast cancer surgery\n",
      "CN59 - A scoping review to establish the utility of patient reported outcome measures in blood cancer\n",
      "CN62 - Patient and public involvement in cancer research: The needs and perceptions of older adults living with and after cancer\n",
      "CN63 - Intervention pathways for low anterior resection syndrome after sphincter-saving rectal cancer surgery: A systematic scoping review.\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA8 - Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)\n",
      "Invited Discussant LBA8\n",
      "LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)\n",
      "Invited Discussant LBA9\n",
      "LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study\n",
      "LBA11 - IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen\n",
      "Invited Discussant LBA10 and LBA11\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "PSMA biology\n",
      "PSMA for diagnosis and staging\n",
      "LU-PSMA for prostate cancer treatment\n",
      "T cell engagers\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Personalizing first-line immunotherapy: Beyond one size fits all\n",
      "What’s next? Emerging next-generation immunotherapy in lung cancer\n",
      "Threading the needle: Considerations for immunotherapy in special populations\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Novel technologies embracing blood-based biomarkers for early detection\n",
      "Pushing the limit of detection for minimal residual disease\n",
      "Tools and clinical application of ctDNA in the adjuvant setting\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "State-of-the art first-line therapy for mCRC\n",
      "Impact of locoregional treatments in the metastatic setting\n",
      "Beyond first-line: Best practices and practical nuances\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Challenge of heterogeneity in gastric cancer\n",
      "Advances in HER2-targeted therapy or novel targeted therapies for HER2\n",
      "Emerging molecular targeted therapies\n",
      "Immunotherapy: Present and future \n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Breast cancer genetics: Where to now?\n",
      "Introduction\n",
      "Introduction\n",
      "TILs\n",
      "Gene-engineered T cells\n",
      "Alternative cell therapies\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Critical organ damage and late toxicities from anti-PD1\n",
      "Late haematological malignancies of systemic anticancer therapies\n",
      "Chronic toxicities of targeted therapies and their implication on compliance: Illustration with new endocrine therapies and CDK4 inhibitors\n",
      "Toxicities of CAR T cell and bispecific\n",
      "Discussion: How to design better trial taking into account toxicities\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "135MO - HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522\n",
      "136MO - Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study\n",
      "137MO - Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer\n",
      "Invited Discussant 135MO, 136MO and 137MO\n",
      "139MO - Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial\n",
      "140MO - HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial\n",
      "Invited Discussant 139MO and 140MO\n",
      "138MO - Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial\n",
      "141MO - Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel\n",
      "Invited Discussant 138MO and 141MO\n",
      "Introduction\n",
      "Introduction\n",
      "786O - Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma\n",
      "788O - Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)\n",
      "Invited Discussant 786O and 788O\n",
      "Q&A\n",
      "787O - Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial\n",
      "789O - Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study\n",
      "Invited Discussant 787O and 789O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "LBA68 - Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)\n",
      "LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)\n",
      "Invited Discussant LBA68 and LBA73\n",
      "Q&A\n",
      "1447O - Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003\n",
      "1448O - Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)\n",
      "Invited Discussant 1447O and 1448O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "The need for discovery science and biological basis in cancer cachexia\n",
      "Biological basis of exercise and physical activity on quality of life in cancer survivors\n",
      "Biological basis of behavioral interventions for cancer survivors: Focus on mindfulness\n",
      "How do you use supportive technology to improve personalised care?\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "What and who to test\n",
      "Systemic treatment implications\n",
      "Surgical implications\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "650O - A phase II study of nivolumab for high-risk oral leukoplakia\n",
      "651O - Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study\n",
      "Invited Discussant 650O and 651O\n",
      "Q&A\n",
      "652O - Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)\n",
      "653O - Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial\n",
      "Invited Discussant 652O and 653O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "LBA41 - Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation\n",
      "LBA42 - Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma\n",
      "790MO - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)\n",
      "Invited Discussant LBA41, LBA42 and 790MO\n",
      "791MO - Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma\n",
      "LBA43 - Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study\n",
      "LBA44 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial\n",
      "792MO - Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable stage III melanoma\n",
      "Invited Discussant 791MO, LBA43, LBA44 and 792MO\n",
      "Introduction\n",
      "Introduction\n",
      "LBA24 - KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation\n",
      "315O - Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort\n",
      "Invited Discussant LBA24 and 315O\n",
      "Q&A\n",
      "LBA25 - FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer\n",
      "316O - Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study\n",
      "Invited Discussant LBA25 and 316O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Pro: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "Contra: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "What is new for the pathologist?\n",
      "ctDNA in bladder and kidney cancers\n",
      "Latest imaging advances in PET and beyond translated to bladder and kidney cancers\n",
      "Microbiome\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Definition and classification, plus presentation of case\n",
      "Surgical treatment\n",
      "Radiation\n",
      "Systemic therapy\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "1451MO - In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial\n",
      "1452MO - Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)\n",
      "LBA69 - Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study\n",
      "Invited Discussant 1451MO, 1452MO and LBA69\n",
      "1736MO - Pure or mixed basal/squamous tumours present decreased outcomes after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial\n",
      "1737MO - Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial\n",
      "Invited Discussant 1736MO and 1737MO\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "The role of surgery\n",
      "Can the molecular classification inform treatment?\n",
      "What is the optimal adjuvant radiation for high-risk EC?\n",
      "Can the molecular classification guide adjuvant medical treatment?\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "LBA26 - BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)\n",
      "LBA27 - Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC\n",
      "Invited Discussant LBA26 and LBA27\n",
      "317MO - Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials\n",
      "318MO - Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)\n",
      "319MO - Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer\n",
      "Invited Discussant 317MO, 318MO and 319MO\n",
      "320MO - A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)\n",
      "LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial\n",
      "Invited Discussant 320MO and LBA28\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Current management of advanced thyroid cancer in the era of targeted agents\n",
      "Tumor agnostics in thyroid cancer: RET\n",
      "Tumor agnostics in thyroid cancer: NTRK, mTOR and immunotherapy\n",
      "Tumor agnostics in thyroid cancer: BRAF\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "The basic scientist’s perspective\n",
      "The phase I perspective\n",
      "The oncologist’s perspective\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Follicular lymphoma\n",
      "Mantle cell lymphoma\n",
      "Diffuse large B-cell lymphoma\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Persister cells: What are they, biology and heterogeneity\n",
      "Modelling and targeting MRD in melanoma\n",
      "Updates in circulating tumor cells for cancer monitoring, screening, metastasis and resistance\n",
      "MRD and adjuvant clinical trial design\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Welcome and introduction\n",
      "Developments in the treatment algorithm of patients with metastatic HER2-amplified/overexpressing breast cancer\n",
      "The promise of novel ADC technologies for the management of patients with HER2-low metastatic breast cancer\n",
      "Novel ADC-based combinations with targeted agents for the continuum of HER2-expressing advanced breast cancer\n",
      "Q&A and discussiond\n",
      "Concluding remarks\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "1529MO - The genomic landscape of small cell lung cancer in never smoking patients\n",
      "930MO - PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091\n",
      "933MO - Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer\n",
      "Invited Discussant 1529MO, 930MO and 933MO\n",
      "LBA71 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743\n",
      "931MO - Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study\n",
      "Invited Discussant LBA71 and 931MO\n",
      "929MO - Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study\n",
      "932MO - Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816\n",
      "LBA50 - Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816\n",
      "Invited Discussant 929MO, 932MO and LBA50\n",
      "Introduction\n",
      "Introduction\n",
      "LBA45 - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)\n",
      "887O - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial\n",
      "Invited Discussant LBA45 and 887O\n",
      "Q&A\n",
      "1644O - Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)\n",
      "1645O - Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial\n",
      "Invited Discussant 1644O and 1645O\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "1646MO - Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma\n",
      "1647MO - BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network\n",
      "Invited Discussant 1646MO and 1647MO\n",
      "888MO - Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors\n",
      "889MO - Comparative expression of driver transcription factors in extra-pulmonary small cell carcinoma\n",
      "890MO - Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients\n",
      "496MO - Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin\n",
      "LBA46 - Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study\n",
      "Invited Discussant 888MO, 889MO, 890MO, 496MO and LBA46\n",
      "1MO - An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma\n",
      "2MO - EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): Phase I/II SPENCER study\n",
      "Invited Discussant 1MO and 2MO\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Systemic treatment as first option\n",
      "Do we need combined treatments?\n",
      "Management of treatment-related neurological complications\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Systemic therapeutic options\n",
      "Radiotherapy\n",
      "Surgery\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair \n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Recent advances in the development of 'liquid biopsy' in early detection and therapeutic monitoring of nasopharyngeal cancer\n",
      "Pivotal new phase III trials in the first-line setting: Incorporating IO into management\n",
      "Second-line and beyond: New targets, new approaches\n",
      "Impact of locoregional therapy in the management of recurrent/metastatic NPC\n",
      "Conclusions and perspectives \n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "623MO - Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients\n",
      "624MO - Retrospective analysis of clinical value of ctDNA in newly diagnosed diffuse large B cell lymphoma\n",
      "Invited Discussant 623MO and 624MO\n",
      "625MO - Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trial\n",
      "626MO - Incidence of cardiovascular disease in Swedish healthy blood stem cell donors\n",
      "627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease\n",
      "Invited Discussant 625MO, 626MO and 627MO\n",
      "621MO - Preclinical study of DASH CAR-T cells manufactured in 48 hours\n",
      "622MO - An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients\n",
      "Invited Discussant 621MO and 622MO\n",
      "Introduction\n",
      "Introduction\n",
      "455MO - NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study\n",
      "456MO - METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors\n",
      "Invited Discussant 455MO and 466MO\n",
      "457MO - A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results\n",
      "458MO - Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)\n",
      "Invited Discussant 457MO and 458MO\n",
      "459MO - Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation\n",
      "460MO - Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers\n",
      "Invited Discussant 459MO and 460MO\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Polygenic risk scores for cancer risk prediction: How far are we from wide clinical use?\n",
      "Identifying targetable risk and prevention biomarkers: Example of the lung pre-cancer molecular landscape\n",
      "How is artificial intelligence assessment of images transforming early cancer detection?\n",
      "How to implement 30-year circulating cancer risk biomarkers discovery into actionable prevention targets\n",
      "Risk stratified approach to cancer screening\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction and scientific background\n",
      "Research and innovation in cancer: Understanding the landscape and impact of pandemic\n",
      "Nearly three years into COVID: Projecting the impact and what we can do better\n",
      "Cancer centres and networks: New ways of delivery care during and after the pandemic\n",
      "Conclusions and perspectives\n",
      "Discussion\n",
      "Introduction\n",
      "Welcome and introduction\n",
      "The conflict in Ukraine and its effect on healthcare inequalities in Europe\n",
      "My story\n",
      "Serving the adult cancer community of Ukrainian refugees\n",
      "The Safer Ukraine Collaborative: Supporting Ukrainian children with cancer affected by war\n",
      "Discussion\n",
      "Introduction\n",
      "Presentation by Expert\n",
      "Discussion led by Chair\n",
      "Introduction\n",
      "Introduction\n",
      "1317MO - Non-OS endpoints in oncology: Strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients\n",
      "1319MO - Actual patient access to innovative medicines in six European countries\n",
      "1320MO - New oncologic drugs since 2010: Differences in approval and access between the United States, Europe and Brazil\n",
      "Invited Discussant 1317MO, 1319MO and 1320MO\n",
      "1321MO - Relevance index by cancer type: Trends and regional variation analysis, 2016-2020, Republic of Korea\n",
      "1322MO - Selection of a set of quality indicators (QIs) on the care pathway in onco-hematology using a panel of experts\n",
      "1318MO - Time to diagnosis among patients with cancer in the US\n",
      "Invited Discussant 1321MO, 1322MO and 1318MO\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "AI-driven drug discovery\n",
      "Innovation drug discovery\n",
      "Designing multispecific antibodies: ANKET for antigen-specific activation of NK cells\n",
      "Cell therapy: Targeting clonal antigen\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "What defines “born to be bad” cancers?\n",
      "Small cell lung cancer: How molecular insights have shed light on aggressive clinical behaviour\n",
      "Dissecting response to treatment in adult patients with a glioma\n",
      "How can we accelerate drug discovery and development for patients with hard-to-treat cancers?\n",
      "Discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "1488MO - Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)\n",
      "1489MO - A phase Ib/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial\n",
      "1486MO - The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor\n",
      "Invited Discussant 1488MO, 1489MO and 1486MO\n",
      "1490MO - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)\n",
      "1491MO - New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis\n",
      "Invited Discussant 1490MO and 1491MO\n",
      "1487MO - A pan-sarcoma investigation of genetic alterations associated with high telomeric content\n",
      "1492MO - Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)\n",
      "1493MO - Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab (neoICB)\n",
      "Invited Discussant 1487MO, 1492MO and 1493MO\n",
      "Introduction\n",
      "Introduction\n",
      "How to write a grant/writing your grant application\n",
      "Effective time management\n",
      "How to move between PhD and medical oncology\n",
      "How to build and manage a research team in a competitive environment\n",
      "Discussion\n",
      "Introduction\n",
      "Molecular Tumor Board: A luxury or a necessity?\n",
      "Discussion led by Chair\n",
      "Introduction\n",
      "RN4CAST data about workforce issues\n",
      "Professional and educational issues in cancer nursing in Eastern European countries\n",
      "ABC4Nurses: Education programme based on Delphi study outcomes\n",
      "CN37 - Patient and public involvement in research: Reflections and experiences of doctoral cancer nurse researchers in Europe\n",
      "CN39 - Development of a reference model for patient and public involvement in oncology research in French-speaking Switzerland\n",
      "CN43 - Addressing the professional and educational issues for the cancer nursing and allied health professions workforce: A collaborative, strategic, UK-wide approach\n",
      "CN38 - The effect of a mindfulness-based stress reduction program on the pediatric hematology: Oncology nurses' professional quality of life and perceived stress level\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Building resilience among young cancer nurses\n",
      "Supporting young cancer nurses academically\n",
      "Career progression among young cancer nurses\n",
      "CN41 - Comparison of professional quality of life, empathy and emotional intelligence in cancer health care professionals: A study of cancer nurses, radiation therapists and oncologists\n",
      "CN42 - The impact of an education WhatsApp group to support nurses working in an acute oncology/haematology setting during the COVID-19 pandemic\n",
      "CN40 - Nurses’ experiences during the COVID-19 pandemic: Multicenter mixed-methods study of coping and resilience strategies\n",
      "CN26 - Nurses caring for patients at the end of life report affected psychosocial work environment when relocated during the COVID-19 pandemic: A cross-sectional study\n",
      "Q&A and discussion\n",
      "Introduction\n",
      "Welcome\n",
      "Cancer nurses’ role and use of clinical guidelines in the nutritional care of people with cancer (EONS)\n",
      "Medical oncologists’ role and use of clinical guidelines in the nutritional care of people with cancer (ESMO)\n",
      "Oncology dietitians’ role and use of clinical guidelines in the nutritional care of people with cancer (EFAD)\n",
      "The use of clinical guidelines in multidisciplinary nutritional care of people with cancer (ESPEN)\n",
      "Patient perspective: how can we provide a personalised response to address the individual nutritional needs of people with cancer\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Panel discussion\n",
      "Conclusion remarks\n",
      "Introduction\n",
      "Introduction\n",
      "Unique national experimentation: Home care and monitoring of cancer patients treated with immunotherapy\n",
      "Roles and responsibilities of nurses in the delivery of cancer care and treatments at home\n",
      "An oncology digital placement: preparing the nursing workforce in community care\n",
      "Q&A and Conclusion remarks\n",
      "Introduction\n",
      "EONS Cancer Nursing Framework update\n",
      "Introducing the European College of Cancer Nursing\n",
      "CN36 - Informal caregivers’ contributions to self-care for patients treated with oral anticancer agents: A qualitative study\n",
      "European Cancer Nursing Day 2022 Award\n",
      "European Cancer Nursing Day 2022 Winning Video\n",
      "People's Choice Poster Award\n",
      "Discussion & farewell\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "Clinical case discussion in melanoma\n",
      "Clinical case discussion in melanoma\n",
      "Breast cancer in pregnancy\n",
      "Breast cancer in pregnancy\n",
      "Genetic counselling (eg. Lynch family)\n",
      "Genetic counselling (eg. Lynch family)\n",
      "Breast cancer\n",
      "Breast cancer\n",
      "Introduction\n",
      "Introduction\n",
      "Breast cancer, early stage\n",
      "Breast cancer, metastatic\n",
      "Gynaecological cancers\n",
      "CNS tumours\n",
      "Policy and preventive strategies\n",
      "Break\n",
      "Basic science & translational research\n",
      "Developmental therapeutics\n",
      "Genitourinary tumours, prostate\n",
      "Genitourinary tumours, non-prostate\n",
      "Investigational immunotherapy\n",
      "Introduction\n",
      "Introduction\n",
      "Melanoma and other skin tumours\n",
      "Sarcoma\n",
      "Head and neck cancer\n",
      "Supportive and palliative care\n",
      "Haematological malignancies\n",
      "Break\n",
      "Gastrointestinal tumours, lower digestive\n",
      "Gastrointestinal tumours, upper digestive\n",
      "NETs and endocrine tumours\n",
      "Non-metastatic NSCLC and other thoracic malignancies\n",
      "NSCLC, metastatic\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(SUB_SESSION)):\n",
    "    print(SUB_SESSION[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "6270025d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Villejuif, Cedex, France\n",
      "Tübingen, Germany\n",
      "Tbilisi, Georgia\n",
      "\n",
      "Sha Tin, Hong Kong PRC\n",
      "Gaborone, Botswana\n",
      "Chicago, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Lausanne, Switzerland\n",
      "Villejuif, France\n",
      "London, United Kingdom\n",
      "Haidari, Greece\n",
      "Villejuif, Cedex, France\n",
      "London, United Kingdom\n",
      "Lisbon, Portugal\n",
      "Villejuif, France\n",
      "Lausanne, Switzerland\n",
      "Barcelona, Spain\n",
      "Milan, Italy\n",
      "Barcelona, Spain\n",
      "Milan, Italy\n",
      "Sao Paulo, Brazil\n",
      "New York, United States of America\n",
      "Amsterdam, Netherlands\n",
      "Milan, Italy\n",
      "\n",
      "Chapel Hill, NC, United States of America\n",
      "Dubai, United Arab Emirates\n",
      "London, United Kingdom\n",
      "New York, United States of America\n",
      "Chapel Hill, NC, United States of America\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "Neu-Isenburg, Germany\n",
      "Rochester, United States of America\n",
      "Beijing, China\n",
      "San Francisco, United States of America\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "New York, United States of America\n",
      "Brussels, Belgium\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "London, United Kingdom\n",
      "Rotterdam, Netherlands\n",
      "Boston, MA, United States of America\n",
      "Madrid, Spain\n",
      "Lugano, Switzerland\n",
      "Cambridge, United Kingdom\n",
      "Sha Tin, Hong Kong PRC\n",
      "Cambridge, United Kingdom\n",
      "Toronto, ON, Canada\n",
      "Vandoeuvre-lès-Nancy, France\n",
      "Lugano, Switzerland\n",
      "Philadelphia, United States of America\n",
      "Madrid, Spain\n",
      "Boston, United States of America\n",
      "London, United Kingdom\n",
      "Philadelphia, United States of America\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "Villejuif, Cedex, France\n",
      "Lyon, France\n",
      "Providence, United States of America\n",
      "Toronto, Canada\n",
      "London, United Kingdom\n",
      "\n",
      "Strasbourg, France\n",
      "Saitama, Japan\n",
      "Copenhagen, Denmark\n",
      "Lugano, Switzerland\n",
      "Amsterdam, Netherlands\n",
      "Baltimore, United States of America\n",
      "Essen, Germany\n",
      "Baltimore, United States of America\n",
      "Lugano, Switzerland\n",
      "Erlangen, Germany\n",
      "Los Angeles, United States of America\n",
      "New Haven, United States of America\n",
      "Lugano, Switzerland\n",
      "Houston, United States of America\n",
      "Barcelona, Spain\n",
      "Houston, United States of America\n",
      "Cambridge, United Kingdom\n",
      "Barcelona, Spain\n",
      "Houston, United States of America\n",
      "London\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "Majadahonda, Spain\n",
      "Tallinn, Estonia\n",
      "Stanford, United States of America\n",
      "Majadahonda, Spain\n",
      "Pennsylvania, PA, United States of America\n",
      "Lugano, Switzerland\n",
      "Milan, Italy\n",
      "Sha Tin, Hong Kong PRC\n",
      "Boston, United States of America\n",
      "Milan, Italy\n",
      "Kingston-Upon-Thames, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Lund, Sweden\n",
      "Melbourne, Australia\n",
      "Stanford, United States of America\n",
      "Zurich, Switzerland\n",
      "Lund, Sweden\n",
      "Lugano, Switzerland\n",
      "San Francisco, CA, United States of America\n",
      "Zurich, Switzerland\n",
      "Zurich, Switzerland\n",
      "San Francisco, CA, United States of America\n",
      "Paris, France\n",
      "London, United Kingdom\n",
      "San Francisco, CA, United States of America\n",
      "Lugano, Switzerland\n",
      "Amsterdam, Netherlands\n",
      "Dresden, Germany\n",
      "Dresden, Germany\n",
      "Leuven, Belgium\n",
      "Amsterdam, Netherlands\n",
      "Lugano, Switzerland\n",
      "Houston, United States of America\n",
      "Napoli, Italy\n",
      "Houston, United States of America\n",
      "Heidelberg, Germany\n",
      "Westmead, Australia\n",
      "Lugano, Switzerland\n",
      "New Heaven, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Villejuif, Cedex, France\n",
      "New Heaven, United States of America\n",
      "Le Kremlin Bicetre, France\n",
      "Villejuif, Cedex, France\n",
      "Limassol, Cyprus\n",
      "Lugano, Switzerland\n",
      "New Heaven, United States of America\n",
      "Siena, Italy\n",
      "Amsterdam, Netherlands\n",
      "San Antonio, United States of America\n",
      "Rochester, United States of America\n",
      "Siena, Italy\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "Houston, United States of America\n",
      "Utrecht, Netherlands\n",
      "Lugano, Switzerland\n",
      "Rome, Italy\n",
      "London, United Kingdom\n",
      "Villejuif, Cedex, France\n",
      "Rome, Italy\n",
      "Lugano, Switzerland\n",
      "Villejuif, Cedex, France\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Berlin, Germany\n",
      "Berlin, Germany\n",
      "New York, NY, United States of America\n",
      "Rouen, France\n",
      "Freiburg im Breisgau, Germany\n",
      "Berlin, Germany\n",
      "\n",
      "San Francisco, United States of America\n",
      "Bergen, Norway\n",
      "Bergen, Norway\n",
      "San Francisco, United States of America\n",
      "Bergen, Norway\n",
      "Trento, Italy\n",
      "Houston, TX, United States of America\n",
      "San Francisco, United States of America\n",
      "Lugano, Switzerland\n",
      "Blackpool, United Kingdom\n",
      "Ljubljana, Slovenia\n",
      "Belfast, United Kingdom\n",
      "Ljubljana, Slovenia\n",
      "Villejuif, Cedex, France\n",
      "Chinnor, United Kingdom\n",
      "Blackpool, United Kingdom\n",
      "Lugano, Switzerland\n",
      "\n",
      "Madrid, Spain\n",
      "Munich, Germany\n",
      "Uppsala, Sweden\n",
      "Brussels, Belgium\n",
      "Munich, Germany\n",
      "Warsaw, Poland\n",
      "Lugano, Switzerland\n",
      "\n",
      "Groningen, Netherlands\n",
      "Jerusalem, Israel\n",
      "Groningen, Netherlands\n",
      "Jerusalem, Israel\n",
      "Chandannath, Nepal\n",
      "Lugano, Switzerland\n",
      "Groningen, Netherlands\n",
      "Oslo, Norway\n",
      "Krems an der Donau, Austria\n",
      "Oslo, Norway\n",
      "Krems an der Donau, Austria\n",
      "Oslo, Norway\n",
      "Rome, Italy\n",
      "Lugano, Switzerland\n",
      "Oslo, Norway\n",
      "Krems an der Donau, Austria\n",
      "Genova, Italy\n",
      "Barcelona, Spain\n",
      "Lisbon, Portugal\n",
      "Camperdown, Australia\n",
      "London, United Kingdom\n",
      "Huddinge, Sweden\n",
      "Munich, Germany\n",
      "Villejuif, Cedex, France\n",
      "Manchester, United Kingdom\n",
      "Manchester, United Kingdom\n",
      "Barcelona, Spain\n",
      "Madrid, Spain\n",
      "Barcelona, Spain\n",
      "London, United Kingdom\n",
      "Geneva, Switzerland\n",
      "Tbilisi, Georgia\n",
      "Valencia, Spain\n",
      "Osijek, Croatia\n",
      "Bonn, Germany\n",
      "Antwerpen, Belgium\n",
      "Lausanne, Switzerland\n",
      "Villejuif, France\n",
      "London, United Kingdom\n",
      "Villejuif, France\n",
      "Mannheim, Germany\n",
      "Lyon, France\n",
      "Amsterdam, Netherlands\n",
      "Pamplona, Spain\n",
      "\n",
      "Madrid, Spain\n",
      "Boston, United States of America\n",
      "Madrid, Spain\n",
      "Villejuif, Cedex, France\n",
      "Boston, United States of America\n",
      "New Haven, United States of America\n",
      "New York, United States of America\n",
      "Madrid, Spain\n",
      "Lugano, Switzerland\n",
      "Boston, United States of America\n",
      "Dublin, Ireland\n",
      "Dublin, Ireland\n",
      "Boston, United States of America\n",
      "Madrid, Spain\n",
      "Amsterdam, Netherlands\n",
      "Sydney, Australia\n",
      "Boston, United States of America\n",
      "Lugano, Switzerland\n",
      "Barcelona, Spain\n",
      "Villejuif, Cedex, France\n",
      "Rome, Italy\n",
      "Barcelona, Spain\n",
      "Paris, France\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "London, United Kingdom\n",
      "Houston, TX, United States of America\n",
      "Munich, Germany\n",
      "London, United Kingdom\n",
      "Boston, United States of America\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "La Jolla, United States of America\n",
      "London, United Kingdom\n",
      "Boston, United States of America\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "London, United Kingdom\n",
      "La Jolla, United States of America\n",
      "\n",
      "Villejuif, France\n",
      "Villejuif, France\n",
      "New York, United States of America\n",
      "Madrid, Spain\n",
      "Sha Tin, Hong Kong PRC\n",
      "Los Angeles, United States of America\n",
      "Nanjing, China\n",
      "San Francisco, United States of America\n",
      "Lugano, Switzerland\n",
      "Osaka, Japan\n",
      "Sha Tin, Hong Kong PRC\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "Hannover, Germany\n",
      "Madrid, Spain\n",
      "Villejuif, France\n",
      "Dublin, Ireland\n",
      "Hannover, Germany\n",
      "New York, NY, United States of America\n",
      "Hannover, Germany\n",
      "Lugano, Switzerland\n",
      "Sutton, United Kingdom\n",
      "Porto Alegre, Brazil\n",
      "Sutton, United Kingdom\n",
      "Boston, MA, United States of America\n",
      "Lyon, France\n",
      "Melbourne, Australia\n",
      "Lugano, Switzerland\n",
      "Brussels, Belgium\n",
      "Munich, Germany\n",
      "Barcelona, Spain\n",
      "Munich, Germany\n",
      "Brussels, Belgium\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "The Woodlands, United States of America\n",
      "Barcelona, Spain\n",
      "Seoul, Korea, Republic of\n",
      "Barcelona, Spain\n",
      "The Woodlands, United States of America\n",
      "London, United Kingdom\n",
      "Wuhan, China\n",
      "London, United Kingdom\n",
      "Columbus, United States of America\n",
      "Rome, Italy\n",
      "London, United Kingdom\n",
      "Luzern, Switzerland\n",
      "Malmo, Sweden\n",
      "Maastricht, Netherlands\n",
      "Amsterdam, Netherlands\n",
      "Genova, Italy\n",
      "Lugano, Switzerland\n",
      "Mönchengladbach, Germany\n",
      "Genova, Italy\n",
      "Luzern, Switzerland\n",
      "Lugano, Switzerland\n",
      "Dubai, United Arab Emirates\n",
      "Seoul, Korea, Republic of\n",
      "Melbourne, Australia\n",
      "Villejuif, France\n",
      "Beijing, China\n",
      "Seoul, Korea, Republic of\n",
      "Rochester, United States of America\n",
      "Madrid, Spain\n",
      "Boston, United States of America\n",
      "Dubai, United Arab Emirates\n",
      "Bordeaux, France\n",
      "Mannheim, Germany\n",
      "Oslo, Norway\n",
      "Milan, Italy\n",
      "Melbourne, Australia\n",
      "Amsterdam, Netherlands\n",
      "Amsterdam, Netherlands\n",
      "Lugano, Switzerland\n",
      "Liverpool, United Kingdom\n",
      "Paris, France\n",
      "\n",
      "\n",
      "Villejuif, Cedex, France\n",
      "Essen, Germany\n",
      "Villejuif, Cedex, France\n",
      "Paris, France\n",
      "Essen, Germany\n",
      "San Diego, CA, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Essen, Germany\n",
      "\n",
      "Villejuif, Cedex, France\n",
      "Boston, United States of America\n",
      "Essen, Germany\n",
      "Zurich, Switzerland\n",
      "Villejuif, Cedex, France\n",
      "\n",
      "Paris, France\n",
      "Houston, United States of America\n",
      "Lausanne, Switzerland\n",
      "\n",
      "Brescia, Italy\n",
      "Brescia, Italy\n",
      "London, United Kingdom\n",
      "Villejuif, France\n",
      "Munich, Germany\n",
      "Lugano, Switzerland\n",
      "Faro, Portugal\n",
      "Woluwe-Saint-Lambert, Belgium\n",
      "Groningen, Netherlands\n",
      "Toronto, Canada\n",
      "New Haven, United States of America\n",
      "Paris, France\n",
      "Groningen, Netherlands\n",
      "Montreal, Canada\n",
      "Kashiwa, Japan\n",
      "Lausanne, Switzerland\n",
      "Faro, Portugal\n",
      "Syracuse, United States of America\n",
      "Woolloongabba, Australia\n",
      "Haidari, Greece\n",
      "Woluwe-Saint-Lambert, Belgium\n",
      "Utrecht, Netherlands\n",
      "Villejuif, Cedex, France\n",
      "Utrecht, Netherlands\n",
      "Aurora, United States of America\n",
      "London, United Kingdom\n",
      "Aurora, United States of America\n",
      "London, United Kingdom\n",
      "Stanmore, United Kingdom\n",
      "Bordeaux, France\n",
      "Aurora, United States of America\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "New York, United States of America\n",
      "Rotterdam, Netherlands\n",
      "New York, United States of America\n",
      "Amsterdam, Netherlands\n",
      "Bologna, Italy\n",
      "Amsterdam, Netherlands\n",
      "Badalona, Spain\n",
      "Rotterdam, Netherlands\n",
      "Lugano, Switzerland\n",
      "Villejuif, France\n",
      "Villejuif, France\n",
      "London, United Kingdom\n",
      "Madrid, Spain\n",
      "Lugano, Switzerland\n",
      "Villejuif, France\n",
      "Krems an der Donau, Austria\n",
      "New Heaven, United States of America\n",
      "Seoul, Korea, Republic of\n",
      "Amsterdam, Netherlands\n",
      "Heidelberg, Germany\n",
      "Villejuif, France\n",
      "Copenhagen, Denmark\n",
      "Rio de Janeiro, Brazil\n",
      "Villejuif, France\n",
      "New Heaven, United States of America\n",
      "Paris, France\n",
      "Rochester, United States of America\n",
      "Leuven, Belgium\n",
      "Krems an der Donau, Austria\n",
      "Sha Tin, Hong Kong PRC\n",
      "Lausanne, Switzerland\n",
      "Sha Tin, Hong Kong PRC\n",
      "Genova, Italy\n",
      "Genova, Italy\n",
      "Genova, Italy\n",
      "Boston, MA, United States of America\n",
      "Brussels, Luxembourg\n",
      "\n",
      "Houston, United States of America\n",
      "Barcelona, Spain\n",
      "Barcelona, Spain\n",
      "Houston, United States of America\n",
      "Munich, Germany\n",
      "Barcelona, Spain\n",
      "Sursee, Switzerland\n",
      "\n",
      "Houston, United States of America\n",
      "Seoul, Korea, Republic of\n",
      "Seoul, Korea, Republic of\n",
      "Seoul, Korea, Republic of\n",
      "Amsterdam, Netherlands\n",
      "London, United Kingdom\n",
      "\n",
      "Amsterdam, Netherlands\n",
      "Amsterdam, Netherlands\n",
      "Utrecht, Netherlands\n",
      "London, United Kingdom\n",
      "Munich, Germany\n",
      "\n",
      "Ferrara, Italy\n",
      "Jerusalem, Israel\n",
      "Ferrara, Italy\n",
      "New York, United States of America\n",
      "Portland, United States of America\n",
      "Tucson, United States of America\n",
      "Leuven, Belgium\n",
      "Kashiwa, Japan\n",
      "Lyon, France\n",
      "Lugano, Switzerland\n",
      "San Antonio, United States of America\n",
      "London, United Kingdom\n",
      "Taipei City, Taiwan\n",
      "Lugano, Switzerland\n",
      "Herlev, Denmark\n",
      "Zurich, Switzerland\n",
      "Pamplona, Spain\n",
      "Hackensack, United States of America\n",
      "Boston, United States of America\n",
      "Herlev, Denmark\n",
      "Villejuif, France\n",
      "Amsterdam, Netherlands\n",
      "Oxford, United Kingdom\n",
      "Munich, Germany\n",
      "Houston, United States of America\n",
      "New York, United States of America\n",
      "Hangzhou, China\n",
      "Zurich, Switzerland\n",
      "Melbourne, Australia\n",
      "London, United Kingdom\n",
      "Melbourne, Australia\n",
      "Paris, France\n",
      "Nice, France\n",
      "Shanghai, China\n",
      "Nice, France\n",
      "\n",
      "Beijing, China\n",
      "Nanning, China\n",
      "Boston, United States of America\n",
      "Paris, France\n",
      "Lugano, Switzerland\n",
      "Lyon, France\n",
      "Milan, Italy\n",
      "Lyon, France\n",
      "Aurora, United States of America\n",
      "Taipei City, Taiwan\n",
      "Sapporo, Japan\n",
      "Santa Monica, United States of America\n",
      "Oslo, Norway\n",
      "Lugano, Switzerland\n",
      "Paris, France\n",
      "Bordeaux, France\n",
      "Aachen, Germany\n",
      "Lugano, Switzerland\n",
      "Dublin, Ireland\n",
      "Leipzig, Germany\n",
      "Barcelona, Spain\n",
      "Shanghai, China\n",
      "Villejuif, France\n",
      "Barcelona, Spain\n",
      "Hannover, Germany\n",
      "Hannover, Germany\n",
      "Madrid, Spain\n",
      "Dublin, Ireland\n",
      "Poitiers, France\n",
      "New York, United States of America\n",
      "Leipzig, Germany\n",
      "Groningen, Netherlands\n",
      "Boston, United States of America\n",
      "Groningen, Netherlands\n",
      "Boston, United States of America\n",
      "London, United Kingdom\n",
      "Geneva, Switzerland\n",
      "Uppsala, Sweden\n",
      "Groningen, Netherlands\n",
      "\n",
      "Barcelona, Spain\n",
      "Munich, Germany\n",
      "Munich, Germany\n",
      "Barcelona, Spain\n",
      "Villejuif, Cedex, France\n",
      "Brussels, Belgium\n",
      "Barcelona, Spain\n",
      "\n",
      "Teilhet, France\n",
      "Prague, Czech Republic\n",
      "Amsterdam, Netherlands\n",
      "Bloemendaal, Netherlands\n",
      "Brussels, Belgium\n",
      "Teilhet, France\n",
      "Rennes, France\n",
      "\n",
      "\n",
      "Singapore, Singapore\n",
      "Villejuif, France\n",
      "Tilburg, Netherlands\n",
      "Orange, United States of America\n",
      "London, United Kingdom\n",
      "\n",
      "Lorenskog, Norway\n",
      "Oslo, Norway\n",
      "Lyon, France\n",
      "Villejuif, France\n",
      "\n",
      "Ljubljana, Slovenia\n",
      "Bucharest, Romania\n",
      "Lincolnshire, United Kingdom\n",
      "Rome, Italy\n",
      "London, United Kingdom\n",
      "Lisbon, Portugal\n",
      "Tadworth, United Kingdom\n",
      "\n",
      "\n",
      "Manchester, United Kingdom\n",
      "Houston, TX, United States of America\n",
      "Manchester, United Kingdom\n",
      "Houston, TX, United States of America\n",
      "Manchester, United Kingdom\n",
      "Trondheim, Norway\n",
      "Atlanta, United States of America\n",
      "Houston, TX, United States of America\n",
      "\n",
      "Goes, Netherlands\n",
      "Wilrijk, Belgium\n",
      "Goes, Netherlands\n",
      "Boston, United States of America\n",
      "Wilrijk, Belgium\n",
      "Heidelberg, Germany\n",
      "Ljubljana, Slovenia\n",
      "Goes, Netherlands\n",
      "\n",
      "Milan, Italy\n",
      "Wilrijk, Belgium\n",
      "Wilrijk, Belgium\n",
      "Milan, Italy\n",
      "Warsaw, Poland\n",
      "Bordeaux, France\n",
      "Milan, Italy\n",
      "\n",
      "Bologna, Italy\n",
      "Zurich, Switzerland\n",
      "Lausanne, Switzerland\n",
      "Vienna, Austria\n",
      "Oslo, Norway\n",
      "Houston, United States of America\n",
      "Bologna, Italy\n",
      "Milan, Italy\n",
      "Zurich, Switzerland\n",
      "Vienna, Austria\n",
      "Lausanne, Switzerland\n",
      "Phoenix, United States of America\n",
      "Vienna, Austria\n",
      "Padova, Italy\n",
      "Zurich, Switzerland\n",
      "London, United Kingdom\n",
      "Warsaw, Poland\n",
      "Villejuif, France\n",
      "Geneva, Switzerland\n",
      "\n",
      "Brussels, Belgium\n",
      "Manchester, United Kingdom\n",
      "\n",
      "Napoli, Italy\n",
      "Torino, Italy\n",
      "Napoli, Italy\n",
      "Gent, Belgium\n",
      "Gent, Belgium\n",
      "Villejuif, Cedex, France\n",
      "Lyon, France\n",
      "Brighton, United Kingdom\n",
      "Zurich, Switzerland\n",
      "Gent, Belgium\n",
      "\n",
      "Dublin, Ireland\n",
      "Stockholm, Sweden\n",
      "Turku, Finland\n",
      "Dublin, Ireland\n",
      "Montreal, Canada\n",
      "Hospitalet de Llobregat, Spain\n",
      "Ankara, Turkey\n",
      "Osijek, Croatia\n",
      "\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "Northolt, United Kingdom\n",
      "Barcelona, Spain\n",
      "London, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "London, United Kingdom\n",
      "Barcelona, Spain\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Rotterdam, Netherlands\n",
      "Limassol, Cyprus\n",
      "London, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "Manchester, United Kingdom\n",
      "\n",
      "Gent, Belgium\n",
      "Gent, Belgium\n",
      "Gent, Belgium\n",
      "Amsterdam, Netherlands\n",
      "Zurich, Switzerland\n",
      "Gent, Belgium\n",
      "London, United Kingdom\n",
      "Southampton, United Kingdom\n",
      "Glasgow, United Kingdom\n",
      "Brighton, United Kingdom\n",
      "Dublin, Ireland\n",
      "\n",
      "Valencia, Spain\n",
      "Warsaw, Poland\n",
      "London, United Kingdom\n",
      "Warsaw, Poland\n",
      "Madrid, Spain\n",
      "Camperdown, Australia\n",
      "Villejuif, Cedex, France\n",
      "Potsdam, Germany\n",
      "Leipzig, Germany\n",
      "New York, United States of America\n",
      "Brussels, Belgium\n",
      "Houston, United States of America\n",
      "Amsterdam, Netherlands\n",
      "Melbourne, Australia\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "Villejuif, Cedex, France\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Madrid, Spain\n",
      "Lugano, Switzerland\n",
      "Montreal, Canada\n",
      "San Francisco, United States of America\n",
      "London, United Kingdom\n",
      "\n",
      "New York, United States of America\n",
      "London, United Kingdom\n",
      "Utrecht, Netherlands\n",
      "Rome, Italy\n",
      "Paris, France\n",
      "Lugano, Switzerland\n",
      "Cordoba, Spain\n",
      "Paris, France\n",
      "New York, United States of America\n",
      "Lugano, Switzerland\n",
      "New York, United States of America\n",
      "Sydney, Australia\n",
      "Barcelona, Spain\n",
      "Toulouse, France\n",
      "Boston, United States of America\n",
      "New York, United States of America\n",
      "\n",
      "Istanbul, Turkey\n",
      "Paris, France\n",
      "Grosshansdorf, Germany\n",
      "Lugano, Switzerland\n",
      "Paris, France\n",
      "Barcelona, Spain\n",
      "Kashiwa, Japan\n",
      "Guangzhou, China\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Amsterdam, Netherlands\n",
      "Santa Monica, United States of America\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "Calgary, Canada\n",
      "Barcelona, Spain\n",
      "Duarte, United States of America\n",
      "Strasbourg, France\n",
      "Calgary, Canada\n",
      "Lugano, Switzerland\n",
      "Melbourne, Australia\n",
      "Melbourne, Australia\n",
      "Amsterdam, Netherlands\n",
      "Amsterdam, Netherlands\n",
      "Sutton, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "Munich, Germany\n",
      "Sutton, United Kingdom\n",
      "\n",
      "Lyon, France\n",
      "Amsterdam, Netherlands\n",
      "\n",
      "Villejuif, Cedex, France\n",
      "Glasgow, United Kingdom\n",
      "\n",
      "Gdansk, Poland\n",
      "Gdansk, Poland\n",
      "Zurich, Switzerland\n",
      "Maastricht, Netherlands\n",
      "Boston, United States of America\n",
      "Lugano, Switzerland\n",
      "Milan, Italy\n",
      "Paris, France\n",
      "Milan, Italy\n",
      "Milan, Italy\n",
      "Lugano, Switzerland\n",
      "Manchester, United Kingdom\n",
      "Heidelberg, Germany\n",
      "Lugano, Switzerland\n",
      "Tbilisi, Georgia\n",
      "Hannover, Germany\n",
      "Lugano, Switzerland\n",
      "Milan, Italy\n",
      "Paris, France\n",
      "Newcastle upon Tyne, United Kingdom\n",
      "London, United Kingdom\n",
      "\n",
      "Senhora da Hora, Portugal\n",
      "Milan, Italy\n",
      "\n",
      "Barcelona, Spain\n",
      "Maastricht, Netherlands\n",
      "Lugano, Switzerland\n",
      "Berlin, Germany\n",
      "Toronto, Canada\n",
      "Toronto, Canada\n",
      "Berlin, Germany\n",
      "Brussels\n",
      "Paris, France\n",
      "La Jolla, United States of America\n",
      "Berlin, Germany\n",
      "Lugano, Switzerland\n",
      "Marburg, Germany\n",
      "Villejuif, Cedex, France\n",
      "Villejuif, Cedex, France\n",
      "Marburg, Germany\n",
      "Candiolo, Italy\n",
      "Melbourne, Australia\n",
      "London, United Kingdom\n",
      "Marburg, Germany\n",
      "Lugano, Switzerland\n",
      "Toronto, Canada\n",
      "Parkville, Australia\n",
      "Parkville, Australia\n",
      "London, United Kingdom\n",
      "Toronto, Canada\n",
      "Edinburgh, United Kingdom\n",
      "Lyon, France\n",
      "Toronto, Canada\n",
      "Lugano, Switzerland\n",
      "San Francisco, United States of America\n",
      "Barcelona, Spain\n",
      "San Francisco, United States of America\n",
      "Barcelona, Spain\n",
      "Sha Tin, Hong Kong PRC\n",
      "London, United Kingdom\n",
      "Kashiwa, Japan\n",
      "Seoul, Korea, Republic of\n",
      "Barcelona, Spain\n",
      "Shanghai, China\n",
      "Shanghai, China\n",
      "Sha Tin, Hong Kong PRC\n",
      "Nashville, United States of America\n",
      "Chicago, United States of America\n",
      "Orbassano, Italy\n",
      "London, United Kingdom\n",
      "Zurich, Switzerland\n",
      "Tuebingen, Germany\n",
      "Tuebingen, Germany\n",
      "Zurich, Switzerland\n",
      "Napoli, Italy\n",
      "Lugano, Switzerland\n",
      "Kashiwa, Japan\n",
      "Kashiwa, Japan\n",
      "Lugano, Switzerland\n",
      "Montreal, Canada\n",
      "Amsterdam, Netherlands\n",
      "Lugano, Switzerland\n",
      "\n",
      "New York, United States of America\n",
      "Liverpool, United Kingdom\n",
      "New York, United States of America\n",
      "Doha, Qatar\n",
      "Montreal, Canada\n",
      "New York, United States of America\n",
      "Lugano, Switzerland\n",
      "Lugano, Switzerland\n",
      "San Francisco, United States of America\n",
      "Vienna, Austria\n",
      "Vienna, Austria\n",
      "San Francisco, United States of America\n",
      "Paris, France\n",
      "Stanford, United States of America\n",
      "Vienna, Austria\n",
      "San Francisco, United States of America\n",
      "Lugano, Switzerland\n",
      "Melbourne, Australia\n",
      "Amsterdam, Netherlands\n",
      "Montreal, Canada\n",
      "Villejuif, France\n",
      "Palermo, Italy\n",
      "Berlin, Germany\n",
      "Villejuif, France\n",
      "Amsterdam, Netherlands\n",
      "Wollstonecraft, Australia\n",
      "Montreal, Canada\n",
      "Montreal, Canada\n",
      "Guangzhou, China\n",
      "Toronto, Canada\n",
      "San Francisco, United States of America\n",
      "Melbourne, Australia\n",
      "Heidelberg, Germany\n",
      "Villejuif, Cedex, France\n",
      "Heidelberg, Germany\n",
      "Freiburg im Breisgau, Germany\n",
      "Houston, TX, United States of America\n",
      "Lugano, Switzerland\n",
      "Villejuif, Cedex, France\n",
      "Boston, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Woluwe-Saint-Lambert, Belgium\n",
      "Woluwe-Saint-Lambert, Belgium\n",
      "Lugano, Switzerland\n",
      "La Jolla, United States of America\n",
      "Lausanne, Switzerland\n",
      "Lugano, Switzerland\n",
      "\n",
      "Hamilton, Canada\n",
      "London, United Kingdom\n",
      "Boston, United States of America\n",
      "Bari, Italy\n",
      "Jena, Germany\n",
      "London, United Kingdom\n",
      "Munich, Germany\n",
      "London, United Kingdom\n",
      "Manchester, United Kingdom\n",
      "Boston, United States of America\n",
      "Tampa, United States of America\n",
      "Bellinzona, Switzerland\n",
      "Uppsala, Sweden\n",
      "Hamilton, Canada\n",
      "Essen, Germany\n",
      "Madrid, Spain\n",
      "New York City, United States of America\n",
      "Prague, Czech Republic\n",
      "Essen, Germany\n",
      "London, United Kingdom\n",
      "Lyon, France\n",
      "London, United Kingdom\n",
      "Madrid, Spain\n",
      "Barcelona, Spain\n",
      "Köln, Germany\n",
      "Barcelona, Spain\n",
      "Liverpool, United Kingdom\n",
      "Stockholm, Sweden\n",
      "Liverpool, United Kingdom\n",
      "Stockholm, Sweden\n",
      "Luxembourg City, Luxembourg\n",
      "Liverpool, United Kingdom\n",
      "Stockholm, Sweden\n",
      "Brussels, Belgium\n",
      "\n",
      "Liverpool, United Kingdom\n",
      "Stockholm, Sweden\n",
      "Lausanne, Switzerland\n",
      "New Haven, United States of America\n",
      "Lausanne, Switzerland\n",
      "Providence, United States of America\n",
      "Amsterdam, Netherlands\n",
      "London, United Kingdom\n",
      "Boston, United States of America\n",
      "Utrecht, Netherlands\n",
      "Boston, United States of America\n",
      "Mannheim, Germany\n",
      "Singapore, Singapore\n",
      "Mannheim, Germany\n",
      "Portland, United States of America\n",
      "Taipei City, Taiwan\n",
      "Portland, United States of America\n",
      "Madrid, Spain\n",
      "Villejuif, France\n",
      "Vienna, Austria\n",
      "Portland, United States of America\n",
      "Taipei City, Taiwan\n",
      "Lugano, Switzerland\n",
      "Boston, United States of America\n",
      "Bari, Italy\n",
      "Boston, United States of America\n",
      "Essen, Germany\n",
      "Boston, United States of America\n",
      "Bari, Italy\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "Bari, Italy\n",
      "Liverpool, United Kingdom\n",
      "Milan, Italy\n",
      "Liverpool, United Kingdom\n",
      "Nijmegen, Netherlands\n",
      "Brescia, Italy\n",
      "Lugano, Switzerland\n",
      "Torino, Italy\n",
      "New York, United States of America\n",
      "New York, United States of America\n",
      "Bronx, United States of America\n",
      "New York, United States of America\n",
      "Torino, Italy\n",
      "\n",
      "Amsterdam, Netherlands\n",
      "Houston, United States of America\n",
      "New York, United States of America\n",
      "Lugano, Switzerland\n",
      "Zurich, Switzerland\n",
      "Rome, Italy\n",
      "Zurich, Switzerland\n",
      "Essen, Germany\n",
      "Rotterdam, Netherlands\n",
      "Saint-Étienne, France\n",
      "Villejuif, Cedex, France\n",
      "London, United Kingdom\n",
      "Saint-Étienne, France\n",
      "Bath, United Kingdom\n",
      "Marseille, Cedex 09, France\n",
      "Essen, Germany\n",
      "St. Gallen, Switzerland\n",
      "Seattle, United States of America\n",
      "Paris, France\n",
      "Villejuif, Cedex, France\n",
      "Rotterdam, Netherlands\n",
      "Boston, United States of America\n",
      "Rotterdam, Netherlands\n",
      "Boston, United States of America\n",
      "Athens, Greece\n",
      "Athens, Greece\n",
      "Tübingen, Germany\n",
      "Athens, Greece\n",
      "Lugano, Switzerland\n",
      "Lugano, Switzerland\n",
      "Leeds, United Kingdom\n",
      "Cambridge, United Kingdom\n",
      "Barcelona, Spain\n",
      "Leeds, United Kingdom\n",
      "Brussels, Belgium\n",
      "Helsinki, Finland\n",
      "Lugano, Switzerland\n",
      "Lugano, Switzerland\n",
      "Nijmegen, Netherlands\n",
      "Lausanne, Switzerland\n",
      "Lyon, France\n",
      "Heidelberg, Germany\n",
      "Barcelona, Spain\n",
      "Nijmegen, Netherlands\n",
      "Lugano, Switzerland\n",
      "Brussels, Belgium\n",
      "Boston, United States of America\n",
      "Boston, United States of America\n",
      "Brussels, Belgium\n",
      "Groningen, Netherlands\n",
      "Villejuif, France\n",
      "Aachen, Germany\n",
      "Villejuif, France\n",
      "Jerusalem, Israel\n",
      "New York, United States of America\n",
      "Groningen, Netherlands\n",
      "Lugano, Switzerland\n",
      "Boston, United States of America\n",
      "Boston, United States of America\n",
      "Paris, France\n",
      "Amsterdam, Netherlands\n",
      "Milan, Italy\n",
      "\n",
      "Blackpool, United Kingdom\n",
      "Madrid, Spain\n",
      "Madrid, Spain\n",
      "Sacramento, United States of America\n",
      "Lisbon, Portugal\n",
      "Stockholm, Sweden\n",
      "Milan, Italy\n",
      "\n",
      "Lugano, Switzerland\n",
      "Rotterdam, Netherlands\n",
      "Madrid, Spain\n",
      "Madrid, Spain\n",
      "Nijmegen, Netherlands\n",
      "Marseille, France\n",
      "Geneva, Switzerland\n",
      "Rotterdam, Netherlands\n",
      "Madrid, Spain\n",
      "Rotterdam, Netherlands\n",
      "Singapore, Singapore\n",
      "Liverpool, United Kingdom\n",
      "Singapore, Singapore\n",
      "Sao Paulo, Brazil\n",
      "Milan, Italy\n",
      "Chicago, United States of America\n",
      "Singapore, Singapore\n",
      "Liverpool, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Prague, Czech Republic\n",
      "Warsaw, Poland\n",
      "Warsaw, Poland\n",
      "Prague, Czech Republic\n",
      "Antwerpen, Belgium\n",
      "Warsaw, Poland\n",
      "Warsaw, Poland\n",
      "Prague, Czech Republic\n",
      "\n",
      "Potsdam, Germany\n",
      "Genova, Italy\n",
      "Villejuif, Cedex, France\n",
      "Portland, United States of America\n",
      "Potsdam, Germany\n",
      "Lugano, Switzerland\n",
      "Heidelberg, Germany\n",
      "Boston, United States of America\n",
      "Houston, United States of America\n",
      "Leeds, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Uppsala, Sweden\n",
      "Milan, Italy\n",
      "Uppsala, Sweden\n",
      "Erlangen, Germany\n",
      "Milan, Italy\n",
      "Lugano, Switzerland\n",
      "Brussels, Belgium\n",
      "Madrid, Spain\n",
      "Brussels, Belgium\n",
      "Brussels, Belgium\n",
      "Madrid, Spain\n",
      "Athens, Greece\n",
      "Madrid, Spain\n",
      "Valencia, Spain\n",
      "Brussels, Belgium\n",
      "Tbilisi, Georgia\n",
      "Tübingen, Germany\n",
      "Brussels, Belgium\n",
      "Brussels, Belgium\n",
      "Madrid, Spain\n",
      "Epalinges, Switzerland\n",
      "Parma, Italy\n",
      "Tübingen, Germany\n",
      "Brussels, Belgium\n",
      "Tübingen, Germany\n",
      "Genova, Italy\n",
      "Madrid, Spain\n",
      "Genova, Italy\n",
      "Tübingen, Germany\n",
      "Vienna, Austria\n",
      "Munich, Germany\n",
      "Lugano, Switzerland\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "\n",
      "Toulouse, France\n",
      "Lugano, Switzerland\n",
      "Amsterdam, Netherlands\n",
      "\n",
      "Genova, Italy\n",
      "Birmingham, United Kingdom\n",
      "Reading, United Kingdom\n",
      "Solna, Sweden\n",
      "Dublin, Ireland\n",
      "Edinburgh, United Kingdom\n",
      "Solna, Sweden\n",
      "Solna, Sweden\n",
      "\n",
      "Amsterdam, Netherlands\n",
      "Istanbul, Turkey\n",
      "Rotterdam, Netherlands\n",
      "Dundonald, United Kingdom\n",
      "Glasgow, United Kingdom\n",
      "Jordanstown, United Kingdom\n",
      "Athens, Greece\n",
      "Zagreb, Croatia\n",
      "\n",
      "Osijek, Croatia\n",
      "Osijek, Croatia\n",
      "Nicosia, Cyprus\n",
      "Cambridge, United Kingdom\n",
      "Zagreb, Croatia\n",
      "Osijek, Croatia\n",
      "Gent, Belgium\n",
      "Edinburgh, United Kingdom\n",
      "Edinburgh, United Kingdom\n",
      "Istanbul, Turkey\n",
      "Lugano, Switzerland\n",
      "Osijek, Croatia\n",
      "Osijek, Croatia\n",
      "Zagreb, Croatia\n",
      "Osijek, Croatia\n",
      "Macclesfield, United Kingdom\n",
      "London, United Kingdom\n",
      "Osijek, Croatia\n",
      "Edirne, Turkey\n",
      "London, United Kingdom\n",
      "Msida, Malta\n",
      "Barcelona, Spain\n",
      "Stockholm, Sweden\n",
      "Bristol, United Kingdom\n",
      "Dublin, Ireland\n",
      "Gent, Belgium\n",
      "\n",
      "Valencia, Spain\n",
      "London, United Kingdom\n",
      "Boston, United States of America\n",
      "Duarte, United States of America\n",
      "Sutton, United Kingdom\n",
      "Bellinzona, Switzerland\n",
      "Nashville, United States of America\n",
      "London, United Kingdom\n",
      "Toronto, Canada\n",
      "Lugano, Switzerland\n",
      "Melbourne, Australia\n",
      "Essen, Germany\n",
      "Essen, Germany\n",
      "New York, NY, United States of America\n",
      "Amsterdam, Netherlands\n",
      "Melbourne, Australia\n",
      "Villejuif, Cedex, France\n",
      "Essen, Germany\n",
      "Lugano, Switzerland\n",
      "Toronto, Canada\n",
      "Boston, United States of America\n",
      "Madrid, Spain\n",
      "Toronto, Canada\n",
      "Grosshansdorf, Germany\n",
      "Lugano, Switzerland\n",
      "Boston, United States of America\n",
      "Boston, United States of America\n",
      "London, United Kingdom\n",
      "Stanford, United States of America\n",
      "Lausanne, Switzerland\n",
      "Boston, United States of America\n",
      "Lugano, Switzerland\n",
      "Pisa, Italy\n",
      "Rotterdam, Netherlands\n",
      "Pisa, Italy\n",
      "Rotterdam, Netherlands\n",
      "Woodville, Australia\n",
      "Lugano, Switzerland\n",
      "Leipzig, Germany\n",
      "Leipzig, Germany\n",
      "Amsterdam, Netherlands\n",
      "Kashiwa, Japan\n",
      "Valencia, Spain\n",
      "Leipzig, Germany\n",
      "Lugano, Switzerland\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Boston, United States of America\n",
      "Herlev, Denmark\n",
      "Amsterdam, Netherlands\n",
      "Herlev, Denmark\n",
      "Rome, Italy\n",
      "Leipzig, Germany\n",
      "Lugano, Switzerland\n",
      "Dublin, Ireland\n",
      "Boston, United States of America\n",
      "Boston, United States of America\n",
      "Dublin, Ireland\n",
      "Villejuif, Cedex, France\n",
      "Boston, United States of America\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "Melbourne, Australia\n",
      "Prato, Italy\n",
      "Barcelona, Spain\n",
      "Singapore, Singapore\n",
      "Brussels, Belgium\n",
      "Mumbai, India\n",
      "Melbourne, Australia\n",
      "Brussels, Belgium\n",
      "Padova, Italy\n",
      "Prato, Italy\n",
      "Edinburgh, United Kingdom\n",
      "Madrid, Spain\n",
      "Barcelona, Spain\n",
      "Zurich, Switzerland\n",
      "Toronto, Canada\n",
      "Zurich, Switzerland\n",
      "Wollstonecraft, Australia\n",
      "Houston, United States of America\n",
      "Lugano, Switzerland\n",
      "Heidelberg, Germany\n",
      "Houston, United States of America\n",
      "Amsterdam, Netherlands\n",
      "Lugano, Switzerland\n",
      "Porto Alegre, Brazil\n",
      "Villejuif, Cedex, France\n",
      "Houston, United States of America\n",
      "New York, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Lugano, Switzerland\n",
      "Coral Gables, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Porto Alegre, Brazil\n",
      "Lugano, Switzerland\n",
      "Villejuif, Cedex, France\n",
      "Seoul, Korea, Republic of\n",
      "Villejuif, Cedex, France\n",
      "London, United Kingdom\n",
      "Seoul, Korea, Republic of\n",
      "Los Angeles, United States of America\n",
      "Villejuif, France\n",
      "Seoul, Korea, Republic of\n",
      "Lugano, Switzerland\n",
      "Genova, Italy\n",
      "Genova, Italy\n",
      "Leuven, Belgium\n",
      "Jerusalem, Israel\n",
      "Luzern, Switzerland\n",
      "Lugano, Switzerland\n",
      "Sha Tin, Hong Kong PRC\n",
      "Brescia, Italy\n",
      "Boston, United States of America\n",
      "Southport, Australia\n",
      "Haidari, Greece\n",
      "Lugano, Switzerland\n",
      "Singapore, Singapore\n",
      "Paris, France\n",
      "Milan, Italy\n",
      "Lugano, Switzerland\n",
      "Tübingen, Germany\n",
      "Los Angeles, United States of America\n",
      "Napoli, Italy\n",
      "Tampa, United States of America\n",
      "Los Angeles, United States of America\n",
      "Tübingen, Germany\n",
      "Amsterdam, Netherlands\n",
      "Amsterdam, Netherlands\n",
      "Utrecht, Netherlands\n",
      "Atlanta, United States of America\n",
      "Los Angeles, United States of America\n",
      "Amsterdam, Netherlands\n",
      "Milan, Italy\n",
      "Boston, United States of America\n",
      "Kashiwa, Japan\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "Houston, United States of America\n",
      "Houston, United States of America\n",
      "Milan, Italy\n",
      "Lugano, Switzerland\n",
      "Cambridge, United Kingdom\n",
      "Cambridge, United Kingdom\n",
      "Lugano, Switzerland\n",
      "New York, United States of America\n",
      "Singapore, Singapore\n",
      "Lugano, Switzerland\n",
      "Lugano, Switzerland\n",
      "Houston, TX, United States of America\n",
      "Rehovot, Israel\n",
      "Houston, TX, United States of America\n",
      "Boston, United States of America\n",
      "Rotterdam, Netherlands\n",
      "Rotterdam, Netherlands\n",
      "Boston, United States of America\n",
      "Aarhus, Denmark\n",
      "Groningen, Netherlands\n",
      ", France\n",
      "Boston, United States of America\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Essen, Germany\n",
      "Ghent, Belgium\n",
      "Bellinzona, Switzerland\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "Amsterdam, Netherlands\n",
      "Boston, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Bethesda, United States of America\n",
      "Madrid, Spain\n",
      "Paris, France\n",
      "Milan, Italy\n",
      "Amsterdam, Netherlands\n",
      "Villejuif, Cedex, France\n",
      "Villejuif, Cedex, France\n",
      "Innsbruck, Austria\n",
      "Vancouver, Canada\n",
      "Leiden, Netherlands\n",
      "Villejuif, Cedex, France\n",
      "Lugano, Switzerland\n",
      "Odense, Denmark\n",
      "Tampere, Finland\n",
      "Barcelona, Spain\n",
      "Barcelona, Spain\n",
      "Durham, United States of America\n",
      "Odense, Denmark\n",
      "Paris, France\n",
      "Melbourne, Australia\n",
      "Seattle, United States of America\n",
      "Barcelona, Spain\n",
      "Duarte, United States of America\n",
      "Dijon, France\n",
      "Tampere, Finland\n",
      "Houston, TX, United States of America\n",
      "London, United Kingdom\n",
      "Houston, TX, United States of America\n",
      "Barcelona, Spain\n",
      "Erlangen, Germany\n",
      "Erlangen, Germany\n",
      "Essen, Germany\n",
      "Barcelona, Spain\n",
      "Milan, Italy\n",
      "Houston, United States of America\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "Boston, United States of America\n",
      "Los Angeles, United States of America\n",
      "Manchester, United Kingdom\n",
      "Boston, United States of America\n",
      "Los Angeles, United States of America\n",
      "Lugano, Switzerland\n",
      "Paris, France\n",
      "Alessandria, Italy\n",
      "Paris, France\n",
      "Alessandria, Italy\n",
      "Copenhagen, Denmark\n",
      "Lugano, Switzerland\n",
      "New Haven, United States of America\n",
      "Melbourne, Australia\n",
      "Melbourne, Australia\n",
      "New Haven, United States of America\n",
      "Manchester, United Kingdom\n",
      "Zurich, Switzerland\n",
      "Melbourne, Australia\n",
      "New Haven, United States of America\n",
      "Lugano, Switzerland\n",
      "Milan, Italy\n",
      "Madrid, Spain\n",
      "Milan, Italy\n",
      "Madrid, Spain\n",
      "Salzburg, Austria\n",
      "Nashville, United States of America\n",
      "Lugano, Switzerland\n",
      "Madrid, Spain\n",
      "Madrid, Spain\n",
      "Tallinn, Estonia\n",
      "London, United Kingdom\n",
      "Los Angeles, United States of America\n",
      "Lausanne, Switzerland\n",
      "Seoul, Korea, Republic of\n",
      "Milan, Italy\n",
      "Paris, France\n",
      "Kashiwa, Japan\n",
      "Madrid, Spain\n",
      "Montreal, Canada\n",
      "Barcelona, Spain\n",
      "Baltimore, United States of America\n",
      "Tallinn, Estonia\n",
      "Bergen, Norway\n",
      "Philadelphia, United States of America\n",
      "Hospitalet de Llobregat, Spain\n",
      "Villejuif, France\n",
      "Tampa, United States of America\n",
      "Lugano, Switzerland\n",
      "Beijing, China\n",
      "Barcelona, Spain\n",
      "Philadelphia, United States of America\n",
      "Lugano, Switzerland\n",
      "Bari, Italy\n",
      "Leiden, Netherlands\n",
      "Houston, United States of America\n",
      "Halle \n",
      "Lyon, France\n",
      "Houston, United States of America\n",
      "Villejuif, Cedex, France\n",
      "Washington, United States of America\n",
      "Bergen, Norway\n",
      "Madrid, Spain\n",
      "Lyon, France\n",
      "Bari, Italy\n",
      "Houston, United States of America\n",
      "Villejuif, France\n",
      "Leiden, Netherlands\n",
      "Siena, Italy\n",
      "Siena, Italy\n",
      "Vienna, Austria\n",
      "New York, United States of America\n",
      "Zurich, Switzerland\n",
      "Lugano, Switzerland\n",
      "Porto Alegre, Brazil\n",
      "Porto Alegre, Brazil\n",
      "Madrid, Spain\n",
      "Villejiuf, France\n",
      "Boston, MA, United States of America\n",
      "Lugano, Switzerland\n",
      "Haidari, Greece\n",
      "Groningen, Netherlands\n",
      "Haidari, Greece\n",
      "Sha Tin, Hong Kong PRC\n",
      "Villejuif, France\n",
      "Sha Tin, Hong Kong PRC\n",
      "Sha Tin, Hong Kong PRC\n",
      "Singapore, Singapore\n",
      "Sha Tin, Hong Kong PRC\n",
      "Villejuif, France\n",
      "Villejuif, France\n",
      "Lugano, Switzerland\n",
      "Lisbon, Portugal\n",
      "Tel Aviv, Israel\n",
      "Toulouse, France\n",
      "Taiyuan, China\n",
      "Tel Aviv, Israel\n",
      "Guiyang, China\n",
      "Uppsala, Sweden\n",
      "Nanning, China\n",
      "Lisbon, Portugal\n",
      "Shanghai, China\n",
      "Seongnam, Korea, Republic of\n",
      "Tel Aviv, Israel\n",
      "Seoul, Korea, Republic of\n",
      "Copenhagen, Denmark\n",
      "Edinburgh, United Kingdom\n",
      "Villejuif, France\n",
      "Copenhagen, Denmark\n",
      "Houston, United States of America\n",
      "Singapore, Singapore\n",
      "Barcelona, Spain\n",
      "Nashville, United States of America\n",
      "New York, United States of America\n",
      "Seoul, Korea, Republic of\n",
      "Lyon, France\n",
      "Villejuif, France\n",
      "Villejuif, France\n",
      "Bethesda, United States of America\n",
      "London, United Kingdom\n",
      "Sutton, United Kingdom\n",
      "Toronto, Canada\n",
      "Lyon, France\n",
      "Lugano, Switzerland\n",
      "Liverpool, United Kingdom\n",
      "Geneva, Switzerland\n",
      "Liverpool, United Kingdom\n",
      "Lyon, France\n",
      "Sao Paulo, Brazil\n",
      "Liverpool, United Kingdom\n",
      "Geneva, Switzerland\n",
      "Lugano, Switzerland\n",
      "Tadworth, United Kingdom\n",
      "Tadworth, United Kingdom\n",
      "London, United Kingdom\n",
      "Kyiv, Ukraine\n",
      "Cluj-Napoca, Romania\n",
      "Lodz, Poland\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Sao Paulo, Brazil\n",
      "Petah Tikva, Israel\n",
      "London, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "Florianopolis, Brazil\n",
      "Petah Tikva, Israel\n",
      "Seoul, Korea, Republic of\n",
      "Villejuif, France\n",
      "San Francisco, United States of America\n",
      "Sao Paulo, Brazil\n",
      "London, United Kingdom\n",
      "Villejuif, France\n",
      "Lugano, Switzerland\n",
      "Villejuif, France\n",
      "Cambridge, United States of America\n",
      "Marseille, France\n",
      "London, United Kingdom\n",
      "Lugano, Switzerland\n",
      "London, United Kingdom\n",
      "Villejuif, France\n",
      "London, United Kingdom\n",
      "New York, United States of America\n",
      "Farmington, United States of America\n",
      "Barcelona, Spain\n",
      "Lugano, Switzerland\n",
      "Essen, Germany\n",
      "Sha Tin, Hong Kong PRC\n",
      "Madrid, Spain\n",
      "London, United Kingdom\n",
      "Barcelona, Spain\n",
      "Leiden, Netherlands\n",
      "Essen, Germany\n",
      "Heidelberg, Germany\n",
      "Brussels, Belgium\n",
      "Sha Tin, Hong Kong PRC\n",
      "Cambridge, United States of America\n",
      "Taipei City, Taiwan\n",
      "Lyon, France\n",
      "Madrid, Spain\n",
      "Huddinge, Sweden\n",
      "Leuven, Belgium\n",
      "Barcelona, Spain\n",
      "Manchester, United Kingdom\n",
      "Vienna, Austria\n",
      "Tübingen, Germany\n",
      "Lugano, Switzerland\n",
      "Newcastle upon Tyne, United Kingdom\n",
      "Brussels, Belgium\n",
      "Newcastle upon Tyne, United Kingdom\n",
      "Glasgow, United Kingdom\n",
      "London, United Kingdom\n",
      "Belgrae, Serbia\n",
      "Dublin, Ireland\n",
      "Gdansk, Poland\n",
      "Lausanne, Switzerland\n",
      "Reading, United Kingdom\n",
      "Istanbul, Turkey\n",
      "Lugano, Switzerland\n",
      "Southampton, United Kingdom\n",
      "Osijek, Croatia\n",
      "Edirne, Turkey\n",
      "Southampton, United Kingdom\n",
      "Waterford, Ireland\n",
      "Dublin, Ireland\n",
      "Aviano, Italy\n",
      "Karlstad, Sweden\n",
      "Lugano, Switzerland\n",
      "Turku, Finland\n",
      "Turku, Finland\n",
      "Lisbon, Portugal\n",
      "Freiburg im Breisgau, Germany\n",
      "Munich, Germany\n",
      "Rome, Italy\n",
      "Amsterdam, Netherlands\n",
      "Turku, Finland\n",
      "Freiburg im Breisgau, Germany\n",
      "Amsterdam, Netherlands\n",
      "Lisbon, Portugal\n",
      "Rome, Italy\n",
      "Munich, Germany\n",
      "Turku, Finland\n",
      "London, United Kingdom\n",
      "London, United Kingdom\n",
      "Lyon, France\n",
      "Manchester, United Kingdom\n",
      "Manchester, United Kingdom\n",
      "London, United Kingdom\n",
      "Turku, Finland\n",
      "Turku, Finland\n",
      "Edinburgh, United Kingdom\n",
      "Rome, Italy\n",
      "Lausanne, Switzerland\n",
      "Lugano, Switzerland\n",
      "Turku, Finland\n",
      "Turku, Finland\n",
      "Newcastle upon Tyne, United Kingdom\n",
      "Leuven, Belgium\n",
      "Napoli, Italy\n",
      "Huddinge, Sweden\n",
      "Newcastle upon Tyne, United Kingdom\n",
      "Tübingen, Germany\n",
      "Genova, Italy\n",
      "Leuven, Belgium\n",
      "Manchester, United Kingdom\n",
      "Napoli, Italy\n",
      "Barcelona, Spain\n",
      "Huddinge, Sweden\n",
      "Milan, Italy\n",
      "Amsterdam, Netherlands\n",
      "Malmo, Sweden\n",
      "Milan, Italy\n",
      "Parkville, Australia\n",
      "Amsterdam, Netherlands\n",
      "Liverpool, United Kingdom\n",
      "\n",
      "Liverpool, United Kingdom\n",
      "Cambridge, United Kingdom\n",
      "Zurich, Switzerland\n",
      "Berlin, Germany\n",
      "Wollstonecraft, Australia\n",
      "Haidari, Greece\n",
      "Leipzig, Germany\n",
      "Toronto, Canada\n",
      "Taipei City, Taiwan\n",
      "Brussels, Belgium\n",
      "Odense, Denmark\n",
      "Uppsala, Sweden\n",
      "\n",
      "London, United Kingdom\n",
      "Amsterdam, Netherlands\n",
      "Manchester, United Kingdom\n",
      "Kashiwa, Japan\n",
      "Boston, United States of America\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(COUNTRY)):\n",
    "    print(COUNTRY[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "e999f4e4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Chair\n",
      "Chair\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n",
      "Speaker\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(ROLE)):\n",
    "    print(ROLE[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "bc1450f1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1647\n",
      "1647\n",
      "1647\n",
      "1647\n",
      "1647\n",
      "1647\n",
      "1647\n"
     ]
    }
   ],
   "source": [
    "print(len(SESSION))\n",
    "print(len(SUB_SESSION))\n",
    "print(len(TIME))\n",
    "print(len(PERSONS))\n",
    "print(len(DATE))\n",
    "print(len(ROLE))\n",
    "print(len(COUNTRY))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "a5733b78",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "ON-SITE ONLY: Young Oncologists Vesalius Talk\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Opening session\n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? \n",
      "Updates in the standard of care of metastatic breast cancer\n",
      "Updates in the standard of care of metastatic breast cancer\n",
      "Updates in the standard of care of metastatic breast cancer\n",
      "Updates in the standard of care of metastatic breast cancer\n",
      "Updates in the standard of care of metastatic breast cancer\n",
      "Updates in the standard of care of metastatic breast cancer\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Proffered Paper session: Breast cancer, metastatic\n",
      "Using molecular data that impacts clinical practice\n",
      "Using molecular data that impacts clinical practice\n",
      "Using molecular data that impacts clinical practice\n",
      "Using molecular data that impacts clinical practice\n",
      "Using molecular data that impacts clinical practice\n",
      "Using molecular data that impacts clinical practice\n",
      "Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status\n",
      "Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status\n",
      "Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status\n",
      "Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status\n",
      "Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status\n",
      "Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status\n",
      "Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)\n",
      "Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)\n",
      "Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)\n",
      "Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)\n",
      "Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)\n",
      "Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Gynaecological cancers\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Proffered Paper session: Investigational immunotherapy\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Exploiting synthetic lethality: The next generation\n",
      "Emerging treatment strategies for non-metastatic NSCLC\n",
      "Emerging treatment strategies for non-metastatic NSCLC\n",
      "Emerging treatment strategies for non-metastatic NSCLC\n",
      "Emerging treatment strategies for non-metastatic NSCLC\n",
      "Emerging treatment strategies for non-metastatic NSCLC\n",
      "Emerging treatment strategies for non-metastatic NSCLC\n",
      "Ultra-rare sarcoma: Navigating an endless sea\n",
      "Ultra-rare sarcoma: Navigating an endless sea\n",
      "Ultra-rare sarcoma: Navigating an endless sea\n",
      "Ultra-rare sarcoma: Navigating an endless sea\n",
      "Ultra-rare sarcoma: Navigating an endless sea\n",
      "Ultra-rare sarcoma: Navigating an endless sea\n",
      "New discoveries in cancer using single cell and spatial technologies\n",
      "New discoveries in cancer using single cell and spatial technologies\n",
      "New discoveries in cancer using single cell and spatial technologies\n",
      "New discoveries in cancer using single cell and spatial technologies\n",
      "New discoveries in cancer using single cell and spatial technologies\n",
      "New discoveries in cancer using single cell and spatial technologies\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "How the tumour microenvironment affects outcome and therapy response?\n",
      "Plenty of choices in rectal cancer\n",
      "Plenty of choices in rectal cancer\n",
      "Plenty of choices in rectal cancer\n",
      "Plenty of choices in rectal cancer\n",
      "Plenty of choices in rectal cancer\n",
      "Plenty of choices in rectal cancer\n",
      "Advances in non-cutaneous melanoma\n",
      "Advances in non-cutaneous melanoma\n",
      "Advances in non-cutaneous melanoma\n",
      "Advances in non-cutaneous melanoma\n",
      "Advances in non-cutaneous melanoma\n",
      "Advances in non-cutaneous melanoma\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Proffered Paper session: CNS tumours\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "Special session: Ovarian cancer Consensus\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "How diagnostic tools impact therapy of haematological malignancies\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "Patient Advocates and their expertise: How to get involved\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "5-year impact of new registered indications on the ESMO-MCBS\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ON-SITE ONLY: Young Oncologist Mentorship sessions\n",
      "ONSITE ONLY: Patient guide: How can cancer affect bone health?\n",
      "ONSITE ONLY: Patient guide: How can cancer affect bone health?\n",
      "ONSITE ONLY: Patient guide: How can cancer affect bone health?\n",
      "ONSITE ONLY: Patient guide: How can cancer affect bone health?\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Presidential Symposium I\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC\n",
      "Is immunotherapy changing the standard of care in gynaecological cancers?\n",
      "Is immunotherapy changing the standard of care in gynaecological cancers?\n",
      "Is immunotherapy changing the standard of care in gynaecological cancers?\n",
      "Is immunotherapy changing the standard of care in gynaecological cancers?\n",
      "Is immunotherapy changing the standard of care in gynaecological cancers?\n",
      "Is immunotherapy changing the standard of care in gynaecological cancers?\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Progress in the identification of new immune targets\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "Proffered Paper session 1: GU tumours, non-prostate\n",
      "What is the future of digital medicine for cancer patients?\n",
      "What is the future of digital medicine for cancer patients?\n",
      "What is the future of digital medicine for cancer patients?\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Proffered Paper session 1: GI, upper digestive\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies\n",
      "Management of challenging situation in urinary cancers\n",
      "Management of challenging situation in urinary cancers\n",
      "Management of challenging situation in urinary cancers\n",
      "Management of challenging situation in urinary cancers\n",
      "Management of challenging situation in urinary cancers\n",
      "Management of challenging situation in urinary cancers\n",
      "Management of challenging situation in urinary cancers\n",
      "The three “Ws” of early breast cancer management\n",
      "The three “Ws” of early breast cancer management\n",
      "The three “Ws” of early breast cancer management\n",
      "The three “Ws” of early breast cancer management\n",
      "The three “Ws” of early breast cancer management\n",
      "The three “Ws” of early breast cancer management\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Mini Oral session 1: Gynaecological cancers\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Proffered Paper session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Mini Oral session: Breast cancer, metastatic\n",
      "Does hyperprogression exist?\n",
      "Does hyperprogression exist?\n",
      "Does hyperprogression exist?\n",
      "Does hyperprogression exist?\n",
      "Does hyperprogression exist?\n",
      "Does hyperprogression exist?\n",
      "Does hyperprogression exist?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Is heterogeneity the limitation of precision oncology in melanoma?\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Proffered Paper session 1: Melanoma and other skin tumours\n",
      "Management of adrenocortical carcinoma\n",
      "Management of adrenocortical carcinoma\n",
      "Management of adrenocortical carcinoma\n",
      "Management of adrenocortical carcinoma\n",
      "Management of adrenocortical carcinoma\n",
      "Management of adrenocortical carcinoma\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "Mini Oral session: Head & neck cancer\n",
      "HIPEC for peritoneal carcinomatosis\n",
      "HIPEC for peritoneal carcinomatosis\n",
      "HIPEC for peritoneal carcinomatosis\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "New avenues for targeting biological mechanisms in sarcoma\n",
      "Management of 21st century CRPC after upfront treatment: Men progressing after androgen deprivation and second generation therapies\n",
      "Management of 21st century CRPC after upfront treatment: Men progressing after androgen deprivation and second generation therapies\n",
      "Management of 21st century CRPC after upfront treatment: Men progressing after androgen deprivation and second generation therapies\n",
      "Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas\n",
      "Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas\n",
      "Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas\n",
      "Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas\n",
      "Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas\n",
      "Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas\n",
      "How can we collaborate better as a multidisciplinary team to develop novel therapeutics?\n",
      "How can we collaborate better as a multidisciplinary team to develop novel therapeutics?\n",
      "How can we collaborate better as a multidisciplinary team to develop novel therapeutics?\n",
      "How can we collaborate better as a multidisciplinary team to develop novel therapeutics?\n",
      "How can we collaborate better as a multidisciplinary team to develop novel therapeutics?\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Mini Oral session: Supportive and palliative care\n",
      "Immunotherapy for lung cancer: The longer the better? The more the better?\n",
      "Immunotherapy for lung cancer: The longer the better? The more the better?\n",
      "Immunotherapy for lung cancer: The longer the better? The more the better?\n",
      "Let’s talk about sex and cancer\n",
      "Let’s talk about sex and cancer\n",
      "Let’s talk about sex and cancer\n",
      "Let’s talk about sex and cancer\n",
      "Let’s talk about sex and cancer\n",
      "Let’s talk about sex and cancer\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics\n",
      "Locally advanced N2/stage III NSCLC\n",
      "Locally advanced N2/stage III NSCLC\n",
      "Locally advanced N2/stage III NSCLC\n",
      "Locally advanced N2/stage III NSCLC\n",
      "Locally advanced N2/stage III NSCLC\n",
      "Locally advanced N2/stage III NSCLC\n",
      "Treating oligometastatic oesophagogastric cancer\n",
      "Treating oligometastatic oesophagogastric cancer\n",
      "Treating oligometastatic oesophagogastric cancer\n",
      "Treating oligometastatic oesophagogastric cancer\n",
      "Treating oligometastatic oesophagogastric cancer\n",
      "Treating oligometastatic oesophagogastric cancer\n",
      "What every oncologist should know about palliative sedation?\n",
      "What every oncologist should know about palliative sedation?\n",
      "What every oncologist should know about palliative sedation?\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Proffered Paper session: Developmental therapeutics\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Mini Oral session: Investigational immunotherapy\n",
      "Treating KRAS mutant tumour\n",
      "Treating KRAS mutant tumour\n",
      "Treating KRAS mutant tumour\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Proffered Paper session: Haematological malignancies\n",
      "Can we cure oligometastatic disease in sarcoma patients?\n",
      "Can we cure oligometastatic disease in sarcoma patients?\n",
      "Can we cure oligometastatic disease in sarcoma patients?\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Proffered Paper session: Sarcoma\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "Mini Oral session: GI, upper digestive\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Complex technologies for diagnosis: How do we implement and use them globally?\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Patient involvement in clinical research: Placing the patient at the centre\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "Proffered Paper session: Policy and preventive strategies\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "The loved ones’ perspective and role: Best practices to support cancer caregiver\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "Current and future perspectives in SCLC\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "De-escalation of treatment in medical oncology\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Elements to build a Molecular Tumour Board\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Mini Oral session: CNS tumours\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Boxing session\n",
      "Young Oncologist Brunch 1: Integrating Patient Reported Outcomes in clinical practice\n",
      "Young Oncologist Brunch 1: Integrating Patient Reported Outcomes in clinical practice\n",
      "Young Oncologist Brunch 1: Integrating Patient Reported Outcomes in clinical practice\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Welcome to the EONS15 conference\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "Health promotion, prevention, and screening\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing\n",
      "eHealth and digital innovations\n",
      "eHealth and digital innovations\n",
      "eHealth and digital innovations\n",
      "eHealth and digital innovations\n",
      "eHealth and digital innovations\n",
      "eHealth and digital innovations\n",
      "Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy\n",
      "Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy\n",
      "Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy\n",
      "Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy\n",
      "Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy\n",
      "Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy\n",
      "Supportive care: Adapting to advances in oncology for better patient outcomes\n",
      "Supportive care: Adapting to advances in oncology for better patient outcomes\n",
      "Supportive care: Adapting to advances in oncology for better patient outcomes\n",
      "Supportive care: Adapting to advances in oncology for better patient outcomes\n",
      "Supportive care: Adapting to advances in oncology for better patient outcomes\n",
      "Supportive care: Adapting to advances in oncology for better patient outcomes\n",
      "ON-SITE ONLY: Medical student session\n",
      "ON-SITE ONLY: Medical student session\n",
      "ON-SITE ONLY: Medical student session\n",
      "ON-SITE ONLY: Medical student session\n",
      "ON-SITE ONLY: Medical student session\n",
      "ON-SITE ONLY: Medical student session\n",
      "ON-SITE ONLY: Medical student session\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Presidential Symposium II\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session: GU tumours, prostate\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session 1: GI, lower digestive\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: NSCLC, metastatic\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Non-clear cell renal cell carcinoma: Best practices\n",
      "Non-clear cell renal cell carcinoma: Best practices\n",
      "Non-clear cell renal cell carcinoma: Best practices\n",
      "Non-clear cell renal cell carcinoma: Best practices\n",
      "Non-clear cell renal cell carcinoma: Best practices\n",
      "Non-clear cell renal cell carcinoma: Best practices\n",
      "Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer\n",
      "Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer\n",
      "Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer\n",
      "Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Proffered Paper session 2: GI, upper digestive\n",
      "Multidisciplinary management of brain metastases with or without driver oncogene\n",
      "Multidisciplinary management of brain metastases with or without driver oncogene\n",
      "Multidisciplinary management of brain metastases with or without driver oncogene\n",
      "Multidisciplinary management of brain metastases with or without driver oncogene\n",
      "Multidisciplinary management of brain metastases with or without driver oncogene\n",
      "Multidisciplinary management of brain metastases with or without driver oncogene\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 1\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "ESMO Clinical Practice Guidelines session 2\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "Application of novel technologies in head & neck cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "New classification and staging of breast cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Targeting DNA repair and beyond in ovarian cancer\n",
      "Selection of first-line and subsequent treatments in HCC\n",
      "Selection of first-line and subsequent treatments in HCC\n",
      "Selection of first-line and subsequent treatments in HCC\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Mini Oral session: NSCLC, metastatic\n",
      "Non-melanoma skin cancers \n",
      "Non-melanoma skin cancers \n",
      "Non-melanoma skin cancers \n",
      "Non-melanoma skin cancers \n",
      "Non-melanoma skin cancers \n",
      "Non-melanoma skin cancers \n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Interplay between host biology and treatment\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Lessons learned and new horizons for treatment of primary brain tumours\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Mini Oral session: Basic science & translational research\n",
      "Minimizing some of the most distressing cancer and cancer treatment related symptoms\n",
      "Minimizing some of the most distressing cancer and cancer treatment related symptoms\n",
      "Minimizing some of the most distressing cancer and cancer treatment related symptoms\n",
      "Minimizing some of the most distressing cancer and cancer treatment related symptoms\n",
      "Minimizing some of the most distressing cancer and cancer treatment related symptoms\n",
      "Minimizing some of the most distressing cancer and cancer treatment related symptoms\n",
      "How to incorporate digital medicine in survivorship care after breast cancer\n",
      "How to incorporate digital medicine in survivorship care after breast cancer\n",
      "How to incorporate digital medicine in survivorship care after breast cancer\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 1: GU tumours, non-prostate\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Mini Oral session 2: Gynaecological cancers\n",
      "Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?\n",
      "Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?\n",
      "Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice\n",
      "Should all advanced ovarian cancer patients receive a PARPi in first-line therapy?\n",
      "Should all advanced ovarian cancer patients receive a PARPi in first-line therapy?\n",
      "Should all advanced ovarian cancer patients receive a PARPi in first-line therapy?\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "What’s old is new again\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer\n",
      "Rare head & neck cancer\n",
      "Rare head & neck cancer\n",
      "Rare head & neck cancer\n",
      "Rare head & neck cancer\n",
      "Rare head & neck cancer\n",
      "Rare head & neck cancer\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Proffered Paper session: Basic science & translational research\n",
      "Germ cell tumors: Prognostic factors, managing poor-risk and progressive/refractory disease\n",
      "Germ cell tumors: Prognostic factors, managing poor-risk and progressive/refractory disease\n",
      "Germ cell tumors: Prognostic factors, managing poor-risk and progressive/refractory disease\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Mini Oral session: GU tumours, prostate\n",
      "Management of different glioma subtypes: Should all lower-grade gliomas be treated equally?\n",
      "Management of different glioma subtypes: Should all lower-grade gliomas be treated equally?\n",
      "Management of different glioma subtypes: Should all lower-grade gliomas be treated equally?\n",
      "Young patients with newly-diagnosed multiple myeloma and severe complications\n",
      "Young patients with newly-diagnosed multiple myeloma and severe complications\n",
      "Young patients with newly-diagnosed multiple myeloma and severe complications\n",
      "Young patients with newly-diagnosed multiple myeloma and severe complications\n",
      "Young patients with newly-diagnosed multiple myeloma and severe complications\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "Sex and gender differences in oncology: From prevention to care\n",
      "CNS metastases in metastatic breast cancer\n",
      "CNS metastases in metastatic breast cancer\n",
      "CNS metastases in metastatic breast cancer\n",
      "CNS metastases in metastatic breast cancer\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "The road towards clinical implementation of artificial intelligence (AI) in oncology\n",
      "Localized extremity STS: Looking beyond surgery\n",
      "Localized extremity STS: Looking beyond surgery\n",
      "Localized extremity STS: Looking beyond surgery\n",
      "Localized extremity STS: Looking beyond surgery\n",
      "Localized extremity STS: Looking beyond surgery\n",
      "Localized extremity STS: Looking beyond surgery\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "I am FINE: Frustrated * Isolated * Neglected * Emotional\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "The enigma of public policy in oncology: ESMO at the forefront\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Join us, learn, and share: Best practices across Europe\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "Proffered Paper session: Supportive and palliative care\n",
      "State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours\n",
      "State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours\n",
      "State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours\n",
      "State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours\n",
      "State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours\n",
      "State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued\n",
      "Young Oncologist Brunch 2: How to write and respond to a critical peer review\n",
      "Young Oncologist Brunch 2: How to write and respond to a critical peer review\n",
      "Young Oncologist Brunch 2: How to write and respond to a critical peer review\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Patient and occupational safety\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Palliative and end-of-life care\n",
      "Mundipharma - Pain management in people with cancer\n",
      "Mundipharma - Pain management in people with cancer\n",
      "Mundipharma - Pain management in people with cancer\n",
      "Mundipharma - Pain management in people with cancer\n",
      "Mundipharma - Pain management in people with cancer\n",
      "Mundipharma - Pain management in people with cancer\n",
      "Cancer accommodation and disruption in young lives\n",
      "Cancer accommodation and disruption in young lives\n",
      "Cancer accommodation and disruption in young lives\n",
      "Cancer accommodation and disruption in young lives\n",
      "Cancer accommodation and disruption in young lives\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Supportive care and symptom management\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Presidential Symposium III\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment\n",
      "The current and future of immunotherapy for metastatic NSCLC\n",
      "The current and future of immunotherapy for metastatic NSCLC\n",
      "The current and future of immunotherapy for metastatic NSCLC\n",
      "The current and future of immunotherapy for metastatic NSCLC\n",
      "The current and future of immunotherapy for metastatic NSCLC\n",
      "The current and future of immunotherapy for metastatic NSCLC\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Creating a new stage between early and metastatic cancers: Illustration with lung cancers\n",
      "Personalizing treatment for mCRC in 2022\n",
      "Personalizing treatment for mCRC in 2022\n",
      "Personalizing treatment for mCRC in 2022\n",
      "Personalizing treatment for mCRC in 2022\n",
      "Personalizing treatment for mCRC in 2022\n",
      "Personalizing treatment for mCRC in 2022\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Evolving targets and treatment options in oesophagogastric cancer\n",
      "Breast cancer genetics: Where to now?\n",
      "Breast cancer genetics: Where to now?\n",
      "Breast cancer genetics: Where to now?\n",
      "Cellular therapies for solid tumours\n",
      "Cellular therapies for solid tumours\n",
      "Cellular therapies for solid tumours\n",
      "Cellular therapies for solid tumours\n",
      "Cellular therapies for solid tumours\n",
      "Cellular therapies for solid tumours\n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Emerging toxicities of new anticancer therapies \n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Mini Oral session: Breast cancer, early stage\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Proffered Paper session 2: GU tumours, non-prostate\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Leveraging biology and technology to improve symptoms and quality of life of cancer survivors\n",
      "Who should I test for genetics outside BRCA?\n",
      "Who should I test for genetics outside BRCA?\n",
      "Who should I test for genetics outside BRCA?\n",
      "Who should I test for genetics outside BRCA?\n",
      "Who should I test for genetics outside BRCA?\n",
      "Who should I test for genetics outside BRCA?\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Proffered Paper session: Head & neck cancer\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Mini Oral session: Melanoma and other skin tumours\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "Proffered Paper session 2: GI, lower digestive\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer\n",
      "Manipulating the microbiome for clinical response\n",
      "Manipulating the microbiome for clinical response\n",
      "Manipulating the microbiome for clinical response\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Multidisciplinary updates in biomarkers in urinary cancers\n",
      "Management of oligometastatic prostate cancer\n",
      "Management of oligometastatic prostate cancer\n",
      "Management of oligometastatic prostate cancer\n",
      "Management of oligometastatic prostate cancer\n",
      "Management of oligometastatic prostate cancer\n",
      "Management of oligometastatic prostate cancer\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "Mini Oral session 2: GU tumours, non-prostate\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "What is the optimal therapeutic approach in high-risk endometrial cancer?\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Mini Oral session: GI, lower digestive\n",
      "Challenges in the treatment of mesothelioma\n",
      "Challenges in the treatment of mesothelioma\n",
      "Challenges in the treatment of mesothelioma\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications?\n",
      "Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients\n",
      "Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients\n",
      "Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients\n",
      "Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients\n",
      "Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients\n",
      "Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients\n",
      "Early relapses in lymphoma: How to treat?\n",
      "Early relapses in lymphoma: How to treat?\n",
      "Early relapses in lymphoma: How to treat?\n",
      "Early relapses in lymphoma: How to treat?\n",
      "Early relapses in lymphoma: How to treat?\n",
      "Early relapses in lymphoma: How to treat?\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "Detection, characterisation and targeting of minimal residual disease\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Proffered Paper session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Mini Oral session: NETs and endocrine tumours\n",
      "Management of brain metastases: Systemic treatment, radiosurgery or both?\n",
      "Management of brain metastases: Systemic treatment, radiosurgery or both?\n",
      "Management of brain metastases: Systemic treatment, radiosurgery or both?\n",
      "Management of brain metastases: Systemic treatment, radiosurgery or both?\n",
      "Management of brain metastases: Systemic treatment, radiosurgery or both?\n",
      "Management of brain metastases: Systemic treatment, radiosurgery or both?\n",
      "Oligometastatic disease and oligoprogression in breast cancer\n",
      "Oligometastatic disease and oligoprogression in breast cancer\n",
      "Oligometastatic disease and oligoprogression in breast cancer\n",
      "Oligometastatic disease and oligoprogression in breast cancer\n",
      "Oligometastatic disease and oligoprogression in breast cancer\n",
      "Oligometastatic disease and oligoprogression in breast cancer\n",
      "How to select patients for immunotherapy-based therapy in the first-line treatment for recurrent/metastatic head and neck squamous cell cancer\n",
      "How to select patients for immunotherapy-based therapy in the first-line treatment for recurrent/metastatic head and neck squamous cell cancer\n",
      "How to select patients for immunotherapy-based therapy in the first-line treatment for recurrent/metastatic head and neck squamous cell cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "New developments in the management of recurrent/metastatic nasopharyngeal cancer\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Haematological malignancies\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "Mini Oral session: Developmental therapeutics\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "How advances in biology and technology are transforming the field of cancer prevention & early detection\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "Supporting Ukraine: The European cancer advocacy community responds\n",
      "How can we use ctDNA for early detection of cancer?\n",
      "How can we use ctDNA for early detection of cancer?\n",
      "How can we use ctDNA for early detection of cancer?\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "Mini Oral session: Policy and preventive strategies\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "ESMO meets pharma: Next frontiers in drug discoveries\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Hard-to-treat cancers: What makes them special?\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Mini Oral session: Sarcoma\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management\n",
      "Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?\n",
      "Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?\n",
      "Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Professional and educational issues in cancer nursing\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Empowering young cancer nurses academically, clinically and in career progression\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream\n",
      "Roche - Cancer care: there is no place like home?\n",
      "Roche - Cancer care: there is no place like home?\n",
      "Roche - Cancer care: there is no place like home?\n",
      "Roche - Cancer care: there is no place like home?\n",
      "Roche - Cancer care: there is no place like home?\n",
      "Roche - Cancer care: there is no place like home?\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "EONS closing session\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 1\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n",
      "Congress Highlights 2\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(SESSION)):\n",
    "    print(SESSION[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "bfb5e93e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1647"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "CONFERENCE=[]\n",
    "for i in range(len(SESSION)):\n",
    "    CONFERENCE.append('European society for Medical Oncology, ESMO - 2022')\n",
    "len(CONFERENCE)    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "id": "fa7d17e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "cf3379f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data=pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "909ba1f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data[\"CONFERENCE\"]=CONFERENCE\n",
    "Data['SESSION_NAMES']=SESSION\n",
    "Data[\"SUB_SESSION\"]=SUB_SESSION\n",
    "Data[\"NAMES\"]=PERSONS\n",
    "Data[\"ROLE\"]=ROLE\n",
    "Data[\"COUNTRY\"]=COUNTRY\n",
    "Data[\"TIME\"]=TIME\n",
    "Data[\"DATE\"]=DATE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "id": "60814c62",
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "index 8 is out of bounds for axis 0 with size 8",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Input \u001b[1;32mIn [103]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[1;34m()\u001b[0m\n\u001b[1;32m----> 1\u001b[0m Data\u001b[38;5;241m=\u001b[39mData\u001b[38;5;241m.\u001b[39mdrop(\u001b[43mData\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcolumns\u001b[49m\u001b[43m[\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m8\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m,axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n",
      "File \u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\pandas\\core\\indexes\\base.py:5055\u001b[0m, in \u001b[0;36mIndex.__getitem__\u001b[1;34m(self, key)\u001b[0m\n\u001b[0;32m   5048\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m com\u001b[38;5;241m.\u001b[39mis_bool_indexer(key):\n\u001b[0;32m   5049\u001b[0m     \u001b[38;5;66;03m# if we have list[bools, length=1e5] then doing this check+convert\u001b[39;00m\n\u001b[0;32m   5050\u001b[0m     \u001b[38;5;66;03m#  takes 166 µs + 2.1 ms and cuts the ndarray.__getitem__\u001b[39;00m\n\u001b[0;32m   5051\u001b[0m     \u001b[38;5;66;03m#  time below from 3.8 ms to 496 µs\u001b[39;00m\n\u001b[0;32m   5052\u001b[0m     \u001b[38;5;66;03m# if we already have ndarray[bool], the overhead is 1.4 µs or .25%\u001b[39;00m\n\u001b[0;32m   5053\u001b[0m     key \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39masarray(key, dtype\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mbool\u001b[39m)\n\u001b[1;32m-> 5055\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mgetitem\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkey\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   5056\u001b[0m \u001b[38;5;66;03m# Because we ruled out integer above, we always get an arraylike here\u001b[39;00m\n\u001b[0;32m   5057\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m result\u001b[38;5;241m.\u001b[39mndim \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m1\u001b[39m:\n",
      "\u001b[1;31mIndexError\u001b[0m: index 8 is out of bounds for axis 0 with size 8"
     ]
    }
   ],
   "source": [
    "Data=Data.drop(Data.columns[[8]],axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "be1df8b7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CONFERENCE</th>\n",
       "      <th>SESSION_NAMES</th>\n",
       "      <th>SUB_SESSION</th>\n",
       "      <th>NAMES</th>\n",
       "      <th>ROLE</th>\n",
       "      <th>COUNTRY</th>\n",
       "      <th>TIME</th>\n",
       "      <th>DATE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>ON-SITE ONLY: Young Oncologists Vesalius Talk</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Maria Kfoury</td>\n",
       "      <td>Chair</td>\n",
       "      <td>Villejuif, Cedex, France</td>\n",
       "      <td>17:30 - 18:30</td>\n",
       "      <td>Fri, 09.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>ON-SITE ONLY: Young Oncologists Vesalius Talk</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Teresa M. Amaral</td>\n",
       "      <td>Chair</td>\n",
       "      <td>Tübingen, Germany</td>\n",
       "      <td>17:30 - 18:30</td>\n",
       "      <td>Fri, 09.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>ON-SITE ONLY: Young Oncologists Vesalius Talk</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Elene Mariamidze</td>\n",
       "      <td>Chair</td>\n",
       "      <td>Tbilisi, Georgia</td>\n",
       "      <td>17:30 - 18:30</td>\n",
       "      <td>Fri, 09.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>ON-SITE ONLY: Young Oncologists Vesalius Talk</td>\n",
       "      <td>Introduction by the Chairs</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>Fri, 09.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>ON-SITE ONLY: Young Oncologists Vesalius Talk</td>\n",
       "      <td>Panel discussion</td>\n",
       "      <td>Tony S.K. Mok</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Sha Tin, Hong Kong PRC</td>\n",
       "      <td>17:40 - 18:30</td>\n",
       "      <td>Fri, 09.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1642</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Congress Highlights 2</td>\n",
       "      <td>Gastrointestinal tumours, lower digestive</td>\n",
       "      <td>Marco Gerlinger</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>London, United Kingdom</td>\n",
       "      <td>11:00 - 11:20</td>\n",
       "      <td>Tue, 13.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1643</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Congress Highlights 2</td>\n",
       "      <td>Gastrointestinal tumours, upper digestive</td>\n",
       "      <td>Hanneke W. Van Laarhoven</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Amsterdam, Netherlands</td>\n",
       "      <td>11:20 - 11:40</td>\n",
       "      <td>Tue, 13.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1644</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Congress Highlights 2</td>\n",
       "      <td>NETs and endocrine tumours</td>\n",
       "      <td>Juan W. Valle</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Manchester, United Kingdom</td>\n",
       "      <td>11:40 - 12:00</td>\n",
       "      <td>Tue, 13.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1645</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Congress Highlights 2</td>\n",
       "      <td>Non-metastatic NSCLC and other thoracic malign...</td>\n",
       "      <td>Masahiro Tsuboi</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Kashiwa, Japan</td>\n",
       "      <td>12:00 - 12:20</td>\n",
       "      <td>Tue, 13.09.2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1646</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Congress Highlights 2</td>\n",
       "      <td>NSCLC, metastatic</td>\n",
       "      <td>Jessica J. Lin</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Boston, United States of America</td>\n",
       "      <td>12:20 - 12:40</td>\n",
       "      <td>Tue, 13.09.2022</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1647 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                             CONFERENCE  \\\n",
       "0     European society for Medical Oncology, ESMO - ...   \n",
       "1     European society for Medical Oncology, ESMO - ...   \n",
       "2     European society for Medical Oncology, ESMO - ...   \n",
       "3     European society for Medical Oncology, ESMO - ...   \n",
       "4     European society for Medical Oncology, ESMO - ...   \n",
       "...                                                 ...   \n",
       "1642  European society for Medical Oncology, ESMO - ...   \n",
       "1643  European society for Medical Oncology, ESMO - ...   \n",
       "1644  European society for Medical Oncology, ESMO - ...   \n",
       "1645  European society for Medical Oncology, ESMO - ...   \n",
       "1646  European society for Medical Oncology, ESMO - ...   \n",
       "\n",
       "                                      SESSION_NAMES  \\\n",
       "0     ON-SITE ONLY: Young Oncologists Vesalius Talk   \n",
       "1     ON-SITE ONLY: Young Oncologists Vesalius Talk   \n",
       "2     ON-SITE ONLY: Young Oncologists Vesalius Talk   \n",
       "3     ON-SITE ONLY: Young Oncologists Vesalius Talk   \n",
       "4     ON-SITE ONLY: Young Oncologists Vesalius Talk   \n",
       "...                                             ...   \n",
       "1642                          Congress Highlights 2   \n",
       "1643                          Congress Highlights 2   \n",
       "1644                          Congress Highlights 2   \n",
       "1645                          Congress Highlights 2   \n",
       "1646                          Congress Highlights 2   \n",
       "\n",
       "                                            SUB_SESSION  \\\n",
       "0                                          Introduction   \n",
       "1                                          Introduction   \n",
       "2                                          Introduction   \n",
       "3                            Introduction by the Chairs   \n",
       "4                                      Panel discussion   \n",
       "...                                                 ...   \n",
       "1642          Gastrointestinal tumours, lower digestive   \n",
       "1643          Gastrointestinal tumours, upper digestive   \n",
       "1644                         NETs and endocrine tumours   \n",
       "1645  Non-metastatic NSCLC and other thoracic malign...   \n",
       "1646                                  NSCLC, metastatic   \n",
       "\n",
       "                          NAMES     ROLE                           COUNTRY  \\\n",
       "0                 Maria Kfoury     Chair          Villejuif, Cedex, France   \n",
       "1             Teresa M. Amaral     Chair                 Tübingen, Germany   \n",
       "2             Elene Mariamidze     Chair                  Tbilisi, Georgia   \n",
       "3                                                                            \n",
       "4                Tony S.K. Mok   Speaker            Sha Tin, Hong Kong PRC   \n",
       "...                         ...      ...                               ...   \n",
       "1642           Marco Gerlinger   Speaker            London, United Kingdom   \n",
       "1643  Hanneke W. Van Laarhoven   Speaker            Amsterdam, Netherlands   \n",
       "1644             Juan W. Valle   Speaker        Manchester, United Kingdom   \n",
       "1645           Masahiro Tsuboi   Speaker                    Kashiwa, Japan   \n",
       "1646            Jessica J. Lin   Speaker  Boston, United States of America   \n",
       "\n",
       "               TIME             DATE  \n",
       "0     17:30 - 18:30  Fri, 09.09.2022  \n",
       "1     17:30 - 18:30  Fri, 09.09.2022  \n",
       "2     17:30 - 18:30  Fri, 09.09.2022  \n",
       "3              None  Fri, 09.09.2022  \n",
       "4     17:40 - 18:30  Fri, 09.09.2022  \n",
       "...             ...              ...  \n",
       "1642  11:00 - 11:20  Tue, 13.09.2022  \n",
       "1643  11:20 - 11:40  Tue, 13.09.2022  \n",
       "1644  11:40 - 12:00  Tue, 13.09.2022  \n",
       "1645  12:00 - 12:20  Tue, 13.09.2022  \n",
       "1646  12:20 - 12:40  Tue, 13.09.2022  \n",
       "\n",
       "[1647 rows x 8 columns]"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "id": "d26d8652",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data.to_excel(\"ESMO_2022.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "a251c528",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "09d3345e",
   "metadata": {},
   "outputs": [],
   "source": [
    "tt = pd.ExcelFile('ESMO_2022.xlsx').parse('Sheet1')\n",
    "sub=tt['SUB_SESSION']\n",
    "names=tt['NAMES']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "7f915804",
   "metadata": {},
   "outputs": [],
   "source": [
    "Initial=[]\n",
    "First=[]\n",
    "Middle=[]\n",
    "Last=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "c8080197",
   "metadata": {},
   "outputs": [],
   "source": [
    "def NameDivider(Name):\n",
    "    inti=\"\"\n",
    "    first=\"\"\n",
    "    last=\"\"\n",
    "    midd=[]\n",
    "    temp=str(Name).split(\" \")\n",
    "    for i in range(len(temp)):\n",
    "        if(len(temp[i])==2 and i==1):\n",
    "            if(temp[i][1]=='.'):\n",
    "                inti=temp[i][0]\n",
    "            continue\n",
    "        if(i==0):\n",
    "           first=temp[i]\n",
    "           continue\n",
    "        if(i==len(temp)-1):\n",
    "           last=temp[i]\n",
    "           continue\n",
    "        else:\n",
    "           midd.append(temp[i])\n",
    "    if(midd==[]):\n",
    "           mid=\"\"\n",
    "    if(midd!=[]):\n",
    "           mid=\" \".join(midd)\n",
    "    return inti,first,mid,last\n",
    "\n",
    "\n",
    "for j in range(len(names)):\n",
    "    inti,first,mid,lst=NameDivider(names[j])\n",
    "    Initial.append(inti)\n",
    "    First.append(first)\n",
    "    Middle.append(mid)\n",
    "    Last.append(lst)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "7271197b",
   "metadata": {},
   "outputs": [],
   "source": [
    "search=['Gadolinium',\n",
    "'MRI+Contrast Agent',\n",
    "'Focal liver lesions',\n",
    "'Liver metastases',\n",
    "'Nephrogenic Systemic Fibrosis',\n",
    "'Colorectal Cancer+Liver Metastasis'\n",
    "'Breast Cancer+Liver Metastasis',\n",
    "'Lung Cancer+Liver Metastatsis',\n",
    "'Gastric Cancer+Liver Metastasis',\n",
    "'Primary Liver Cancer',\n",
    "'Gadolinium toxicity',\n",
    "'Gadolinium deposition']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "4a212af9",
   "metadata": {},
   "outputs": [],
   "source": [
    "s_ele=[]\n",
    "found=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "8bd138de",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(len(sub)):\n",
    "    f=-1\n",
    "    for j in range(len(search)):\n",
    "        if(('+' not in search[j]) and (type(sub[i])!=float)):\n",
    "            if(search[j].lower() in sub[i].lower()):\n",
    "                f=j\n",
    "        else:\n",
    "            if(type(sub[i])!=float):\n",
    "                temp=search[j].split('+')\n",
    "                if((temp[0] in sub[i].lower()) and (temp[1] in sub[i].lower())):\n",
    "                    f=j\n",
    "    if(f!=-1):\n",
    "        s_ele.append(search[j])\n",
    "        found.append('Found')\n",
    "    else:\n",
    "        s_ele.append('No search term')\n",
    "        found.append('Not found')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "dcf5bd95",
   "metadata": {},
   "outputs": [],
   "source": [
    "bt=pd.DataFrame()\n",
    "bt['Session ST']=found\n",
    "bt['InSession']=s_ele\n",
    "# bt['Abstract ST']=ab_found\n",
    "# bt['InAbstract']=ab_s_ele\n",
    "bt['Initial']=Initial\n",
    "bt['First Name']=First\n",
    "bt['Middle Name']=Middle\n",
    "bt['Last Name']=Last"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "05a16fd4",
   "metadata": {},
   "outputs": [],
   "source": [
    "bt.to_excel('search_terms_2022.xlsx')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a9cfd1a6",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
